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G protein-coupled receptors (GPCRs) are a large family of trans-membrane receptors 
that transmit signals from extracellular stimuli to target intracellular signal 
transduction pathways. The gonadotropin-releasing hormone receptor (GnRH-R) is a 
GPCR which binds the decapeptide GnRH. In the pituitary gonadotrope, GnRH 
stimulates gonadotropin (LH and FSH) biosynthesis and secretion to regulate 
reproduction. GnRH and the GnRH-Rs are also present in many extra-pituitary 
tissues, although their role at these sites remains largely undetermined. GnRH-Rs are 
known to recruit a diverse array of signalling pathway mediators in different cell-
types. These include; Gq/11-PLC-IP3/DAG-Ca
2+
/PKC signalling, monomeric G-
proteins and integrins to mediate cell adhesion and migration, the activation of the 
major members of the mitogen-activated protein kinase (MAPK) super-family 
(extracellular signal-regulated kinase (ERK), c-Jun N-terminal Kinase (JNK) and 
p38MAPK), and β-catenin and other mediators of the canonical Wnt signalling 
pathway. 
 
This thesis describes the regulation of Forkhead Box O (FOXO) transcription factors 
by GnRH. The mammalian FOXO transcription factors, FOXO1, FOXO3a and 
FOXO4, are emerging as an important family of proteins that modulate the 
expression of genes involved in cell-cycle regulation, induction of apoptosis, DNA 
damage repair and response to oxidative stress. In this thesis, emphasis is placed on 
delineating the novel role of FOXO transcription factors in mediating two important 
and widely-researched areas of GnRH biology. Firstly, the role of FOXO 
transcription factors in mediating cell-growth inhibition in response to GnRH 
vi 
 
treatment is assessed in a heterologous HEK293/GnRH-R expressing cell line. 
Secondly, the role of transcription factors in regulating luteinising hormone- (LH)-
subunit expression is investigated in the LT2 gonadotrope cell line. 
 
Activation of the GnRH-R can inhibit cell proliferation and induce apoptosis in 
certain tumour-derived cell lines. Several studies have reported that these events can 
occur as a result of changes in the expression profiles of specific cell-cycle 
regulatory and apoptotic genes, many of which are FOXO-target genes, including 
GADD45, FasL, p21Cip1 and p27Kip1. In this thesis, a role for FOXOs in targeting 
the expression of several of these genes in response to GnRH is assessed, 
highlighting a specific role for FOXO3a in mediating GADD45 and FasL expression. 
The signalling mechanisms through which FOXO3a regulates GADD45 expression 
in response to GnRH is also described. Finally, a stable FOXO3a-knock-down cell 
line was generated in order to further examine FOXO3a involvement in GnRH-
induced cell-growth inhibition. 
 
GnRH is an essential regulator of the reproductive process by stimulating the 
synthesis of LH and FSH in pituitary gonadotropes, thereby regulating 
gametogenesis and steroidogenesis. Diverse signalling pathways have been reported 
to regulate LHβ-subunit expression in response to GnRH, including the 
ERK/JNK/p38MAPK cascades and factors such as Egr1, SF1 and β-catenin. In the 
second part of this thesis, the role of FOXOs in regulating LHβ-subunit expression in 
response to GnRH is described. The data presented suggests that GnRH can regulate 
LHβ-subunit expression through both indirect and direct FOXO3a-mediated 
mechanisms. Firstly, FOXO3a was found to regulate Egr1 expression to indirectly 
vii 
 
target LHβ-promoter activity. Secondly, a role for -catenin as a FOXO3a co-factor 
to directly regulate LH-subunit expression, together with Egr1 and SF1, is also 
proposed. FOXO3a expression and sub-cellular localisation was assessed and 
demonstrated in LT2 cells and in adult human male pituitary sections. 
 
The research presented in this thesis adds to the diversity of signalling pathways and 
mediators that GnRH can target in different cellular backgrounds in order to mediate 
a variety of cellular processes. The antiproliferative and apoptotic effects of GnRH 
on tumour-derived cell lines are well-documented, and this research highlights a 
novel role for FOXO3a in mediating these events. The regulation of gonadotropin 
synthesis remains an important topic of research, and the novel implication of 
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In the first part of this Chapter, a brief description of the hypothalamic-pituitary axis, 
and GnRH/GnRH-R structure/function will be given. This will be followed by a 
review of GnRH-induced signalling pathways, among them the PI3K/Akt pathway. 
Next, the mechanisms through which GnRH induces cell-growth inhibition will be 
reviewed. In the second part of this Chapter, the signalling pathways that mediate 
LHβ-subunit expression in response to GnRH will be outlined. In addition, a number 
of transcription factors that are required to maximal LHβ promoter transcriptional 
activity will be discussed in some detail. Finally, the third part of this Chapter will 
provide an overview of FOXO transcription factors. This will be followed by a 
review of the FOXO-target genes and the role of FOXOs in cancers. 
 
 
1.1  OVERVIEW 
 
The G protein-coupled receptor (GPCR) super-family represents the largest group of 
cell-surface membrane receptors. They are seven-transmembrane domain receptors 
that are activated by extracellular signals, leading to the induction of intracellular 
signal transduction pathways. GPCRs are located within the plasma membrane and 
contain an extracellular N-terminus which is followed by seven transmembrane (TM) 
domains connected by three intracellular (ICL), and three extracellular (ECL) loops, 
and an intracellular C-terminal tail. While GPCRs are common drug targets, only a 





into five major families; the Rhodopsin-like family, the Secretin family, the 
Adhesion family, the Glutamate family and the Frizzled/Taste family (Millar and 
Newton, 2010). Gonadotropin-Releasing Hormone Receptors (GnRH-Rs) belong to 
the Rhodopsin-like family of the GPCRs, and are activated following the binding of 
Gonadotropin-Releasing Hormone (GnRH). 
 
The hypothalamic neuropeptide GnRH is synthesised and released by GnRH neurons 
in the hypothalamus. GnRH stimulates pituitary gonadotrope cells to synthesise and 
release the gonadotropins, Luteinising Hormone (LH) and Follicle Stimulating 
Hormone (FSH) (Naor, 2009). Binding of GnRH to the GnRH-R on the surface of 
gonadotropes in the anterior pituitary initiates a variety of signalling pathways that 
leads to the synthesis the gonadotropins, and their release into the blood-stream 
(Ferris and Shupnik, 2006; Lim et al., 2009; Seeburg et al., 1987; Vale et al., 1977).  
 
Forkhead Box O (FOXO) proteins constitute a large family of transcription factors 
that mediate diverse cellular responses. These proteins have a 
characteristic/conserved DNA-binding motif, known as the “forkhead domain”. 
Although, they contain this conserved DNA-binding domain, they show differences 
between their C-terminal and N-terminal trans-activation domains (Burgering, 2008). 
Over the past 15 years, a number of FOX subclasses have been identified with 
different biological roles. Among the FOX family is the “O” sub-group (FOXO) 
which consists of four members, three of which are mammalian, namely FOXO1 
(FKHR), FOXO3a (FKHRL1) and FOXO4 (AFX). FOXOs share similar DNA-
binding domains, and were originally thought to regulate the expression of the same 





be determined by post-translational modification and/or the action of co-factors. 
FOXOs are also involved in a number of cellular processes such as cell proliferation, 
apoptosis and cell metabolism, and are of great interest because they play a pivotal 
role in cell-fate decision and in tumour suppression in a variety of cancers (Fu and 
Tindall, 2008).  
 
 
1.2  THE HYPOTHALAMIC-PITUITARY AXIS 
 
The reproductive axis consists of three endocrine organs; the hypothalamus, pituitary 
and gonads. The hypothalamus is located at the base of the brain. It contains the 
hypothalamic areas or nuclei consisting of a relatively compact cluster of neurons 
(Sisk and Foster, 2004). GnRH is produced by specialised neurons (parvocellular 
neurons), whose cell bodies reside in the parvocellular nuclei. The axons of GnRH 
neurons terminate at the median eminence of the basal hypothalamus, where they 
secrete pulses of GnRH (Johnson, 2007). GnRH enters the hypothalamo-pituitary 
portal vessels, and travels to the anterior pituitary to stimulate the synthesis and 
secretion of LH and FSH. LH and FSH in turn regulate gonadal steroidogenesis and 
gametogenesis in both sexes (Fig. 1-1) (Sisk and Foster, 2004). 
 
The pituitary gland or hypophysis is an endocrine gland that is located posterior to 
the hypothalamus at the base of the brain. It is composed of two main lobes, the 
anterior and the smaller posterior regions. Gonadotropes are located in the anterior 
lobe of the pituitary. The anterior pituitary contains a variety of cells types, including 





2007; Ooi et al., 2004). Approximately, 50% of the anterior pituitary cells are 
somatotropes, 10–20% are lactotropes, 10–20% are thyrotropes, 10–20% are 
corticotropes and 10–20% are gonadotropes (Horváth and Palkovits, 1988). 
 
 
Figure 1-1: The hypothalamic-pituitary-gonadal axis.  
GnRH is synthesised by specialised neurons in the hypothalamus and packaged into storage granules. 
GnRH is secreted from nerve terminals located at the median eminence of the basal hypothalamus. 
GnRH enters the hypothalamo-pituitary portal vasculature and is transported to the anterior pituitary. 
In the anterior pituitary, GnRH stimulates the synthesis and secretion of LH and FSH from 
gonadotropes, which stimulate the testis and ovaries to mediate steroidogenesis and gametogenesis. 
Figure reproduced from Sisk and Foster, 2004. 
 
1.2.1  Kisspeptin (Kiss1) and kisspeptin receptor (Kiss1r) 
 
Kisspeptin receptor (Kiss1r; also known as GPR54) is a G protein-coupled receptor 
which binds the peptide hormone kisspeptin. Although this thesis will focus on the 
signalling pathways downstream of the GnRH-R, a brief introduction on kisspeptin 





neuroendocrine regulators of reproduction through stimulation of GnRH neurons 
(Oakley et al., 2009). 
 
Kiss1r is a GPCR, with three glycosylation sites at the N-terminus (Clements et al., 
2001). Kisspeptin (Kiss1) is the product of the Kiss1 gene. The initial Kiss1 product 
is a 145-amino acid peptide, from which is cleaved a 54-amino acid protein, which 
can be further truncated to 14, 13 or 10 amino acid carboxyl-terminal fragments, all 
known as kisspeptins. These N-terminal truncated peptides belong to a large family 
of peptides known as RFamides which all share a common Arg–Phe–NH2 motif at 
their C-terminus (Roseweir and Millar, 2009). Kiss1 and its receptor are highly 
involved in the regulation of the reproduction. Indeed, mutations in the Kiss1r gene 
are associated with the idiopathic hypothalamic hypogonadism. Moreover, Kiss1 
stimulates GnRH secretion and regulates gonadotropin production (Fig. 1-2) (Oakley 
et al., 2009). 
 
Neurons that express Kiss1r and Kiss1 are found in discrete nuclei in the 
hypothalamus, and in other brain regions in many vertebrates. Kiss1r and Kiss1 are 
also expressed in other tissues including pancreas, adipocytes, ovary, placenta and 
pituitary (Oakley et al., 2009). 
 
As discussed above, Kiss1 regulates GnRH release from GnRH neurons in the 
hypothalamus. GnRH then regulates gonadotropin production, at the level of the 
pituitary to stimulate LH and FSH secretion (Oakley et al., 2009). Double 
immunofluorescence labelling for LHβ and Kiss1, or Kiss1r has been demonstrated 
in gonadotropes (Richard et al., 2008), as has Kiss1 secretion into the hypophysial 





at the pituitary level. In contrast, other studies have reported that Kiss1 does not act 
at the pituitary level (Reviewed by Oakley et al. (2009)). The stimulatory effect of 
Kiss1 was blocked by a GnRH antagonist. This finding suggests that the effect of 




Figure 1-2: Regulation of the reproductive axis by kisspeptin in mouse. 
Kisspeptin is released from Kisspeptin neurons mainly in the arcuate nucleus (ARC) and in the 
anteroventral periventricular nucleus (AVPV) to stimulate GnRH release from GnRH neurons, which 
in turn stimulates the secretion of LH and FSH from the anterior pituitary. LH and FSH stimulate 
steroidogenesis and gametogenesis, which feed-back to regulate the activity of Kisspeptin neurons. 
Figure reproduced from Gottsch et al., 2006.  
 
1.2.2  Gonadotropin-Releasing Hormone (GnRH) 
 
GnRH is the central regulator of the reproductive system downstream of Kiss1 and 
exists as 23 isoforms in vertebrates. In most vertebrates, there are three forms of 
GnRH; GnRH I, GnRH II and GnRH III. The mammalian hypophysiotropic form, 





primarily involved in the synthesis and secretion of LH and FSH from gonadotropes 
(discussed in Section 1.5). The second form is GnRH II. It is ubiquitously expressed, 
conserved in structure, and was first isolated from chicken brain (Miyamoto et al., 
1984). GnRH II is widely distributed in discrete regions of the central and peripheral 
nervous system and in non-neural tissues (Millar, 2003). Finally, a third form of 
GnRH, GnRH III, has been isolated in many vertebrates species (Millar, 2003, 2005; 
Millar and Newton, 2010; Pawson et al., 2003). 
 
1.2.3  The Gonadotropin-Releasing Hormone Receptor (GnRH-R) 
 
The GnRH-R is a member of the GPCR super-family, and belongs to the Rhodopsin-
like family. In mammals, there are two forms of GnRH-R, the Type I and Type II 
GnRH-Rs.  
 
The Type I GnRH-R is expressed in pituitary gonadotropes and regulates 
gonadotropin synthesis. It is also expressed in other tissues, including prostate, breast 
and ovary (Dubois et al., 2002; Millar, 2005; Millar and Newton, 2010). Structurally, 
the mammalian GnRH-Rs differ from other GnRH-Rs in vertebrates, in that they 
completely lack the cytoplasmic C-terminal tail (Fig. 1-3). The cytoplasmic C-
terminal tail is involved in receptor desensitisation, and the mammalian Type I 
GnRH-Rs which lack a cytoplasmic C-terminal tail do not undergo rapid 
desensitisation (Davidson et al., 1994; McArdle et al., 1999). 
 
mRNAs of Type II GnRH-Rs are expressed in many parts of the human and 
marmoset brain and peripheral tissues. However, Type II GnRH-R mRNAs in human 





length and functional GPCR due to the presence of various mutations including a 
frame-shift and internal stop codon (Faurholm et al., 2001; Millar, 2003).  
 
GnRH I binds both Type I and Type II GnRH-Rs, however, it binds the Type I 
GnRH-R with higher affinity. GnRH I binds to and activates Type I GnRH-R 
inducing a number of signalling pathways. Despite the lack of a full-length 
functional Type II GnRH-Rs in human, GnRH II is able to bind the Type I GnRH-R 
with high affinity. The ability of GnRH II to bind to the Type I GnRH-R suggests 
that the Type I GnRH-R is able to take over the role of the Type II GnRH-R in 
humans (Millar et al., 2004). GnRH I or GnRH II binding to the Type I GnRH-R 
recruits different intracellular signalling proteins to produce different phenotypic 
effects in different cells, a phenomenon called ligand-induced selective signalling 
(LiSS) (Millar and Newton, 2010). In particular, GnRH I binding to the Type I 
GnRH-R is more potent at generating Gq-coupled inositol phosphate production, 
which is the predominant signalling pathway in gonadotropes. In contrast, binding of 
GnRH II to the Type I GnRH is more potent at activating antiproliferative signalling 
pathways in cancer-derived cell lines (Millar and Newton, 2010).  
 
GnRH-Rs are primarily localised within the plasma membrane, however a number of 
studies have demonstrated that GnRH-Rs are also localised on the nuclear membrane 
(Janovick et al., 2003; Millar et al., 1983; Re et al., 2010). More recently, the nuclear 
localisation of functional human Type I GnRH-Rs was confirmed (Re et al., 2010). 
The nuclear membrane localisation of GnRH-Rs suggests the potential for novel 








Figure 1-3: The Human Gonadotropin-Releasing Hormone Receptor.  
The GnRH-R consists of seven trans-membrane domains which are connected by three intracellular 
and extracellular loops. Figure reproduced from Millar and Newton, 2010. 
 
 
1.3  GnRH-R SIGNALLING 
 
1.3.1  Coupling to G-proteins 
 
Activation of the GnRH-R induces a conformational change leading to coupling and 
activation of heterodimeric G-proteins. G-proteins consist of α-, β- and γ-subunits, 
which transduce signals from GPCRs to intracellular mediators (Naor et al., 2000). 
The α-subunit is a 37-42KDa protein, which contains a guanine nucleotide-binding 
pocket with intrinsic GTPase activity. The 35KDa β-subunit and the 8-11KDa γ-
subunit are tightly associated with each other (Goldsmith and Dhanasekaran, 2007). 
There are over 20 Gα-subunit which are divided into four major families; Gαq/11 
which activates phospholipase C (PLC), Gαs which activates adenylyl cyclase, Gαi/o 
which inhibits adenylyl cyclase and Gα12/13 which activates small GTPases (Naor, 





bound guanosine-5-diphosphate (GDP) to GTP guanosine-5-triphosphate (GTP) on 
the α-subunit. The GTP-bound α-subunit in turn dissociates from the receptor and βγ-
subunit, and initiates distinct signalling pathways (Goldsmith and Dhanasekaran, 
2007). The Gβγ-subunit is also capable of activating other effector systems (Naor, 
2009). The amino acid residues of GnRH-R which are essential for G-protein 
activation are conserved among mammalian and non-mammalian GnRH-Rs (Naor, 
2009). In particular, GnRH-R coupling to Gαq/11 occurs through the intracellular 
loops 2 and 3, while coupling to Gs occurs through intracellular loop 1 (Millar et al., 
2004). In the remainder of this Section 1.3, only the mediators activated by GnRH-R 
coupling to Gq will be reviewed 
 
1.3.2  Phospholipase C 
 
PLC is a soluble multi-domain protein found in eukaryotes. Four β, two γ and four δ 
isoforms have been described in mammals (Rebecchi and Pentyala, 2000). 
 
The PLCβ isoforms are regulated by the coupling of Gαq- and Gβγ-proteins. 
Following GnRH-R activation, Gαq family proteins and Gβγ subunits activate PLCβ, 
which hydrolyses the highly phosphorylated lipid phosphatidylinositol 4,5-
bisphosphate [PIP2], generating two intracellular products, inositol 1,4,5-
trisphosphate (InsP3 or IP3), a calcium-mobilising second messenger, and 
diacylglycerol (DAG), an activator of protein kinase C (PKC) (Naor, 2009; Rebecchi 







Figure 1-4: Regulation of PLCβ by GPCRs.  
The Gαq-subunit activates PLCβ causing hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) 
generates diacylglycerol (DAG) and IP3, which in turn releases calcium from internal stores. Gβγ-
subunits released from Gαi/o also activate PLCβ (RGS: Regulators of G protein signalling). Figure 
reproduced from Berecchi, 2000.  
 
 




When IP3 is released into the cytosol it binds to IP3 receptors located on the 
endoplasmic reticulum. The activation of IP3 receptors stimulates rapid Ca
2+
 





channels (Fig. 1-4) (Berridge, 2009; Naor, 2009). The IP3/Ca
2+
 pathway is a 
versatile signalling system that regulates many processes including exocytosis, cell 
proliferation, apoptosis and cell metabolism. The IP3/Ca
2+
 pathway also mediates 
gonadotropin exocytosis in gonadotropes. The involvement of Ca
2+
 in cell 
proliferation is well illustrated in lymphocytes responding to antigen, where Ca
2+
 
functions in conjugation with other signalling pathways such as the MAPK and PI3K 
pathways (Berridge et al., 2000). In general, Ca
2+
 controls cell proliferation by 





(cAMP response element-binding(CREB)). These transcription factors then mediate 
expression of a number of genes that are involved in cell proliferation, including 
interleukin 2 and Fas ligand (FasL) (Reviewed by Berridge et al. (2000)).  
 
1.3.4  Diacylglycerol (DAG) and phosphatidic acid (PA) 
 
As previously mentioned, DAG is formed from [PIP2] by the action of PLCβ. DAG 
regulates a number of cellular functions through the binding to and activation of 
PKC. DAG is also phosphorylated by DAG kinase (DGK) to phosphatidic acid (PA). 
PA in turn regulates a number of signalling proteins, including the atypical PKCs, the 
Raf-1 kinase and the mammalian target of rapamycin (mTOR). Notably, the list of 
PA-dependent protein members is still growing (Sakane et al., 2007). 
 
1.3.5  Protein Kinase C 
 
PKC is a serine/threonine kinase lipid activated kinase, and consists of at least 10 
related isoforms. PKC has a regulatory domain and a carboxyl-terminal catalytic 
domain. DAG binds to the regulatory domain of the PKC leading to activation. 
Activation of PKC by DAG leads to the activation of major members of the mitogen-
activated protein kinase (MAPK) family including extracellular signal-regulated 
kinase (ERK), c-Jun N-terminal Kinase (JNK) and p38 mitogen-activated protein 
kinases (p38MAPK) (Dobkin-Bekman et al., 2006). Activation of PKC contributes 
to the activation of the MAPK cascade through directly phosphorylating and 
stimulating c-Raf. c-Raf is a member of the Raf kinase family of serine/threonine-










1.3.6  Mitogen-activated protein kinase (MAPK) 
 
GnRH-R activation initiates diverse signalling cascades including the MAPK 
pathways. Four major MAPK cascades are activated by GnRH-R; ERK1/2, c-Jun N-
terminal kinase, p38MAPK and the big MAPK (BMK) (Naor, 2009). The MAPK 
cascade consists of at least three distinct kinases, the upstream mitogen-activated 
protein (MAP) kinase kinase kinase (MAP3K), MAP kinase kinase (MAP2K) and a 
downstream MAP kinase (MAPK). Therefore, the MAPK cascade proceeds through 
sequential phosphorylation of the MAP3K, MAP2K and MAPK (Goldsmith and 
Dhanasekaran, 2007). 
 
The main characteristic of the MAPK family is their ability to translocate to the 
nucleus and activate a variety of transcription factors (Dobkin-Bekman et al., 2006), 
including early growth response factor 1 (Egr1), c-Fos, c-Jun and STAT (Naor, 
2009).  
 
1.3.7  The phosphatidylinositol 3-Kinase (PI3K)/Akt signalling pathway 
 
PI3K is a minor inositol lipid kinase that is involved in many cellular processes, 
including cell survival, proliferation and differentiation. PI3K is activated by 
receptor tyrosine kinases (RTKs) and by GPCRs, and transduces signals by 
generating phospholipids. There are three classes of PI3K, however only Class I is 





and a p85 regulatory subunit. Class I PI3Ks activated by RTKs and GPCRs, 
phosphorylate the inositol ring of inositol phospholipids (Foster et al., 2003; Liu et 
al., 2009; Vanhaesebroeck and Alessi, 2000). These phospholipids then bind to and 
activate Akt. 
 
Akt (also known as PKB) is a 57KDa serine/threonine protein kinase which contains 
a pleckstrin homology (PH) domain and is activated by the PI3K. PH domains are 
globular protein domains which are found in over 150 proteins, and are activated by 
binding phospholipids with high affinity (Vanhaesebroeck and Alessi, 2000). The PH 
domain of Akt binds to the phospholipids which are produced by PI3K activation, 
and Akt is subsequently activated. Akt is primarily located in the cytoplasm in 
unstimulated cells and translocates to the plasma membrane following PI3K 
activation, where it binds phospholipids via its PH domain to become activated 
(Scheid and Woodgett, 2003).  
 
Another PH domain-containing serine/threonine kinase is 3’-phosphoinositide-
dependent kinase-1 (PDK1). Like Akt, PDK1 is primarily located in the cytoplasm in 
unstimulated cells and translocates to the plasma membrane following PI3K 
activation, where it binds phospholipids via its PH domain and phosphorylates Akt 
(Vanhaesebroeck and Alessi, 2000). Akt translocation to the plasma membrane 





phosphorylation sites. Phosphorylation of Akt at these sites is required for 
its full activation (Liu et al., 2009; Vanhaesebroeck and Alessi, 2000). A number of 
studies have also demonstrated PI3K-independent activation of Akt via a variety of 







cyclic adenosine monophosphate (cAMP). However, although different studies 
reported a heat-shock-dependent activation of Akt, their results are contradictory in 
relation to PI3K-dependent activation (Vanhaesebroeck and Alessi, 2000). Once Akt 
is phosphorylated and activated, it phosphorylates a diverse array of signalling 
mediators including the IκK kinase (IKK) (discussed in Section 1.6.2.1.2) and FOXO 
transcription factors (discussed in Section 1.6.2.1.1) (Liu et al., 2009).  
 
 
1.4  GnRH-INDUCED ANTIPROLIFERATION AND APOPTOSIS 
As described above, GnRH-Rs are not only expressed in gonadotropes, but also in 
extra-pituitary tissues, including breast, prostate, placenta, endometrium and ovary. 
In addition, GnRH has been found in extra-pituitary tissues such as in placenta, 
ovary, mammary gland and lymphoid cells (Kraus et al., 2006; Millar, 2005; Millar 
et al., 2004). While GnRH acts at its receptor in gonadotropes to regulate the 
expression of the gonadotropins (LH and FSH), numerous studies have demonstrated 
that GnRH-R activation in extra-pituitary cell types can mediate inhibition of cell 
proliferation
1
 or lead to a programmed cell-death (apoptosis). In vitro and tumour 
xenograft studies have demonstrated that GnRH treatment causes cell-growth 
inhibition
2
 in cell lines that express the GnRH-R (Cheng and Leung, 2005; Everest et 
al., 2001; Franklin et al., 2003; Kraus et al., 2006; Limonta et al., 2003; Maudsley et 
al., 2004; Miles et al., 2004; Morgan et al., 2008). In addition, in vitro and in vivo 
studies have demonstrated that treatment of cancer cells with GnRH analogues 
results in a reduction of cell proliferation (Kraus et al., 2006). GnRH analogues are 
                                                 
1
Cell proliferation:  refers to the increase of cells number 
2





widely used for cancer treatment. They were first used to treat prostate cancer (Tolis 
et al., 1982) and uterine leiomyomas (Carr et al., 1993). GnRH analogues are now 
more widely used in the treatment of ovarian cancer (Bifulco et al., 2004), uterine 
cancer (Hofstra et al., 1999), breast cancer (Klijn and de Jong, 1982) and endometrial 
cancer (Mizutani et al., 1998). 
 
The antiproliferative effects of GnRH have been shown to be dependent on GnRH-R 
expression levels and different cellular environments. GnRH initiates distinct 
signalling pathways in various cancer-derived cell lines depending on different 
cellular environments and GnRH-R expression levels (Fister et al., 2009; Kraus et 
al., 2006; Morgan et al., 2008). A number of signalling pathways mediate the 
antiproliferative effects of GnRH. Several of these will be reviewed below.  
 
As described above, a number of studies have examined the signalling pathways via 
which GnRH mediates its antiproliferative or apoptotic effect in a variety of model 
cell lines and cancer-derived cell lines. A common feature for these signalling 
pathways, is that the intracellular signalling activated by the GnRH-R is mediated 
through coupling to the Gq protein (Emons et al., 1998; Imai et al., 1997; Limonta et 
al., 2001; Lopez de Maturana et al., 2008; White et al., 2008a).  
 
A variety of downstream mediators have been implicated in the antiproliferative 
effects of GnRH, in different cell types. Elevated levels of cleaved poly (ADP-
ribose) polymerase (PARP), a substrate of caspase 3 was observed in HEK293/rat 
GnRH-R expressing cells in response to GnRH (Lopez de Maturana et al., 2008). 
The role of PKC and caspases to completely or partially rescue the cell-growth 





examined (Morgan et al., 2008). The involvement of JNK and PI3K/Akt in the 
apoptotic process in prostate cancer cell lines was examined. Inhibition of JNK 
rescued prostate cancer cells from the apoptotic effect of GnRH, whereas inhibition 
of PI3K/Akt increased the apoptotic effect of GnRH in prostate cancer cells (Kraus et 
al., 2004). The role of ERK in the antiproliferative effect of GnRH was also assessed 
in Caov-3 human ovarian cancer cells, and was suggested to be mediated by coupling 
to the Gαi protein (Kimura et al., 1999). GnRH also induces activation of JunD, 
which negatively regulates proliferation, and affects cell-cycle regulation and DNA 
synthesis in primary human ovarian cancer cells and EFO-21 and EFO-27 human 
ovarian cancer cell lines (Gunthert et al., 2002). The involvement of ERK1/2 and 
p38MAPK pathways in the antiproliferative effects of GnRH in ECC-1 endometrial 
cancer cells was also demonstrated. Cells pre-treated with MAPK inhibitors were 
rescued from GnRH II-mediated cell-growth inhibition (Wu et al., 2009). A 
reduction of PI3K/Akt activity by the GnRH analogue leuprolide acetate (LA) in 
uterine leiomyomas has been demonstrated to mediate the reduction of leiomyoma 
volume (Bifulco et al., 2004). GnRH also induced apoptosis in tissues derived from 
women with endometriosis, adenomyosis and uterine myoma, while activated 
caspase 3 was demonstrated in response to GnRH (Khan et al., 2010). Treatment of 
MCF-7 and triple-negative MDA-MB-231 human breast-cancer cells (triple-negative 
breast cancer does not express estrogen and progesterone receptors, and no 
overexpression/amplification of the HER2-neu gene occurs (Grundker et al., 2010)) 
with a GnRH II antagonist results in apoptotic cell death in vitro via activation of 
stress-activated p38MAPK and loss of mitochondrial membrane potential. 





Ala10] also induced activation of caspase 3 in MDA-MB-231 human breast-cancer 
cells (Grundker et al., 2010). 
 
The effect on cell-cycle regulation following GnRH stimulation has been examined 
in a number of studies (Gunthert et al., 2002; Kim et al., 1999; Miles et al., 2004). 
GnRH treatment of HEK293 cells expressing the rat GnRH-R induced an 
accumulation of cells in G2/M phase, whereas no G1 block was observed (Miles et 
al., 2004). GnRH also blocked cell-cycle progression in the G0/G1 phase without 
inducing apoptosis in OVCAR-3 and SKOV-3 human ovarian cancer cells (Kim et 
al., 1999). Finally, treatment of primary human ovarian cancer cells and EFO-21 and 
EFO-27 human ovarian-cancer cell lines with the GnRH agonist Triptorelin caused 
an increase in the proportion of cell found in G0/G1 phase, and a decrease of cells in 
G2/S phase of the cell-cycle (Gunthert et al., 2002). 
 
1.4.1  The role of FasL and GADD45 in GnRH-induced apoptosis  
 
GnRH-induced cell-growth inhibition is also mediated via the pro-apoptotic protein 
FasL and the growth arrest and DNA damage (GADD45) protein (Imai et al., 1998b; 
Wu et al., 2009). FasL induces apoptosis in a variety of cell types via activation of 
the Fas receptor (discussed in Section 1.6.3.2), while GADD45 is a regulator of cell-
cycle progression, DNA repair and apoptosis (discussed in Section 1.6.3.4). The role 
of FasL in GnRH-induced cell-growth inhibition was first revealed in a study by Imai 
et al. (1998). An increase in the levels of FasL mRNA and protein, following GnRH 
stimulation has been demonstrated in the endometrial and ovarian carcinoma cells 
expressing the GnRH-R (Imai et al., 1998a). The speculation that GnRH-induced 





confirmed in a follow-up study by the same group, where the antiproliferative effect 
of GnRH analogues on cells bearing Fas receptor compared with Fas receptor-
negative cells was examined. Indeed, the antiproliferative effect of GnRH analogues 
was demonstrated only on cells expressing the Fas receptor, and not in Fas receptor-
negative cells (Imai et al., 1998b). In contrast, treatment of uterine leiomyomas with 
a GnRH analogue failed to increase apoptosis, and moreover, lead to a decrease in 
FasL expression (Huang et al., 2002). 
 
The involvement of GADD45 in GnRH-induced cell-growth inhibition was 
demonstrated in a recent study conducted by Wu et al. (2009). The mechanism by 
which GnRH II induced apoptosis of human endometrial cancer cells was examined. 
Binding of GnRH II to the Type I GnRH receptor was demonstrated to induce 
apoptosis of human endometrial cancer cells by activating the expression of 
GADD45a gene (Wu et al., 2009).  
 
Although FasL and GADD45 mediate GnRH-induced cell-growth inhibition, the 
exact mechanisms involved has not yet been completely characterised. 
 
 
1.5  THE GONADOTROPINS  
 
1.5.1  Luteinising Hormone 
 
Reproduction in males and females is dependent on the physiological function of the 
hypothalamic-pituitary-gonadal axis, and the synthesis and release of several 





Rs) on Leydig cells in the testis for spermatogenesis, and on granulosa and theca 
cells in the ovary for follicular maturation and ovulation (Pierce and Parsons, 1981). 
In order to identify the role of LH in reproduction, knock-out mice lacking the LHβ 
(Luteinizing hormone beta)- subunit gene have been generated. Mutations of the LHβ 
gene that lead to its inactivation are very rare in nature (Kumar, 2007). LHβ-null 
mice were viable with postnatal defects in gonadal growth and infertility, and LHβ-
null male mice were hypogonadal with decreased size of testis and accessory glands, 
and showed decreased serum and intra-testicular testosterone level. LHβ-null female 
mice were also hypogonadal and had low serum of estradiol and progesterone levels 
(Kumar, 2007; Ma et al., 2004). 
 
LH and FSH are heterodimer glycoproteins which are composed of common α-
glycoprotein (αGSU) and hormone-specific β-subunits. The LHβ-subunit confers LH 
binding specificity to LH-Rs, which are GPCRs found in the ovary, testis and 
extragonodal organs like the uterus (Thackray et al., 2010). Each subunit of the LH 
protein is produced by a separate gene, and both subunits are glycosylated and 
assembled non-covalently as heterodimers in secretory granules where they are 
stored (Jorgensen et al., 2004; Pierce and Parsons, 1981; Thackray et al., 2010). 
 
1.5.2  Follicle-Stimulating Hormone  
 
FSH is a heterodimer glycoprotein which is composed of a common αGSU and 
hormone-specific β-subunit (Pierce and Parsons, 1981). In females, FSH stimulates 
ovarian follicle growth and maturation, while in males it stimulates androgen 






As previously mentioned, the main regulator of FSH expression is GnRH. The 
mechanism through which GnRH stimulates FSHβ (Follicle-Stimulating Hormone 
beta)- subunit transcription includes several signalling pathways and transcription 
factors. GnRH stimulates FSHβ-subunit expression via the ERK1/2 cascade; 
however the involvement of ERK1/2 is not yet well established (Bliss et al., 2009; 
Kanasaki et al., 2005). Several in vivo and in vitro studies have shown that although 
GnRH stimulates the p38MAPK and JNK cascades, a definitive role for these 
pathways in GnRH-induced regulation of FSH expression has not yet been 
established (Reviewed in Bernard et al. (2010)). A number of transcription factors, 
including the steroidogenic factor 1 (SF1), pituitary homeobox 1 (Pitx1), the LIM 
homeobox gene 3 (LHX3) and the GATA-binding protein 2 (GATA2) have also 
been implicated in FSHβ expression. However, their role in GnRH-induced FSHβ 
expression has not been definitively demonstrated (Bernard et al., 2010).  
 
Another important regulator for FSHβ production is activin, a member of the 
transforming growth factor β (TGFβ) super-family (Vale et al., 1988). Activin is 
involved in the up-regulation of FSHβ levels via the regulatory proteins SMAD2 and 
SMAD3. However, the role of activin in GnRH-induced FSHβ expression is not 
entirely clear due to the contradictory effect of activin action on FSHβ-expression 
following acute and chronic administration of GnRH (Xia and Schneyer, 2009).  
 
1.5.3  LHβ promoter structure 
 
All the important DNA elements of the LHβ promoter essential for its transcription 





the distal promoter domains. The proximal promoter region (140bp) is highly 
conserved across all mammals (Jorgensen et al., 2004), with small differences in the 
nucleotide sequence between species, and comprises of two DNA binding sites for 
Egr1 (Halvorson et al., 1998; Lee et al., 1996; Topilko et al., 1998) and SF1 
(Halvorson et al., 1998; Halvorson et al., 1996; Keri and Nilson, 1996), and one 
binding site for Pitx1 (Quirk et al., 2001) which is flanked by the Egr1 and SF1 
binding sites (Fig. 1-5A).  
 
Regulatory elements have been also found on the distal domain of the LHβ promoter. 
Gonadotrope-specific elements (GSEs) that bind the transcription factor Sp1 (Kaiser 
et al., 1998; Weck et al., 2000), and a CC(A/T)6GG motif (CArG) (Weck et al., 
2000) have been found in the distal rodent promoters, and binding sites for the 
nuclear transcription factor-Y (NF-Y) have been found in the distal bovine promoter 
(Keri et al., 2000) (Fig. 1-5B). 
 
1.5.4  Regulation of LHβ expression – Transcription factors 
 
In addition to gonadotropes, there are other cell types that express and secrete 
hormones in the anterior pituitary which also indirectly regulate the synthesis of the 
LH. Thus, gene regulation and the biosynthesis of LH and FSH in gonadotropes are 
also regulated by multiple factors that are expressed by nearby cells (Kaiser et al., 
2000). In this section, the transcription factors that mediate GnRH-induced LHβ 
expression will be reviewed. The main transcription factors dealt with are the Egr1, 






1.5.4.1  Egr1 
 
Egr1, a member of the immediate early gene (IEG) family of proteins, is a zinc-
finger transcription factor that is rapidly induced in many cell lines by growth, 
differentiation and apoptotic stimuli (Lee et al., 1996; Salisbury et al., 2008). GnRH 
treatment up-regulates the expression of Egr1 via a PKC-mediated pathway 
(Tremblay and Drouin, 1999; Wolfe and Call, 1999). A study by Trembley et al. 
(1999) reported that one hour after GnRH treatment Egr1 mRNA increased 
transiently to a maximal level compared to the non-stimulated αT3-1 and LβT2 
gonadotrope cells. Egr1 binds to the LHβ promoter in gonadotropes at two Egr1 
DNA binding sites. Over-expression of Egr1 up-regulates the expression of the LHβ-
subunit through action at both Egr1 binding sites (Fortin et al., 2009; Halvorson et 
al., 1998; Kaiser et al., 2000; Lee et al., 1996). Several studies have shown that 
GnRH-induced LHβ expression is mediated by Egr1 (Kaiser et al., 2000; Tremblay 
and Drouin, 1999; Wolfe and Call, 1999), and mutations of the Egr1 binding sites 
reduced GnRH-induced LHβ gene expression (Kaiser et al., 2000).  
 
1.5.4.2  SF1 
 
SF1 is an orphan member of the nuclear receptor super-family, initially identified as 
a transcription factor that controls expression of the cytochrome P-450 steroid 
hydroxylase genes in gonads and adrenal cortex (Ikeda et al., 1993). SF1 also binds 
to and regulates the transcription of the LHβ gene. A study by Ingraham et al. (1994) 
first demonstrated expression of SF1 in pituitary tissues by in situ hybridisation 
(Ingraham et al., 1994). In vitro studies revealed that SF1 directly regulates the 





al., 1996; Keri and Nilson, 1996; Tremblay and Drouin, 1999; Wolfe and Call, 
1999). Indeed, over-expression of SF1 increases LHβ expression (Halvorson et al., 
1996; Kaiser et al., 2000; Keri and Nilson, 1996). However, GnRH treatment does 
not up-regulate SF1 gene expression (Tremblay and Drouin, 1999). While SF1-/- 
mice exhibited decreased LHβ gene expression (Ingraham et al., 1994; Shinoda et 
al., 1995; Zhao et al., 2001b), GnRH treatment increased LHβ expression (Ikeda et 
al., 1993). In contrast, an in vivo study by Kaiser et al. (1998) demonstrated that LHβ 
promoter activity is not increased in response to GnRH in transgenic mice with a 
mutation of the SF1 binding site (Kaiser et al., 1998). Another study by the same 
group, demonstrated that over-expression of LHβ promoter with a mutation at the 
SF1 binding site reduced the LHβ promoter activity in rat pituitary adenoma GH3 
cells in response to GnRH. However, over-expression of LHβ promoter with a 
mutation on the SF1 binding site did not reduce the LHβ promoter activity in LβT2 
cells in response to GnRH (Kaiser et al., 2000). Therefore, the role of SF1 in the 
GnRH-induced LHβ expression is not yet completely clear. 
 
1.5.4.3  Pitx1 
 
Pitx1 is a transcription factor that is expressed in gonadotropes (Tremblay et al., 
1998). Pitx1 activates LHβ gene expression in addition to the transcription of a large 
number of gonadotrope genes, including FSHβ and GnRH-R (Tremblay et al., 1998). 
Pitx1 regulates the LHβ gene expression via direct binding to the LHβ promoter 
(Quirk et al., 2001), however Pitx1 mRNA expression is not regulated by GnRH 
(Tremblay and Drouin, 1999). A study by Quirk et al. (2001) demonstrated that 





site resulted in reduced LHβ promoter activity compared to the wild type LHβ 
promoter in response to GnRH. However, following GnRH treatment, the LHβ 
promoter activity was similar when either LHβ promoter bearing mutations at the 
Pitx1 binding site or the wild type LHβ promoter were over-expressed (Quirk et al., 
2001), indicating that Pitx1 protein is critical for the basal but not for the GnRH-






Figure 1-5: Structure of LHβ-subunit gene promoter.  
(A) The transcription factors binding sites on the rat LHβ promoter. Figure reproduced from Thackray 
et al., 2010. (B) DNA binding elements on the proximal and distal regions of the LHβ promoter of 
different species. DNA binding elements of the proximal region (0/-140bp) are highly conserved 
among the species. Distal regions are less well characterised. (NF-Y: Nuclear transcription factor Y, 
Sp1: selective promoter factor 1 or specificity protein 1, CArG: CC(A/T)6GG, GSE: Gonadotropin-







1.5.4.4  Sp1 
 
Sp1 is a member of the zinc finger family of transcription factors (Berg, 1992). Sp1 
binds to the LHβ promoter at two binding sites, and regulates its transcriptional 
activity. These two binding sites are located in positions −490/−352 and −207/−82 on 
the rat LHβ promoter. Mutations of these binding sites reduce the basal level of LHβ 
promoter activity, and also reduce GnRH-induced LHβ expression (Kaiser et al., 
2000; Kaiser et al., 1998; Weck et al., 2000).  
 
A number of in vivo studies have been conducted in mice with targeted deletion of 
additional proteins which bind to and regulate LHβ promoter in order to determine 
their biological role. These are summarised in Table 1-1. 
 
1.5.4.5  Transcription factor synergism at the LHβ promoter 
 
The transcription factors described above act synergistically to regulate maximal 
activity of the LHβ promoter. Co-expression of Egr1 and SF1 results in maximal 
LHβ protein expression (Dorn et al., 1999; Halvorson et al., 1998; Kaiser et al., 
2000; Tremblay and Drouin, 1999; Wolfe and Call, 1999). In addition, the physical 
interaction of Egr1 with Ptx1 and SF1, and the resultant synergy between Egr1, SF1 
and Pitx1 leads to maximal Egr1-mediated GnRH-induced LHβ expression 
















 male mice  Decreased  Fertile (Lee et al., 1996) 
NGFI
-/-(1) 
female mice Undetectable  Unfertile (Lee et al., 1996) 
Krox-24
-/-(1) 
male/female Absence of LH Sterile (Topilko et al., 1998) 
Ftz-F
(2) 
l-disrupted mice Undetectable No data (Ingraham et al., 1994) 
mFtz-FI
(2) 
-disrupted mouse Decreased  No data (Shinoda et al., 1995) 
Pituitary-specific SF1 
knockout mice  
Markedly decreased Infertile (Zhao et al., 2001a) 
(1)
 Egr1 (Krox-24, NGFI-A, Zif268) 
(2)
 SF1 (Ftz-F1) 
Table 1-1: Effect on LHβ expression and fertility in mice by knocking-down transcription 
factors known to regulate the LHβ promoter activity. 
 
A mechanism of GnRH-induced regulation of LHβ promoter activity has been 
proposed by Kaiser et al. (2000) (Fig. 1-6). An interaction between the proximal and 
the distal domains of the rat LHβ promoter in response to GnRH was proposed. 
When an LHβ promoter bearing a inactivating mutation at the Sp1 binding site was 
over-expressed in GH3 cells, GnRH-induced LHβ expression was decreased, 
suggesting that Sp1 is involved in the regulation of the LHβ promoter activity (Kaiser 
et al., 2000). Overall, this study proposed a mechanism by which GnRH treatment 
increases Egr1 protein level, which together with Sp1 and SF1 binds to an 
unidentified transcription factor (co-factor). This complex which includes Egr1, Sp1, 
SF1 with the co-factor causes a conformational change in the promoter that leads to 
enhanced LHβ promoter activity (Fig. 1-6).  
 
A recent study by Walsh et al. (2009) also demonstrated a proteasome-based 
regulation of the LHβ gene in response to GnRH. This study reported that two of the 





the ubiquitin proteasome system. Fluctuation in Egr1 and SF1 levels leads to their 
cyclic association with the LHβ promoter, thus allowing the LHβ gene to respond to 







Figure 1-6: Model for interaction of SF1, SP1 and Egr1 on the promoter of LHβ gene in 
response to GnRH.  
All three transcription factors interact with an unidentified transcription co-factor to mediate the full 
response to GnRH at the LHβ promoter activity (Basal indicates a possible transcription factors that is 
important in the transcription in this complex). Figure reproduced from Kaiser et al., 2000.  
 
1.5.4.6  β-catenin 
 
β-catenin is a transcription co-activator, and a member of the canonical Wnt 
signalling pathway. There is a well-established role for β-catenin in the formation of 
the active complex required for the LHβ expression (Salisbury et al., 2008). This was 
first demonstrated in a study by Salisbury et al. (2007) where reduction of β-catenin 
levels resulted in a decrease in GnRH-induced LHβ gene expression. β-catenin was 
demonstrated to interact with SF1, and this interaction is a requirement for the 
formation of an active complex between the SF1 and Egr1 following GnRH 
treatment, resulting in maximal GnRH-induced LHβ gene expression (Salisbury et 
al., 2007). Following GnRH treatment β-catenin associates with the proximal region 
of the LHβ promoter in a complex comprising of SF1 and Egr1 to maximise LHβ 
expression levels (Gardner et al., 2007; Gardner et al., 2010; Salisbury et al., 2007). 





In contrast, in the absence of GnRH treatment, a complex between β-catenin, SF1 
and Pitx1 maintains the LHβ gene expression at basal levels (Fig. 1-7) (Salisbury et 
al., 2008).  
 
1.5.5  Regulation of Luteinising Hormone expression – signalling 
pathways  
 
Induction of LHβ expression by GnRH is dependent on a number of mediators, 
including members of the MAPK cascade (Reviewed by Thackray et al. (2010)). The 
involvement of the three sub-families of the MAPKs, ERK1/2, p38MAPK and JNK 
in the GnRH-induced LHβ expression has been reported (Liu et al., 2002a).  
 
Several studies have reported the involvement of ERK1/2 in GnRH-induced LHβ 
expression (Call and Wolfe, 1999; Harris et al., 2002; Liu et al., 2002a; Maudsley et 
al., 2007; Yamada et al., 2004), while others have found no role for ERK1/2 in the 
transcriptional regulation of the LHβ gene by GnRH (Weck et al., 1998; Yokoi et al., 
2000). In GnRH-induced LHβ expression pathway, ERK1/2 activation is mediated 
by coupling to Gαq proteins (Liu et al., 2002b). In addition, elevated levels of LHβ 
protein expression has been demonstrated with over-expression of a constitutively 
active Gαq construct, while expression of inhibitory peptides of Gαq and Gαs, 
inhibited the GnRH-induced ERK1/2 activation and GnRH-stimulated LHβ 
production (Liu et al., 2002b). A more specific role for ERK1/2 in the GnRH-
induced LHβ expression was reported in a study conducted by Maudsley et al. 
(2007). The formation of a proline-rich tyrosine kinase 2 (Pyk2)-dependent multi-
protein complex was demonstrated following GnRH-R activation. This complex 





nucleus in LβT2 cells. Activated ERK1/2 regulates LHβ expression via the 
regulation of Egr1 expression. The Egr1 promoter is also activated by p38MAPK, 
but not by JNK (Maudsley et al., 2007). In addition, the involvement of JNK in the 
stimulation of LHβ production has also been demonstrated (Harris et al., 2002; 




Figure 1-7: A potential mechanism describing an involvement of β-catenin in GnRH-induced 
LHβ gene expression.  
In the absence of GnRH treatment, Egr1 protein levels are extremely low, and a complex comprising 
of β-catenin, SF1 and Pitx1 maintains LHβ gene expression at basal levels. GnRH treatment increases 
Egr1 levels, and Egr1 forms a complex with β-catenin, SF1 and Pitx1 increasing the transcriptional 
activity of LHβ promoter. Figure reproduced from Salisbury et al., 2008.  
 
The role of PKC in LHβ production has also been examined, with conflicting results 
being reported. In particular, a positive role of PKC in this pathway has been 
demonstrated in several studies (Call and Wolfe, 1999; Harris et al., 2002; Saunders 
et al., 1998; Vasilyev et al., 2002), while one study has reported that PKC is not 






The role of calcium (Ca
2+
) in the GnRH-induced LHβ expression pathway has also 
been reported. Weck et al. (1998) demonstrated that GnRH regulation of LHβ 
expression is mediated by an elevation of Ca
2+
 levels (Weck et al., 1998), however a 
number of other studies have reported conflicting results (Call and Wolfe, 1999; 
Saunders et al., 1998; Yokoi et al., 2000) The opposing results regarding the 
involvement of the above mediators on GnRH-induced LHβ expression can be 
explained by the use of different cell types and promoter constructs used in each 
study. All the above signalling pathways are summarised in Figure 1-8. 
 
Finally, the role of other receptors in the regulation of LHβ expression has been 
assessed (Naor et al., 2007). For example, reciprocal stimulation of GnRH-R and 
prostaglandin receptors regulate LHβ expression. In particular, activation of 
prostaglandin receptors via prostaglandin F2α (PGF2a) reduced GnRH-R-stimulated 
LHβ expression in LβT2 cells (Naor et al., 2007). While many factors have been 
reported to be involved in GnRH-induced LHβ expression in gonadotropes, the 
mechanisms, signalling pathways and mediators involved are not yet completely 
understood (Thackray et al., 2010). 
 
1.5.6  Pulsatile regulation of LH and FSH expression by GnRH 
 
The frequency of GnRH release influences the differential regulation of LH and FSH 
expression in gonadotropes of the pituitary. Low GnRH pulses (>120-240min) 
favour the expression of FSH, while high pulses (<1hour) favour the expression of 
LH (Ferris and Shupnik, 2006). However, to date it is not clear how the pulses 





mechanism by which this occurs appears to include signalling pathways that are 
stimulated or suppressed, transcription factors that are bound and released from the 
promoter of these genes, or proteins (such as transcription factors) that are degraded 
(ubiquitinated) during pulsative GnRH stimulation (Ferris and Shupnik, 2006; 
Tsutsumi and Webster, 2009). Two recent studies by Armstrong et al. (2009 and 
2010) examined the possible mediators that could mediate the pulsatile effect of 
GnRH on gonadotropin expression. The involvement of ERK in FSHβ- and Egr1-
promoter luciferase activity (Armstrong et al., 2010), and of 
Ca
+2
/calmodulin/calcineurin/NFAT pathways on LHβ-, FSHβ- and αGSU-promoter 









Figure 1-8: Schematic representation of the signalling pathways initiated by GnRH-R or EGFR 
resulting in the synthesis and secretion of the gonadotropins. (PKA: Protein Kinase A, AA: AA, 
arachidonic acid, PLD, phospholipase D, iPLA2:calcium-independent phospholipase A2, COX2: 
Cyclooxygenase-2, SNAP25: Synaptosomal-associated protein 25, PGs: Prostagladins, PLCβ: 
Phospholipase beta, MMPs: Matrix metalloproteinases, Hb-EFG: Heparin-binding EGF-like growth 
factor, ECM: extracellular matrix, Ras: RAt Sarcoma, Grb2: Growth factor receptor-bound protein 2, 
CAMK2: Calcium/calmodulin-dependent Protein Kinase II, CDC42: Cell division control protein 42 
homolog, Rac1: Ras-related C3 botulinum toxin substrate 1, Elk1: Ets-like transcription factor-1, 
MEK1/2: MAP Kinase Kinase, MAP3Ks: MAP kinase kinase kinase, CRE: cAMP response elements 
Figure reproduced from Naor., 2009.  
 
 
1.6  FORKHEAD TRANSCRIPTION FACTORS 
 
The FOXO family of transcription factors consists of four members, three of which 
are mammalian, namely FOXO1 (FKHR), FOXO3a (FKHRL1) and FOXO4 (AFX) 





a number of biological processes, including cell-fate decision and tumour 
suppression in a variety of cancers (Fu and Tindall, 2008). FOXOs are generally 
found in their active form in the nucleus where they bind to the promoters of genes 
and modulate their transcriptional activity. FOXOs also constitute an important 
downstream target of the PI3K/Akt and IKK signalling pathways which regulate 
FOXO localisation and transcriptional activity (Hu et al., 2004; van der Horst and 
Burgering, 2007). This regulation is mainly determined by post-translational 
modification such as phosphorylation, acetylation and ubiquitination. FOXO 
regulation is also determined by interaction with co-factors such as β-catenin 
(Burgering, 2008; Gardner et al., 2010; Obsil and Obsilova, 2008).  
 
1.6.1  FOXO structure and function 
 
Each member of the FOXO family consists of four domains; a highly conserved 
DNA binding domain (DBD), a nuclear localization signal (NLS) domain, a nuclear 
export sequence (NES) and a C-terminal trans-activation domain (Obsil and 
Obsilova, 2008) (Fig. 1-9).  
 
FOXO1 and FOXO3a proteins contain approximately 650 amino-acids, and FOXO4 
contains about 500 amino-acids. Analysis of FOXO sequences revealed that several 
regions on FOXO proteins show high levels of similarity (Obsil and Obsilova, 2008). 
 
The DNA binding domain, also called “the winged helix/forkhead domain”, contains 
100 amino acids, and its structure constitutes three α-helices, three small β-strands, 
one wing and the C-terminal α-helix (Obsil and Obsilova, 2008). FOXOs bind via 





demonstrated that the highly conserved helix H3 among the FOXO DBDs acts as the 
main DNA recognition site, while other regions, such as the C-terminal region, the 
N-terminal region and the wing W1 region are also important for DNA-DBD binding 
specificity and stability (Tsai et al., 2007) (Fig. 1-10). 
 
 
Figure 1-9: Structure of FOXO proteins.  
Conserved FOXO domains are shown. Figure reproduced from Obsil and Obsilova, 2008.  
 
The NES, which is involved in the translocation of FOXOs from the nucleus to the 
cytoplasm, consists of a leucine-rich sequence. 14-3-3, a 30kDa protein with a U-
shaped structure, is member of the cellular chaperones that interact with 
phosphorylated residues on proteins, and shuttles them out of the nucleus. 14-3-3 
recognises and binds to Akt-phosphorylated serine and threonine residues of FOXOs 
resulting in the translocation of FOXO/14-3-3 complex into the cytoplasm (Van Der 
Heide et al., 2004). 
 
The NLS domain contains another Akt phosphorylation site. Phosphorylation of this 
site also allows binding of 14-3-3 protein. By masking the NLS domain, 14-3-3 
prevents FOXO re-import from the cytoplasm to the nucleus. The localisation and 
transcriptional activity of FOXOs are also affected by exposure of their domains to 
acetylation and ubiquitination (discussed in Sections 1.6.2.2 and 1.6.2.3) (Obsil and 






Figure 1-10: Structure of FOXO3a and sequence alignment with other FOX proteins.  
(A) Akt/PKB phosphorylation (red) and acetylation (green) sites in FOXO3a. The DBD is coloured 
yellow. (B) Sequence alignment of the DBDs of several FOX proteins (α-helices, black, β-strands, 
yellow). Figures reproduced from Tsai et al., 2007.  
 
1.6.2  Regulation of FOXO transcription factors  
 
1.6.2.1  Phosphorylation 
 
FOXO transcriptional activity is regulated by phosphorylation via a variety of 
signalling pathways. The main regulators of FOXO phosphorylation are the 
PI3K/Akt and IKK signalling pathways. However, other kinases such as the protein 
kinase casein kinase 1 (CK1), serum and glucocorticoid inducible kinase (SGK), and 
dual-specificity regulated kinase 1A (DYRK1A) can also phosphorylate FOXOs 
(Van Der Heide et al., 2004). The phosphorylation, acetylation and ubiquitination 
sites on FOXO1/3a/4 are shown in Figure 1-11. In this section, the role of the 









Figure 1-11: Post-translational modifications of FOXOs.   
The phosphorylation (P: orange), acetylation (Ac: green) and ubiquitination (Ub: blue) sites on 
FOXO1/3a/4 transcription factors (see for details sections 1.3.3.1, 2 and 3). (SGK: serum- and 
glucocorticoid-inducible kinase, cGK1: cGMP-activated kinase, MST1: mammalian sterile 20-like 
kinase 1, DYRK1: Dual specificity tyrosine-phosphorylation-regulated kinase 1, CBP: (CREB)-
binding protein. Figure reproduced from van der Horst et al., 2007.  
 
1.6.2.1.1  The PI3K/Akt signalling pathway  
 
FOXOs are generally found in their active form in the nucleus where they bind to 
promoters and modulate expression. Changes in FOXO transcriptional activity are 
induced by their phosphorylation status at specific sites. In particular, FOXOs 
constitute an important downstream target of the PI3K/Akt signalling pathway. Akt 
phosphorylates FOXOs at specific amino acids (Fig. 1-11), which leads to their 
retention in the cytoplasm, and therefore a significant reduction in their 












 have been mutated to Alanine residues, was 
significantly higher when compared with the transcriptional activity induced by wild 
type FOXO3a (Brunet et al., 1999). This clearly indicates that these Akt 
phosphorylation sites are responsible for the translocation of FOXOs from the 
nucleus to the cytoplasmic, thus reducing their transcription activity (Tran et al., 
2002).  
 
Each of the Akt phosphorylation sites has a specific role in how it affects FOXO 
function (Obsil and Obsilova, 2008). Active Akt phosphorylates FOXOs thereby 
generating two consensus binding sites for the 14-3-3 chaperone protein. The binding 
of 14-3-3 to FOXOs results in their release from the DNA. However, binding of 
FOXOs to 14-3-3 is not sufficient for their translocation to cytoplasm. FOXOs also 
contain the NLS region which is responsible for their localisation to the nucleus. 
Thus, Akt phosphorylation may regulate the translocation of FOXOs to the 
cytoplasm by disrupting the function of the NLS region due to phosphorylation at 
specific sites (Fig. 1-12) (Huang and Tindall, 2007; Tran et al., 2003).  
 
Several kinases including Akt, PKC and JNK also phosphorylate 14-3-3. 
Phosphorylation of 14-3-3 by JNK is able to release FOXO from 14-3-3, even when 
FOXO3a is phosphorylated by Akt. The translocation of FOXOs from the cytoplasm 
to the nucleus is mediated by their de-phosphorylation at the Akt sites, however the 
protein phosphatases that are responsible for this have not yet been identified 





are therefore modulated by two different mechanisms which are opposed to each 
other (Obsil and Obsilova, 2008; Sunayama et al., 2005). 
 
 
Figure 1-12: FOXO movement between nucleus and cytoplasm in response to growth signals. 
The mechanism by which FOXOs translocate from the nucleus to the cytoplasm following Akt 
phosphorylation. 14-3-3 proteins have been postulated to play a direct role in nuclear export of 
FOXO. Following FOXO de-phosphorylation, 14-3-3 is released and FOXO translocates into the 
nucleus. Figure reproduced from Birkenkamp and Coffer, 2003.  
  
1.6.2.1.2  The IKK signalling pathway 
 
FOXO3a can also be phosphorylated by the IKK (Hu et al., 2004). IKK belongs to 
the IKK/NF-κB pathway which appears to be involved in the regulation of FOXO3a 
activity. Hu et al. (2004) demonstrated that FOXO3a was found in the cytoplasm in 
breast tumour cells in the absence of active Akt. This was shown to occur due to 
FOXO3a phosphorylation by IKKβ at Ser
644
, resulting its translocation to the 





recent study, conducted by Chapuis et al. (2010) has also demonstrated IKK-
dependent FOXO3a nuclear exclusion in acute myeloid leukemia (AML) cells. 
FOXO3a nuclear localisation, which was also independent of Akt phosphorylation, 
resulted in its transcriptional inactivation (Chapuis et al., 2010). 
 
IKK is phosphorylated by both the PI3K/Akt and PI3K/PDK1 signalling pathways 
(Fig. 1-13) (Salminen and Kaarniranta, 2010; Tanaka et al., 2005). In particular, Akt 
activates the IKKα kinase by phosphorylating it at Thr
23
 inducing NF-κB activity 
(Ozes et al., 1999), while PDK1, which is activated by Akt, phosphorylates IKKβ at 
Ser
181
, inducing the nuclear translocation of NF-κB complexes, resulting in the 
expression of NF-κB-dependent genes (Tanaka et al., 2005).  
 
Figure 1-13: The PI3K-PDK1-IKK-FOXO and PI3K-PDK1-Akt-FOXO signalling pathways.  
FOXO activity is inhibited by the PI3K/PDK1/Akt, or PI3K/PDK1/IKKα/β signalling pathways. 
FOXOs inhibit NF-κB signalling. Figure reproduced from Salminen and Kaarniranta, 2010.  
 
 
1.6.2.2  Acetylation  
 
FOXO function and translocation is also regulated by acetylation by histone acetylo-





acetylates a variety of proteins (Giannakou and Partridge, 2004). Acetylation of 
FOXOs by SIRT1 leads to their nuclear translocation. Thus, SIRT1 modulates 
FOXO transcriptional activity. Interestingly, the interaction of FOXO and SIRT1 
appears to require the presence of 14-3-3. Indeed, a Caenorhabditis elegans (C. 
elegans) 14-3-3 protein mediates the interaction of SIR-2.1 (the C. elegans ortholog 
of SIRT1) with DAF-16/FOXO (Wang et al., 2006). There are conflicting reports 
with regard to whether de-acetylation of FOXO by SIRT1 increases or decreases 
FOXO activity (Obsil and Obsilova, 2008). The majority of published studies 
suggest that FOXO de-acetylation by SIRT1 enhances its transcriptional activity, and 
increased FOXO-mediated apoptosis or cell-cycle arrest (Daitoku et al., 2004; van 
der Horst et al., 2004). In contrast, de-acetylation has also been reported to suppress 
the transcriptional activity of the three mammalian FOXOs (FOXO1/3a/4) (Motta et 
al., 2004). Overall, although the majority of studies indicate that FOXO de-
acetylation enhances its transcriptional activity, SIRT1 has been proposed to have a 
dual role in FOXO activity (Daitoku et al., 2004), and it is therefore apparent that the 
exact role of FOXO acetylation/de-acetylation requires further investigation (Obsil 
and Obsilova, 2008). 
 
1.6.2.3  Ubiquitination 
 
Another post-translational modification that regulates the transcription of FOXO 
transcription factors is ubiquitination. Ubiquitination is an enzymatic, protein post-
translational modification process which leads to protein degradation by 
proteosomes. A polyubiquitin chain is covalently linked to the protein, and it enters 





2009). The level of FOXO protein in mammalian cells has been demonstrated to be 
regulated by PI3K/Akt-dependent poly-ubiquitylation and proteasome degradation 
processes (Matsuzaki et al., 2003; Plas and Thompson, 2003). For example, in cells 
treated with insulin, FOXO1 levels are reduced due to mono-ubiquitination via a 
Skp-ubiquitin ligase (Vogt et al., 2005). In addition, FOXO3a phosphorylation at 
Ser
644
 by IKK leads to its translocation to the cytoplasm where it is ubiquitinated and 
degraded (Hu et al., 2004). More recently, the MDM2, an E3 ubiquitin ligase, was 
demonstrated to bind to FOXO1 and FOXO3a and promotes their ubiquitination and 
degradation (Fu et al., 2009).  
 
The signalling pathways that regulate FOXO movement between nucleus and 
cytoplasm, and FOXO ubiquitination and degradation are still not well understood. It 
appears that there are competitive signalling pathways that determine the activation 
and inactivation of FOXO transcriptional activity. Reduction of their activity via 
ubiquitination/proteasome-mediated degradation appears to be the mechanism that 
mediates their inactivation (Vogt et al., 2005). 
 
1.6.2.4  FOXO co-factors 
 
FOXOs interact with a variety of co-factors which are involved in regulating their 
transcriptional activity. For example, FOXOs interact with the Runt domain-
containing transcription factor (RUNX3), SMAD3 and SMAD4,  STAT5, androgen 
receptor, estrogen receptor (ERα) and β-catenin, resulting in the regulation of FOXO 
trans-activation potential (Reviewed in Calnan and Brunet. 2008). In this section, 






The first indication that FOXOs bind and interact with accessories proteins came 
from a study by Ramaswamy et al. (2002), which demonstrated that a mutant of 
FOXO1, in which the DBD was disrupted, was still able to effectively regulate 
expression of a specific number of the genes that wild-type FOXO could regulate 
(Ramaswamy et al., 2002). An active interaction between FOXO3a and FOXO4 with 
β-catenin that enhances the transcriptional activity of FOXO4 has been demonstrated 
(Essers et al., 2005). Interestingly, this interaction has a dual role (Hoogeboom et al., 
2008). Binding of β-catenin to FOXOs enhance their transcriptional activity and 
inhibits the T cell factor (TCF) transcriptional activity, since FOXO competes with 
TCF for binding to β-catenin. Interaction between FOXO4 and β-catenin, and 
competition between FOXO4 and TCF for β-catenin binding has also been observed 
in a recent study in various colon cell lines (Kwon et al., 2010). To date, an 
interaction of β-catenin with a number of transcription factors, and among them the 
FOXOs, has been demonstrated, with β-catenin/FOXO interaction resulting in 
enhanced FOXO activity (Hoogeboom and Burgering, 2009).  
 
1.6.2.5  FOXO auto-regulation  
 
FOXO transcriptional activity is regulated by growth factors via the regulatory 
mechanisms described above. However, growth factors also regulate FOXO activity 
by targeting FOXO gene expression (Essaghir et al., 2009). Although the mechanism 
for the regulation of FOXO gene expression is still not clear, transcription factors 
such as E2F1 has been demonstrated to induce the expression of endogenous FOXO1 





decrease the expression of FOXO1, FOXO3a and FOXO4 (Essaghir et al., 2009). In 
addition, FOXO binding sites on the FOXO1 promoter have been identified 
(Essaghir et al., 2009). In particular, FOXO3a regulates the mRNA expression of 
FOXO1 and FOXO4, and FOXO1 is able to regulate its own expression (Essaghir et 
al., 2009). 
 
1.6.3  FOXO-target genes  
 
FOXOs bind the promoters of a variety of genes that are involved in apoptosis (FasL, 
BIM), cell-cycle regulation (p21Cip1, p27Kip1) and oxidative stress resistance 
(GADD45) (Table 1-2). The role of FOXOs in cell function, and several of the 
FOXO-target genes that mediate these functions will be reviewed in this section.  
 
In mammalian cells, the apoptotic response can be mediated through caspase 
activation, via either an intrinsic or extrinsic pathway, depending on the origin of the 
stimuli. There are two types of caspases; the initiator and the effectors caspases 
(Riedl and Shi, 2004). Following external or internal death stimuli, initiator caspases 
are activated, and in turn activate the effectors caspases. The effector caspases are 
then responsible for the proteolytic cleavage of a broad spectrum of cellular targets, 
which subsequently leads to apoptosis (Riedl and Shi, 2004). FOXO activation, 
which leads to nuclear localisation, has been shown to promote apoptosis and cell-
growth inhibition in several cell lines including cerebellar granule neurons, Jurkat T 
lymphocytes, CCL39 fibroblasts and mouse pre-B cell line (Brunet et al., 1999; 
Dijkers et al., 2002; Roy et al., 2010; Srinivasan et al., 2005; Zheng et al., 2002). In 





survival (Srinivasan et al., 2005). However, the majority of studies have reported that 
FOXOs mediates apoptosis via regulating the expression of a number of apoptotic 
genes, including BIM and FasL (Dijkers et al., 2000; Gilley et al., 2003; Kops et al., 
2002a; Peng et al., 2010; Sunters et al., 2003). These studies are summarised in 
Tables 1.3 and 1.4.  
 
 Gene Function References 
Apoptosis BIM Pro-apoptotic activity (O'Connor et al., 1998) 
Apoptosis FasL Triggers apoptosis via Fas receptor  (Imai et al., 1998b) 
G1 cell-cycle arrest p21Cip1 Cell-cycle arrest at G1/S (Seoane et al., 2004) 
G1 cell-cycle arrest p27Kip1 Cell-cycle arrest at G1/S (Nakamura et al., 2000) 
G2 cell-cycle arrest GADD45 Mediates G2/M arrest (Tran et al., 2002) 
DNA repair GADD45 Mediates DNA repair (Tran et al., 2002) 
Table 1-2: FOXO-target genes and their functions. 
FOXOs bind to and regulate the promoters of genes that are involved in cell proliferation, either by 
regulating cell-cycle progression or by promoting apoptosis.  
 
1.6.3.1  BIM 
 
BIM is a pro-apoptotic member of the Bcl-2 family which includes anti- and pro-
apoptotic factors (O'Connor et al., 1998). BIM contains a BH3 domain which allows 
the formation of hetero-dimers with other anti-apoptotic Bcl-2 members, neutralising 
their function (Dijkers et al., 2000). Following activation, BIM induces the release of 
apoptogenic factors (cytochrome c, Smac/Diablo homolog, Omi) from the 
mitochondria, which in turn, activate caspase 9. Caspase 9 then triggers a cascade of 





therefore participates in the intrinsic apoptotic pathway that is mediated by 
mitochondria (Riedl and Shi, 2004). 
 
1.6.3.2  FasL 
 
The pro-apoptotic FasL gene, which participates in the extrinsic apoptotic pathway, 
is a trans-membrane protein that induces apoptosis via the binding to the Fas receptor 
(Brunet et al., 1999; Fu and Tindall, 2008) (Fig. 1-14). This binding recruits further 
cytoplasmic factors, including the FAS-associated death domain (FADD) and 
caspase 8, forming a death-inducing signalling complex. Formation of this complex 
leads to the activation of caspase 8, which then cleaves and activates caspase 3.  
 
1.6.3.3  p21Cip1 and p27Kip1 
 
FOXOs are involved in cell-cycle regulation, since over-expression of FOXO1 and 
FOXO3a induce cell-cycle arrest at the G1/S and G2 phases (Dijkers et al., 2000; 
Medema et al., 2000; Ramaswamy et al., 2002; Schmidt et al., 2002). FOXOs 
mediate cell-cycle progression via the regulation of cyclin dependent kinases (Cdks). 
The Cdk family includes the cell-cycle activators, cyclin D1 and cyclin D2, that 
promote cell-cycle progress, and which inhibit the cell-cycle inhibitors, p27Kip1 and 
p21Cip1 which block cell-cycle progress (Table 1-5). FOXOs regulate cell-cycle 
arrest at G1/S either by repressing cell-cycle activators, cyclin D1 and cyclin D2 or 
by activating the cell-cycle inhibitors, p21Cip1 and p27Kip1 (Dijkers et al., 2000; 






Figure 1-14: FOXO-induced apoptosis by FasL and BIM.  
FOXOs bind to the FasL promoter and up-regulates its expression. FasL then binds to the Fas receptor 
which leads to the formation of a complex which includes FADD and caspase 8. Activated caspase 8 
activates caspase 3 and subsequently induces apoptosis. FOXOs also bind to the promoter of the BIM 
gene and up-regulate its expression. This leads to increased mitochondria permeability and several 
proteins are released into the cytoplasm, including cytochrome c. Cytochrome c binds and activates 
protein apoptotic protease activating factor 1 (APAF1), and forms the apoptosome which mediates the 
activation of caspase-9. (TRAIL: [TNF-related apoptosis inducing ligand, DR4,5: Death Receptor 4,5, 
Bcl-XL: B-cell lymphoma-XL, bNIP-3: BCL2/adenovirus E1B 19 kDa protein-interacting protein 3, 
Apaf1: Apoptotic protease activating factor 1, CARD: caspase recruitment domain) Figure reproduced 








Table 1-3: FOXO3a and FOXO1 regulate the expression of BIM gene in different cellular environments. 
This table summarises the effect of FOXO over-expression on BIM expression in different cell lines. The effect on FOXO transcriptional activity in response to different 














 Ba/F3 cells 
 
Increases BIM mRNA level and 
protein expression   
IL-3
(1)
 deprivation, BIM expression 
increased steadily  
  
In lymphocytes, BIM is the dominant transducer of 
death signals by controlling its expression level via 
cytokine-mediated regulation of forkhead 
transcription factors 
















, causes FOXO3a inactivation via 
the PI3K/Akt signalling pathway and 
therefore reduction of BIM mRNA 
expression 
FOXO transcriptional activity contributes to NGF 
withdrawal–induced death in sympathetic neurons 
 









MCF-7 and MDA 
MB-231 cells  
 
FOXO3a directly activates the 
BIM promoter in MCF-7 but has 
a minor effect in MDA MB-231 
Paclitaxel, there is an up-regulation of 
FOXO3a activationwhich can result in 
increased levels of BIM mRNA and 
protein 
 
Paclitaxel-induced FOXO3a transcriptional activity 
increases BIM expression which could result in 
apoptosis in MCF-7 but not in MDA-231 breast 
cancer cells  
 








 DL23 and Ba/F3 
cells 
Activation of FOXO3a in DL23 
cells does not up-regulate BIM 
expression, but does in Ba/F3 
cells 
No data  No data 








 Cells from the 
neural region of 
zebrafish embryo 
Loss-of-function of FOXO3a 
induces BIM expression 
No data  Loss-of-function of FOXO3a causes an increase of 
apoptotic cells in the neural region of zebrafish 
embryo 
























, the expression of the FasL-promoter 
luciferase reporter gene was significantly 
reduced by FOXO3a, via of PI3K/Akt 
signalling pathway  
FOXO3a induces apoptosis by induction of FasL pathway in 







 Glioma cells  
 




, expression of FasL-promoter 
luciferase reporter gene may be regulated by 
FOXO1, via PI3K/Akt signalling pathway 
Inhibition of Akt signaling may be critical for Forkhead-dependent 
up-regulation of FasL expression in glioma cells, but activation of 
other transcription factors  is required to induce FasL expression 
and cell death 
(Ciechomska 














No data  IKK-dependent repression of FOXO3a can promote cell growth 
and tumorigenesis  
 




IL-3 : Interleukin 3 
(2)
NGF : Nerve growth factor 
(3)
IGF1 : Insulin-like growth factor 1 
(4)
CsA : cyclosporin A 
Table 1-4: FOXO3a and FOXO1 regulate the expression of FasL gene in different cellular environments. 
This table summarises the effect of FOXO over-expression on FasL expression in different cell lines. The effect on FOXO transcriptional activity in response to different 






















tumor cell)  
FOXO1 Increases 
p27Kip1 mRNA level 
and prolonged the half 
life of p27Kip1 protein  
No data  Low level of p27Kip1 in PTEN-null cells 
may arise as a consequence of a lack of 










 Ba/F3 cells  
 
FOXO3a increases 
p27Kip1 promoter  
activity  
 
IL-3, there is inhibition of p27Kip1 transcription through 
PI3K-induced FOXO3a phosphorylation 
 
Repression of p27Kip1 levels through Akt-
mediated FOXO3a phosphorylation may be 
necessary for cytokine-mediated survival 
and proliferation 












p27Kip1 expression  
No data  No data 
(Martinez-Gac 












No data  No data  












Nuclear accumulation of 
FOXO3a increases 
p27Kip1 expression  
Insulin, serum or growth media, the mRNA expression level 
of p27kip1 was significantly reduced (compared with 
treatment with the starving control medium) 
TSH
(5)
, mRNA expression of p27kip1 did not significantly 
alter compared with starved controls 
No data  
(Karger et al., 
2009) 
 
Table 1-5: FOXO3a and FOXO1 regulate the expression of p27Kip1 gene in different cellular environments. 
This table summarises the effect of FOXO over-expression on p27Kip1 expression in different cell lines. The effect on FOXO transcriptional activity in response to different 

























oxidative stress, FOXOs increases GADD45 (in HeLa cells) 
 
FOXOs play a key role 
in the regulation of G2 
checkpoint by inducing 
GADD45 (in HeLa cells) 
(Furukawa-












No data  No data  















in Thyroid cancer 
cells 
 
oxidative stress, activates FOXO3a in thyrocytes with JNK (MAPK8)-mediated 
nuclear accumulation of FOXO3a and increased expression of GADD45A 
TSH, there is nuclear accumulation of FOXO3a, together with a decrease in 
GADD45A mRNA expression 
insulin, there is a cytoplasmic accumulation of FOXO3a in line with increased 
expression of GADD45A 
No data  
(Karger et al., 
2009) 
 
Table 1-6: FOXO3a and FOXO1 regulate the expression of GADD45 gene in different cellular environments. 
This table summarises the effect of FOXO over-expression on GADD45 expression in different cell lines. The effect on FOXO transcriptional activity in response to different 
stimuli, and the biological significance of FOXOs in different cellular environments are also shown.  
 (5)








1.6.3.4  GADD45 
 
FOXO3a also induces expression of the GADD45 gene (Furukawa-Hibi et al., 2002; 
Tran et al., 2002). GADD45 belongs to the family of growth arrest and DNA damage 
(GADD) proteins which comprises of five members, the GADD45α, GADD45β, 
GADD45γ, GADD34 and GADD153 (Reddy et al., 2008). However, GADD45α 
(also referred as GADD45) is the most well-characterised member, and its induction 
and subsequent effects will be reviewed in this section.  
 
GADD45 is a 18.4KDa protein which mediates G2/M arrest, DNA repair and 
apoptosis. Following exposure to UV or ionising radiation, GADD45 gene 
expression is induced by p53-independent or p53-dependent mechanisms 
respectively (Yang et al., 2009). When the GADD45 promoter is activated by p53, 
GADD45 interacts with and activates MTK1, a MAP3K with a unique N-terminal 
regulatory domain, which in turn activates the JNK and p38MAPK to induce cell-
growth inhibition and apoptosis (Sheikh et al., 2000; Yang et al., 2009). In addition, 
following cellular stress response, GADD45 gene expression is induced by FOXO3a 
resulting in the initiation of DNA repair pathways (Tran et al., 2002). GADD45 also 
binds other regulatory proteins in order to exert its function. Specifically, p21Cip1 
binds to the central region of GADD45. The biological significance of this 
interaction remains unclear, however this interaction suggests a cross-talk between 
these two important cell-cycle regulators that act at different stages of the cell-cycle 
(Yang et al., 2009). GADD45 also binds to Cdc2, and inhibits the activity of 
Cdc2/Cyclin B1 complex, which results in cell-cycle arrest at G2/M (Taylor and 





activation down-regulates the expression of GADD45, via the regulation of another 
transcription factor, c-myc. Thus c-myc gene expression is activated by NF-κB, 
however the mechanism by which c-myc represses GADD45 gene expression is not 
yet well understood (Rosemary Siafakas and Richardson, 2009; Yang et al., 2009). 
 
1.6.4  Cell-type specific FOXO activity 
 
Activation of FOXOs mediates different biological effects dependent on intracellular 
environment (these different biological effects are summarised in Tables 1-3, 1-4, 1-
5 and 1-6). For example, although activation of FOXOs induces apoptosis in some 
cell lines (Brunet et al., 1999), they can induce cell-cycle arrest in others (Furukawa-
Hibi et al., 2002). In addition, activation of FOXOs differentially effects the 
regulation of specific target genes in a variety of cell types. For example, FOXO3a 
activation increases BIM mRNA expression in Ba/F3, MCF-7 and MDA MB-231 
cell lines (Dijkers et al., 2000; Gilley et al., 2003), whereas decreases BIM 
expression in cells derived from neural region of zebrafish embryo (Peng et al., 
2010). A mechanism of gene regulation by FOXO transcription factors has been 
suggested, which could explain the differences in the effect of FOXOs at specific 
genes (Ramaswamy et al., 2002). In particular, utilising gene expression profile 
analysis, FOXOs were found to regulate two types of genes; genes that require 
FOXO binding, and genes that are regulated independently of FOXO binding to their 
promoters. In the latter case, FOXOs interact with other transcription factors to 
modulate their activities. Therefore, the cellular environment is important for 
determining the functional effect of FOXOs in different cell types (Birkenkamp and 





1.6.5   The role of FOXOs in cancer progression 
 
FOXO phosphorylation by PI3K/Akt, IKK or ERK signalling pathways, leads to 
FOXO inactivation by their exclusion from the nucleus, and subsequently their 
degradation. Inactivation of FOXOs, either by chromosomal deletion of the FOXO 
gene or by cytoplasmic localisation, is associated with a variety of cancers, including 
breast cancer, prostate cancer and leukemia (Yang and Hung, 2009). Indeed, 
FOXO3a activation not only promotes apoptosis in vitro but also restricts tumour 
growth in vivo, in breast cancer cells (Yang and Hung, 2009). Furthermore, 
constitutively active FOXO4 reduces tumour size (Greer and Brunet, 2005).  
 
Thus, activation of FOXOs could be a potential anticancer therapeutic strategy. An 
advantage for targeting FOXO activation is that FOXO3a mutations have not been 
found in human cancers. Therefore, activation of functional FOXO3a could be 
sufficient to target tumour suppression. A number of FOXO3a-activating target drugs 
have been developed, including paclitaxel for breast cancer treatment and KP372-1 
for treating acute myeloid leukemia (Ho et al., 2008; Yang and Hung, 2009). 
 
1.6.6  FOXO knock-down mice 
 
Although in vitro studies have revealed many functions for FOXOs in diverse cell 
lines, animal studies have also been conducted in order to further understand the role 
of the specific FOXO sub-types. FOXO null mice, FOXO knock-down mice targeted 
in specific tissues, transgenic mice that over-express particular type of FOXO, or 
mice with disrupted FOXO genes in somatic cells have been generated. The 










 null mice Embryonic lethal phenotype due to incomplete 
vascular development 
(Nakae et al., 2002) 
FOXO1
+/-
 mice Has a role in a negative regulator of insulin 
sensitivity 
(Nakae et al., 2002) 
FOXO3a-null mice Show age-dependent infertility and suppressed 
follicular activation  
(Castrillon et al., 2003) 
FOXO3a-null mice Inreased lympho-proliferation and wide-spread 
organ inflammation 
(Lin et al., 2004) 
FOXO4-null mice No histological abnormalities and normal in 
appearance 
(Hosaka et al., 2004) 
FOXO1/3/4 deletion  Show metastatic cancer (Paik et al., 2007) 
 
Table 1-7: The phenotype observed in FOXO knock-down in mice 
 
1.6.7  FOXO transcription factors and LH  
 
A role for FOXO3a in regulating LH levels was demonstrated in vivo in a study 
conducted by Castrillon et al (2003) in which female FOXO3a knock-down mice 
(FOXO3a-/-) were generated. The FOXO3a-/- mice were viable and showed age-
dependent infertility with no histological abnormalities of the pituitary tissues. 
However, serum LH levels were lower compared to control FOXO3a+/+ mice. 
Therefore, the effect of FOXO3a knock-down with regards to mice infertility was 
assessed. Since FOXO3a knock-down was not specific to the pituitary, the infertility 
of FOXO3a-/- mice could be due to the effect of FOXO3a knock-down on ovarian 
function. However, administration of gonadotropins induced ovulation and restored 
fertility, suggesting that FOXO3a is not required for gonadotropin responsiveness at 








Thesis aims and objectives: 
In Chapter two, the regulation of FOXO transcriptional activity following GnRH-R 
activation is investigated. Since the transcriptional activity of FOXO is determined 
by post-translational modifications and the action of co-factors, such as β-catenin, the 
role of these post-translational modifications and the involvement of β-catenin are 
characterised. Finally, the role of FOXOs in targeting the expression of several 
FOXO-target genes is assessed. In Chapter three, the role of FOXO3a in the GnRH-
induced cell-growth inhibition was examined, by targeting genes that are involved in 
apoptosis and cell proliferation, such as GADD45 and FasL. 
 
In Chapter five, the role of FOXO1 and FOXO3a in GnRH-induced expression of 
LHβ, FSHβ and the GnRH-R in gonadotropes is examined. The expression of 
FOXO3a and FOXO in human pituitary gonadotropes is also examined, and a role 
for FOXO3a in the regulation of LHβ expression in response to GnRH treatment is 
highlighted. In addition, the regulation of Egr1 expression via a FOXO3a-dependent 
signalling pathway was demonstrated. Chromatin immunoprecipitation (ChIP) assays 
were used to assess FOXO3a recruitment to Egr1 and LHβ promoters. FOXO3a 
targets Egr1 expression to, at least in part, indirectly regulate LHβ promoter activity. 
These findings suggest that GnRH regulates LHβ-subunit expression through one or 













































2.1  MAMMALIAN CELL CULTURE  
 
2.1.1  Cell Media  
 
HEK293 embryonic kidney cells (originally obtained from ATCC) stably expressing 
the rat Type I GnRH-R (designated SCL60 (Stable Cell Lines)) were generated 
within our laboratory (Anderson et al., 1995). Cells were maintained in complete 
medium (as described in the table below) supplemented with G418 (Sigma) (unless 
otherwise specified, all materials utilised in this study, were supplied from Sigma) 
and plasmocin (all cell lines were grown at 37
o
C in a humidified 5% CO2 
atmosphere unless otherwise indicated). 
 
LβT2 mouse gonadotrope cells (obtained from P. Mellon, University of California) 
were maintained on complete medium. LβT2 cells were grown on Matrigel (BD 
Biosciences) coated plastic flasks.  
 
WPE1-NB26-3 prostate cancer cells (WPE1-NB26 cell line originally obtained from 
ATCC and clone 3 was made by Dr. Kevin Morgan) stably expressing the rat Type I 
GnRH-R were generated in our laboratory. These cells were maintained in serum-
free keratinocyte medium (Invitrogen) (Keratinocyte-SFM containing BPE (bovine 
pituitary extract) (25μg/ml), rEGF (Rat Epidermal Growth Factor) (0.1-0.2ng/ml) 








Complete Media:  
 Dulbecco’s modified Eagles medium (DMEM) 
 10% fetal calf serum 
 2% glutamine 
 1% penicillin (10,000 units/ml) / streptomycin (10,000 units/ml) 
 
Starving Media (Serum Free Media):  
 Dulbecco’s modified Eagles medium (DMEM) 
 2% glutamine 
 1% penicillin (10,000 units/ml) / streptomycin (10,000 unit/ml) 
 
2.1.2  Sub-culturing of cells  
 
SCL60 and LβT2 cells were grown until they were 80-90% confluent. The medium 
was removed and cells washed twice with Dulbeccos Phosphate Buffered Saline 
(PBS). 2ml of 1x trypsin was added to each 162cm
2
 flask and the flask return to the 
incubator (for 3-5 minutes at 37
o
C) until the cell monolayer detached. Trypsin was 
inactivated by adding 8ml of complete medium. The cells then were plated on a 
162cm
2 
plate at a ratio of 1:5. Cells were counted in a haemocytometer and were 




PWE-1-NB26-3 cells were grown until they were 80-90% confluent. The medium 
then was removed and washed twice with PBS. 2ml of 1x trypsin was added to each 
162cm
2
 flask and the flask returned to the incubator (for 10minutes at 37
o
C) until the 
cell monolayer detached. Trypsin was inactivated by adding 8ml (0.1% in PBS) 
trypsin inhibitor (Invitrogen). The cell suspension was centrifuged at 500 x g for 2 
minutes at room temperature. The cell pellet was gently re-suspended in 8ml of 
serum-free keratinocyte medium containing BPE (25μg/ml) and rEGF (0.1-0.2 








2.1.3  Cryopreservation of cells  
 
Cells from a confluent (~80% confluent) dish were trypsinised and the trypsin 
inhibited as described above. Cells were then pelleted at 500 x g for 2 minutes to 
remove residual trypsin. The resulting pellet was re-suspended in cryoptotectant 
(10% dimethylsulphoxide (DMSO) (v/v) in fetal calf serum). Cells were transferred 
to cyrotubes and frozen at -80
o
C. The tubes were then transferred to liquid nitrogen 
after 48 hours.  
 
2.1.4  Recovery of frozen cells 
 
Cells were removed from liquid nitrogen storage and thawed rapidly at 37
o
C. They 
were re-suspended in complete medium, and then were pelleted at 500 x g for 2 
minutes. The cell suspension was added to 9ml of complete medium and seeded into 
an appropriate culture vessel. 
 
2.1.5  Generation of stable FOXO3a knock-down SCL60 and PWE-1-
NB26-3 lines, and LBT2 transient FOXO3a knock-down cell lines 
 
In order to examine the effect of FOXO3a in different cellular processes in response 
to GnRH, stable and transient FOXO3a knock-down cell lines were generated. A 
lentiviral-based delivery system was utilised. Mission shRNA Plasmid DNA 
(pLKO.1-pure vector system; the mission vector has a U6 promoter) 
(http://www.sigmaaldrich.com/etc/medialib/docs/ Sigma/ Bulletin/ shc001bul.Par 
.0001.File.tmp/shc001bul.pdf) was used, and were transfected into lentivirus using 
the Mission Packaging Mix (http://www.sigmaaldrich.com/ etc/ medialib /docs 





Brown (MRC HRSU Unit, Edinburgh). Using this system allowed efficient lentiviral 
infection and integration of the specific shRNA construct into cells mediating life-
long gene specific silence. This happens because the lentivirus used was a non-
replicating virus. The basic principle is that these viruses after a single round of 
infection ensure stable integration of the transgene with only a minimal component 
of viral genome, so that the transgene (in this case the shRNA) continuously 
expresses but the infectious virus is not generated in order to infect the cells again. 
This is achieved by selectively splitting the different components of the viral genome 
into 3-4 separate plasmid vectors which are needed in order for a new virus to be 
generated (Manjunath et al., 2009).  
 
Before using the lentiviral shRNA system, pilot experiments were performed 
whether that lentiviral infection caused any change in cell number. Cells were seeded 
at density of 1x10
6 
in 60mm plates with 5ml complete medium. The next day, 
medium was removed and cells were infected with different titres of GFP-lentivirus 
and were incubated for 24 hours at 37
o
C in a 5% CO2 humidified incubator. The 
next day, medium with the GFP-lentivirus was removed and was replaced with fresh 
complete medium. After 1,2,3,4 and 5 days of incubation cells was visualised with a 
Zeiss Axioskop microscope. The results showed that lentiviral infection caused no 
change in cell number The most effective ratio of virus:cells for maximal 
transduction was also assessed. 
 
Stable and transient FOXO3a knock-downs using the shRNA lentivirus system were 







 cells were seeded in complete medium in a 6-well plate and were incubated for 
24 hours. Complete medium was removed and 2ml of shRNA lentivirus or scrambled 
shRNA lentivirus in DMEM (negative control) (1:2 cells/virus) plus 3ml of complete 
medium was added to the cells, and cells were incubated for a further 24 hours at 
37
o
C. Virally transduced cells were trypsinised and re-seeded into 60mm plates with 




Transient knock-down: (LBT2 cells) Cells were harvested and were assayed for 
interference of the target genes over 1, 2, 4 and 5 days. Western Blot analysis was 
performed in order to detect clones with significant reduction of FOXO3a protein 
level. Cells with the higher knock-down (i.e. with the most reduced target protein 
level) were used for further experiments. 
 
Stable knock-down: (SCL60 and PWE-1-NB26-3 cells) The medium was removed 
and replaced with fresh medium containing puromycin (3µg/ml) for selection of 
transduced cells. The medium was replaced with fresh, puromycin-containing 
medium every 3-4 days until resistant colonies could be identified. The colonies were 
picked using glass cloning cylinders, and these cells were seeded in a new plate with 
fresh puromycin containing complete medium. Generally, 10-12 days after colony 
selection, when plates were about 80% confluent, cells were trypsinised and split into 
two plates. Cells from the first plate were allowed to grow to confluency and were 
cryopreserved. Cells from the second plate were assessed for FOXO3a protein level 
by Western Blot analysis. Cells with the higher knock-down (i.e. with the most 
reduced target protein level) were used for further experiments. The shRNAs used to 










































































Table 2-1: shRNA sequences against human and mouse FOXO3a gene 
 
2.1.6  DNA transfection of mammalian cells 
 




SCL60 were transfected with Superfect® Transfection reagent (Qiagen) using 6µl of 
Superfect® per 1µg of plasmid DNA. The day before transfection 2x10
6 
cells were 
seeded into 100mm dishes in complete medium and were incubated overnight. Cells 









incubated at room 
temperature for 










Table 2-2: Mixture for Superfect® transfection 
 
Prior to transfection, medium was removed and cells washed twice with PBS. After, 
DNA/Superfect complexes had formed, the transfection mixture was added to the 
cells with complete medium in a total volume of 3ml. The transfection mix was left 
on the cells in the incubator for 3 hours. Subsequently, cells were washed twice with 
PBS, and fresh complete medium was added. Cells were then incubated at 37
o
C 
overnight before experiments were carried out.    
 




LβT2 cells were transfected with Fugene® reagent (Roche) using 6µl of Fugene® 




were seeded into 100mm dishes and 
incubated overnight. The following day cells were transfected with the following 
mixture (per 100mm dish): 
 
 
incubated at room 
temperature for 
30mins prior to 
transfection 








Table 2-3: Mixture for Fugene® transfection 
 
Prior to transfection, medium was removed and cells were washed twice with PBS. 
After DNA/Fugene complexes had formed, the transfection mixture was added to the 





on the cells in the incubator for 3 hours, then 7mls of complete medium was added to 
the cells and they were left for overnight incubation before experiments were carried 
out.  
 
2.1.6.3  Dual light reporter gene luciferase assay 
 
Luciferase assay is used in order to assess the transcriptional activity of a gene. In 
particular, cells are transfected with a construct containing the luciferase gene under 
the control of a promoter of interest. The detected luciferase activity is used in order 
to assess the transcriptional activity of the gene of interest.  
 
Transient transfections with luciferase reporter constructs, or co-transfection with 
various mutant constructs or vector controls where appropriate, as well as with a 
renilla luciferase construct to control for transfection efficiency, was performed using 
Superfect® reagent for SCL60 cells and Fugene® reagent for LβT2 cells, as 
described above (Sections 2.1.6.1 and 2.1.6.2). Transfected cells from 100mm plates 
were seeded into 12-well plates and after 6 hours the complete medium was removed 
and replaced by starving medium with or without ligand as dictated by the length of 
ligand stimulation. For stimulations of 8 hours or less complete medium was 
replaced by starving medium and cells were serum starved overnight. The following 
day starving medium was replaced by starving medium containing the appropriate 
concentration of ligand for cell treatment.    
 
Luciferase assays were performed with Dual-Luciferase Reporter Assay System 
(Promega) according to manufacturer’s instructions using a FLUOStar Optima 





units relative to the activity observed in the non-stimulated control cells and was 
normalized for Renilla luciferase activity.  
 
 
2.2  IMMUNOFLUORESCENCE CONFOCAL MICROSCOPY 
 
SCL60 cells were plated in eight-well Chamber Slides (Lab-TEK) at a density of 
2×10
5
 cells per well. Cells were cultured in starving medium for 24 hours before cell 
stimulation with 1μM of GnRH I. After stimulation, cell monolayers were washed 




) and then fixed in 200μl of 100% methanol 
(MeOH) at –20°C for 10 minutes. Following fixing, monolayers were washed in PBS 
and incubated for 30 minutes in an NP-40 based cell permeabilisation buffer (PBS, 
10% fetal calf serum, 1% bovine serum albumin, 0.2% NP-40) at room temperature. 
After permeabilisation, fixed cells were blocked in a PBS-based blocking solution 
(PBS, 10% fetal calf serum, 1% bovine serum albumin) for 1 hour at room 
temperature or 16 hours at 4°C. To visualise the proteins, 100μl of primary antibody 
(1:100) per well was added and slides were incubated overnight at 4
o
C. The next day, 
cells were washed twice with PBS and were visualised using an Alexafluor 
(Molecular Probes, Invitrogen) Goat-Anti-Rabbit (488nM) secondary antibody 
(1:200 dilution). After incubation for 1 hour, slides were washed twice with PBS and 
incubated with 4’,6-diamidino-2-phenylindole (DAPI 1:2000) for 5 min and then 
washed three times with PBS. Slides were mounted in Permafluor fixative 
(Immunotech). Confocal laser microscopy was performed on a Zeiss LSM510 laser 






2.3  DNA MANIPULATION 
 
2.3.1  Plasmid constructs 
 
Plasmids used in this study are listed in Table 2-4: 
Plasmid  Vector Reference/source 
FLAG-FOXO1 (pCMV5) 






HA-FOXO3a-TM delta CT 
HA-FOXO3a-WT delta CT 




















































Prof. Domenico Accili (Kitamura YI et al., 2005) 
Prof. Domenico Accili (Kitamura YI et al., 2005) 
Prof. Michael Greenberg (Brunet A et al., 1999) 
Prof. Michael Greenberg (Brunet A et al., 1999) 
Prof. Michael Greenberg (Brunet A et al., 1999) 
Prof. Michael Greenberg (Brunet A et al., 1999) 
Prof. Michael Greenberg (Brunet A et al., 1999) 
Prof. Michael Greenberg (Tran H et al., 2002) 
Prof. Michael Greenberg (Tran H et al., 2002) 
Prof. Michael Greenberg (Tran H et al., 2002) 
 
Prof. Michael Greenberg (Tran H et al., 2002) 
Prof. Michael Greenberg (Tran H et al., 2002) 
Prof. Michael Greenberg (Brunet A et al., 2004) 
Prof. Michael Greenberg (Brunet A et al., 2004) 
Prof. Michael Greenberg (Brunet A et al., 1999) 
Tatsuo Furuyama, University of Osaka (Furuyama et 
al., 2000) 
Invitrogen 
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh  
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh 
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh 
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh  
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh  
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh  
Dr. Pamela Brown, MRC HRSU Unit, Edinburgh 
(Larder et al, 2006) 
W. Miller, North Carolina States University, Raleigh 
(Huang et al., 2001) 
J.N.Laverriere, Universite Pierre et Marie Curie, 
Paris (Pincas et al., 2001) 





2.3.2  Transformation of competent E.Coli 
 
10ng of DNA was mixed with OneShotTop10
®
 E.coli for 30 minutes on ice. Then, 
bacteria were shocked at 42
o
C for 30 seconds and immediately returned to ice for 2-3 
minutes. 200μl of S.O.C (Super Optimal broth with Catabolite repression) medium 
was added and the mix was incubated at 37
o
C for approximately one hour. 10μl of 
this medium was spread out on Luria Broth (LB)-agar plates containing the selective 
antibiotic (Ampicillin - stock solution 50mg/ml) and incubated over-night (maximum 
incubation 16 hours). If DNA plasmid has already been transformed into bacteria and 
stored as a glycerol stock, then recovery of bacteria from that glycerol stock is 
required. To recover the bacteria, a small amount of the bacteria were streaked out on 
a LB-agar plate containing selective antibiotic and incubated overnight at 37
o
C 
(maximum incubation 16 hours).   
 
2.3.3  Extraction and purification of plasmid DNA 
 
A single bacterial colony was picked from agar plates and incubated in 15ml of LB 
medium containing the appropriate selective antibiotic, at 37
o
C overnight with 
shaking (maximum incubation 16 hours). After overnight incubation 5ml of this 
culture was used to inoculate 250ml of fresh antibiotic containing LB medium, for 
overnight growth at 37
o
C with shaking (maximum incubation 16 hours). Plasmid 
DNA was purified using Quiagen maxi-preparation columns and eluted using TE 
(Tris-EDTA) buffer according to the manufacturer’s instruction (QIAGEN
®
 Plasmid 







2.3.4  DNA quantification 
 
DNA concentration and quantity was determined using the Nanodrop (Nanodrop 
Technologies, Delaware).   
 
2.3.5  Preparation of glycerol stocks of transformed bacteria  
 
500μl of the bacterial culture (which had grown overnight at 37
o
C) was mixed with 




2.4  RNA MANIPULATION  
 
2.4.1  Total RNA extraction  
 
Cells were seeded at density of 2x10
6
 per 60mm dish and were incubated overnight. 
Next day, cells were stimulated for the appropriate time with ligand (GnRH I or D-
Tpr
6
-GnRH I). After treatment, medium was removed and RNA was extracted with 
“Total RNA Isolation Reagent” (TRIR; Abgene) according to the manufacturer’s 
instructions. Briefly, 1ml of TRIR was added to each plate. TRIR was left on the 
plate on ice for 5 minutes to lyse cells completely. Lysed cells were transferred to a 
MaXtract
TM
 High Density Gel tube (Qiagen) with 200μl of chloroform, vortexed and 
incubated on ice for 10 minutes. The MaXtract
TM
 was centrifuged at 8000 x g for 15 
minutes at 4
o
C allowing the gel to create a solid barrier between the lower phenol 
layer and the upper aqueous phase, which contains the nucleic acid. The aqueous 
phase was transferred to a clean tube and 0.5ml of iso-propanol was added to each 
tube. The tubes were vortexed and RNA allowed to precipitate in ice for up to one 
hour. Then, the samples were centrifuged at 8000 x g for 15 minutes at 4
o





supernatant was removed carefully so as not to dislodge the RNA pellet. 0.2ml of 
70% ethanol was added to each tube and the samples were centrifuged at 8000 x g 
for 5 minutes at 4
o
C. Ethanol was removed and the RNA pellet, which was formed, 
was allowed to dry. The pellet was re-suspended in an appropriate volume of RSB 
(RNA Storage Buffer). RNA was stored at -80
o
C.            
 
2.4.2  Quantitative Real Time PCR (qRT-PCR) 
 
2.4.2.1  Reverse Transcription for quantitative RT-PCR - cDNA synthesis  
 
The single strand of RNA that was isolated, was used as a template in order to 
produce cDNA. RNA was diluted to 50ng/µl in RNase free water. Then, 4µl of the 
diluted RNA was added to a 200µl thin-walled PCR tube (Adgene). 6µl of the 
mastermix (Table 2-5) was added to each sample and placed in the BioRad DNA 

















C  hold 
 
Samples were then stored long term at -20
o
C. For each PCR reaction two types of 
controls were used; one in which the reverse transcriptase was not added in order to 
check for genomic DNA contamination and a second in which water (H2O) was 
added to the Reverse Transcriptase PCR reaction instead of RNA to check for 







Mastermix (to give a 20µl reaction mix): 
5X Vilo Reaction Mix (Invitrogen) 
10X Superscript
®







Table 2-5: Mastermix for RT-PCR reaction 
 
2.4.2.2  Designing primers for qRT-PCR 
The primers and probes sequences are listed in the Table 2-6 in the following page. 















LHβ promoter (F) 
LHβ (distal upstream region of the LHβ gene) (F) 
Erg1 promoter (F) 






































Table 2-6: Primers and probes used for PCR amplification of DNA 













2.4.2.3  qRT-PCR  
 
DEPC water was added to the cDNA to give 8ng/µl equivalent input starting RNA. 
The stock solutions of primers and probes were made up with sterile water at 
concentrations of 100µM and 50µM respectively. The primers and probes were then 
diluted in sterile water before use to 250nM and 900nM respectively. Then, a 
“primers and probe mix” was used in order to make the mastermix for the RT-PCR 
reaction:  
 










Table 2-7: Mastermix used for the RT-PCR reaction 
 
The samples were mixed and 19µl was added in triplicate to a 96-well plate (Applied 
Biosystems). The expression of each gene was normalized for RNA loading for each 
sample using 18S rRNA as an internal standard. Data was analysed using the ΔΔCT 
method. 
 
2.5  PROTEIN ANALYSIS 
 
2.5.1  Total protein extraction  
 
Following ligand stimulation, cell monolayers were placed on ice, washed once with 




) and lysed in an NP40-based solubilisation buffer 
(250mM NaCl, 50mM HEPES, 0.5% Nonidet P-40, 10% glycerol, 2mM EDTA pH 





fluoride and 1mg/ml leupeptin). Total proteins were extracted from solubilised 
lysates by centrifugation at 20,000 x g for 12 minutes. 
 
2.5.2  Immunoblotting 
 
Total protein extracts were mixed with an equal volume of 2x Laemmli Sample 
buffer (LSB) (10% (w/v) SDS, 5% (v/v) β-mercaptoethanol, 10% (v/v) glycerol, 
2.5% (v/v) 1M Tris (pH 7.0), 2.5% (v/v) distilled H2O), and were resolved by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) before being transferred to PVDF 
membrane (NEN Life Sciences) for protein immunoblotting. The amount of proteins 
loaded on the gel lanes, within any single experiment were constant. However, the 
loading volumes of homogenized protein were varied according to what was 
appropriate for cell number and protein abundance in each different experiment. 
PVDF membranes were blocked in 4% bovine serum albumin, 50mM Tris-HCl, pH 
7.0, 0.05% Tween-20 and 0.05% NP-40 blocking solution for one hour at room 
temperature prior to incubation with primary antibodies at the appropriate dilution, at 
4
o
C, with gentle shaking over-night. β-actin was detected with a 1:1000 dilution of 
the antibody. Alkaline phosphatase-conjugated anti-rabbit, anti-goat or anti-mouse 
IgG were employed as secondary antibody as appropriate to the primary antibody. 
Anti-goat (Sigma) was employed as the secondary antibody for anti-β-actin. 
Visualization of alkaline phosphatase-labelled protein bands was performed using 
Enzyme linked Chemi-fluorescence Substrate (ECF) (GE Healthcare). The intensity 
of bands was quantified with ImageQuant version TL (GE Healthcare, Buckinghamshire, 
UK). The intensity of each band (for the protein of interest) is normalised with the 





to 1, the NS value that was extracted from the previous calculation (intensity of each 
band (for the protein of interest) is normalised with the intensity of the band for β-
actin) was divided by itself. All the other values (which correspond to time points) 
are divided to the NS value.  
 
2.6  MATERIALS 
 
2.6.1  Chemical inhibitors  
 
Chemical inhibitors that are used in this study are listed in Table 2-8 below: 
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2.7  CELL NUMBER ASSAY AND CELL COUNTING 
 
2.7.1  Cell number assay  
 
Cell seeding and treatment  
 
SCL60 cells were seeded in 6-well plates at density of 0.2x10
6
 cells per well in 















M) and were incubated for 5 days.  
Cell fixation  
Cells attached to the plastic substratum were fixed by gentle addition of 0.5ml of 
25% (v/v) trichloroacetic acid (TCA) on top of the growth medium in each well. The 
cultures were incubated at 4°C for 1 hour and then washed five times with tap water 
to remove TCA, growth medium, low-molecular-weight metabolites, and serum 




Sulforhodamine B (SRB) staining  
TCA-fixed cells were stained for 30 minutes with 0.4% (w/v) SRB in 1% (v/v) acetic 
acid. At the end of the staining period, SRB was removed and cultures were quickly 
rinsed five times with 1% (v/v) acetic acid to remove unbound dye. Plates were dried 




Protein-bound dye extraction 
Protein-bound dye was solubilised and extracted in 1ml of 10mM Tris (tris 
(hydroxymethyl) aminomethane, pH 10.5) per well.  
 





 The OD of these protein extracts was measured in 590nm using a spectrophotometer. 
This assay gives a direct indication of remaining number of live cells following GnRH 
treatment.  
 
2.7.2  Cell counting  
 
The growth rate of the SCL60 cells in response to D-Trp
6
-GnRH I was measured by 
cell counting using a haemocytometer. SCL60 cells were seeded in 6-well plates at a 
density of 0.2x10
6
 cells per well in complete medium. The next day (day 1), cells 
were treated with D-Trp
6
-GnRH I. The cell number was counted in a similar manner 
every day thereafter (days 2, 3, 4, 5 and 6) after washing and trypsinisation.    
 
 
2.8  PHARMACOLOGIGAL CHARACTERISATION OF GnRH 
FUNCTION 
 
2.8.1  GnRH binding assay  
 











)-GnRH I analogue) was added to HEPES/DMEM/0.1%BSA so that 0.5ml 
contained approximately 100,000cpm, and this mixture was kept on ice (labelled 
media). Unlabelled native GnRH I (cold ligand) was added to the mixture at a 
concentration of 10
-6
M (labelled media plus cold ligand). Cells were washed twice 




). 500μl of the mixture (labelled media plus cold 
ligand) was added to the wells in triplicate and cells were incubated for a minimum 
of 4 hours at 4
o





with ice cold PBS. 500μl of 0.1M NaOH was added to each well and the plates were 
shaken for 15-20 minutes at room temperature in order to solubilise cells. Samples 
were transferred (from each well) into individual 12x75mm plastic tubes and 
radioactivity was counted on 1470 Automatic Gamma Counter (Perkin Elmer).    
 
2.8.2  Inositol Phosphate (IP) assay 
 




in 12-well plates and were incubated 
at 37
o
C overnight. The next day, cells were loaded with [
3
H] myo-inositol in pre-
warmed inositol free SPECIAL DMEM at a concentration of 0.5μCi [
3
H] myo-
inositol/0.5ml SPECIAL DMEM/well. The cells were then incubated overnight. 
Media was aspirated off and the cells were washed with 0.5ml HEPES-
DMEM/0.1%BSA. 0.5ml HEPES-DMEM/0.1%BSA containing a final concentration 
of 10mM LiCl was added to each well and plates were incubated at 37
o
C for 30 
minutes. This buffer was removed from the wells and 0.5ml HEPES-DMEM/10mM 
LiCl/0.1%BSA with or without GnRH I was added at appropriate dilutions. Cells 
were incubated at 37
o
C for 60 minutes. Media was aspirated from the wells and 1ml 
of 10mM formic acid was added to each well followed by incubation at 4
o
C for 30 
minutes. 0.5ml of AG-1-X8 resin (Bio-Rad) was added into plastic tubes (12x75mm) 
and formic acid samples were transferred from the wells to the tubes containing AG-
1-X8 resin and the mixture vortexed. Resin was allowed to settle and the supernatant 
was aspirated. 1 ml of water was added, the mixture was vortexed and resin was 
allowed to settle. Then supernatant was aspirated and 1ml of 60mM ammonium 
formate/5mM sodium tetraborate was added, vortexed and resin was allowed to 





formate/0.1M formic acid was added vortexed and resin was allowed to settle. 0.8ml 
of the supernatant was removed into scintillation vials and 2.5ml of scintillation fluid 
(Optiphase Hisafe 3, Fisher Scientific) was added and 
3
H was counted for 1 minute 
on a 1450 Microbeta Beta counter (TriLux; Perkin Elmer).       
 
2.9  CHROMATIN IMMUNOPRECIPITATION (ChIP) ASSAY 
 
LβT2 cells were seeded at a density of 2x10
6 
in 60mm plates. 37% formaldehyde in 
DMEM was added directly to the cell culture and cross-linking was allowed to 
proceed for 10 min at room temperature. Cross-linking was stopped by the addition 
of glycine stop-fix solution (Active Motif). Cross-linked cells were scraped with cell 
scraping solution (Active Motif). Pellets were collected by micro-centrifugion, re-
suspended and incubated in ice-cold lysis buffer supplemented with PIC (protease 
inhibitor) and PMSF (phenylmethanesulfonylfluoride) and lysed with an ice cold 
dounce homogenizer. Nuclei were again pelleted by centrifugation. These pellets 
were resuspended in Digestion Buffer (Active Motif) and incubated at 37
o
C for 5 
minutes. Chromatin was sheared with the Enzymatic Shearing Cocktail (Active 
Motif). Sheared chromatin was collected by centrifugation for 10 minutes at 
15.000rpm. 7µg of sheared chromatin was added to the ChIP reaction. 1-3µg of the 
appropriate antibody was added to the aliquots of chromatin and mixed gently on an 
end-to-end rotator for 16 hours at 4
o
C. Antibody against FOXO3a was purchased 
from Abcam and IgG (sc-2027) was purchased from Santa Cruz. Following 
extensive washing, bound DNA fragments were eluted and analyzed by qRT-PCR.  
Bound DNA fragments were analyzed by qRT-CR with TaqMan DNA Polymerase 





2.10  CELL-CYCLE ANALYSIS 
 
LβT2 and PWE-1-NB26-3 cells were plated at a density of 0.5x10
6
 cells per dish in 
complete medium and in serum-free keratinocyte medium respectively. After 
treatment with 100nM D-Trp
6
-GnRH I for 96 hours, 10μg/ml Hoechst stain was 
added to the medium, and cells were incubated for 60 more minutes at 37
o
C. After 
trypsinisation and centrifugation, the cell pellets were resuspended in the appropriate 
complete medium. The cellular content of DNA was determined by flow cytometry 
analysis with a BD LSR Fortessa cell analyzer. Cells were gated according to 
physical characteristics and therefore subcellular debris and clumps were 
distinguished from single cells during the analysis. The data were analyzed with 
DIVA Software. (Data analysis (gating and computational analysis) was performed 
with the cooperation of Ms. Shonna Jonhston from University of Edinburgh, Centre 
for Inflammation Research, Flow Cytometry Facility).  
 
2.11  IMMUNOHISTOCHEMISTRY  
 
2.11.1  Tissues 
 
Tissues that are used in this study are listed on Table 2-9 below: 



















Table 2-9: Tissues that are used in this study 
(NBF: neutral buffered formalin, is a general purpose fixative for all tissues for surgical tissues and 





2.11.2  Immunohistochemistry procedure  
 
Fixation and Tissue processing  
The tissues that were used in this study had been fixed previously (the fixation 
methods are listed in the table above) and processed with paraffin prior to use.  
Tissue sectioning  
Sections were cut on a paraffin microtome (Leica RM2125RTF) in sections of 5μm. 
Sections were floated onto heated water at 45
o
C and were lifted onto superfrost plus 
microscope slides. Slides were then dried in an incubator overnight at 37
o
C. 
Staining    
Paraffin wax was removed from the slides in xylene, series dilutions of ethanol 
(100%, 95% and 70%) and distilled water. In selective cases antigen retrieval was 
performed using the pressure cooking method in pre-heated 0.01M sodium citrate 
buffer pH 6.0 followed by cooling for a further 20 minutes under running tap water 
(Tissue fixation alters the three dimensional structure of the tissue proteins which 
results in a modification of the antigen’s epitope. The loss of an epitope results in an 
antigen’s inability to react with the paratope of the antibody, and this can only be 
corrected by the restoration (antigen retrieval process) of the epitope). Next, slides 
were blocked in 300mls 3% hydrogen peroxidase in methanol, on a rocker at room 
temperature for 30 minutes, to block endogenous peroxide. Two washes with tris 
buffered saline (TBS) followed. Afterwards slides were incubated in normal goat 
serum (NGS) diluted in TBS (1:5 v/v) containing 5% (w/v) BSA for 30 minutes at 
room temperature. Slides were drained, and primary antibody diluted in 
NGS/TBS/BSA was added. Slides were incubated overnight at 4
o
C. Two staining 






1. DAB detection method  
After over-night incubation, slides were washed twice in TBS for 5 minutes and 
biotinylated goat anti-Rabbit at 1:500 in NGS/TBS/BSA was added and incubated 
for 30 minutes at room temperature. Slides were washed twice with TBS for 5 
minutes and streptavidin HRP at 1:1000 in TBS was added and incubated for 30 
minutes at room temperature. Slides were washed twice in TBS for 5 minutes and 
3,3' Diaminobenzidine (DAB substrate) was added. The colour development was 
monitored microscopically (the usual time for DAB exposure was 5 minutes) and the 
colour development was stopped by washing in water. Next nuclear counterstain was 
performed using heamatoxylin; washed slides were rinsed in acid alcohol 
(ethanol/distilled water/hydrochloric acid) for 5 seconds. Then slides were washed in 
water and were added to Scott’s tap water (sodium hydrogen carbonate/magnesium 
sulphate/distilled water) for blueing up the nucleus and nuclear membrane for 30 
seconds. Next, slides were washed in water for 20 seconds and were dehydrated in 
70% ethanol, 95% ethanol and absolute ethanol for 20 seconds and in xylene for 5 
minutes. Finally, slides were cover-slipped using Pertex (   ). The immunostaining 




2. Tyramide detection method-double staining  
After over-night incubation, slides were washed twice with TBS for 5 minutes and 
goat anti-Rabbit peroxidise Fab at 1:500 in NGS/TBS/BSA was added and incubated 
for 30 minutes at room temperature. Slides were washed twice in TBS for 5 minutes 





room temperature. Slides were washed twice in TBS for 5 minutes and antigen 
retrieval process was performed (as described above). Afterwards slides were 
incubated in normal goat serum (NGS) diluted in TBS (1:5 v/v) containing 5% (w/v) 
BSA for 30 minutes at room temperature., slides were drained, and primary antibody 




After over-night incubation, slides were washed twice in TBS for 5 minutes and goat 
anti-mouse peroxidise Fab at 1:500 in NGS/TBS/BSA was added and incubated for 
30 minutes at room temperature. Slides were washed twice in TBS for 5 minutes and 
Tyramide-Fluorescent Red (1/50) was added and incubated for 10 minutes at room 
temperature. Slides were washed twice in TBS for 5 minutes. Nuclei were 
counterstained using DAPI (1:1000 in TBS) for 10 minutes. Finally slides were 
cover-slipped using permafluor (   ).  
 
2.12  STATISTICAL ANALYSIS  
 
All data from each experiment were combined and presented as means and standard 
error of the mean (±SEM). The numbers of independent experiments are denoted by 
the number (n) and are given in figures legends and text. Statistical analysis was 
performed using the student t-test with Graph Prism 5.00 software (Graph Prism 













REGULATION OF FOXO TRANSCRIPTIONAL 





















3.0  ABSTRACT  
 
In this Chapter, the regulation of FOXO transcriptional activity following 
GnRH-R activation is investigated, and a novel mechanism by which GnRH 
targets FOXO3a activity is described. Since the transcriptional activity of 
FOXO is determined by post-translational modifications and the action of co-
factors, such as β-catenin, the role of these post-translational modifications and 
the involvement of β-catenin are characterised. Finally, the role of FOXOs in 
targeting the expression of several FOXO-target genes is assessed, highlighting a 
specific role for FOXO3a in mediating GADD45 and FasL expression in 
response to GnRH.  
 
3.1  BACKGROUND AND OBJECTIVES  
 
The mammalian FOXOs are emerging as an important family of proteins that are 
involved in a variety of cellular processes, including cell-cycle regulation, apoptosis, 
DNA damage repair and response to oxidative stress (Burgering, 2008). FOXOs 
modulate the expression of specific genes that mediate these processes, including the 
apoptotic FasL and the oxidative stress resistant GADD45 genes. The most well-
characterised regulatory mechanism of FOXO transcriptional activity is through their 
phosphorylation by the PI3K/Akt signalling pathway. Interestingly, the PI3K/Akt 
signalling pathway is also regulated by GnRH-R activation (Birkenkamp and Coffer, 
2003). However, to date, there are no studies describing the regulation of FOXO 
transcriptional activity by GnRH. Thus, the potential regulation of FOXO activity by 






In this Chapter, the mechanisms and signalling pathways through which GnRH 
regulates FOXO transcriptional activity was examined. In particular, the main 
objectives of this Chapter were the following: 
 to examine whether GnRH regulates FOXO transcriptional activity  
 to investigate the mechanisms and signalling pathways through which GnRH 
regulates FOXO activity 
 to examine whether GnRH targets the expression of FOXO-target genes, and 
whether FOXOs are involved in this expression. 
 
In Chapters three, four and five cells were treated with GnRH I (referred to 
as GnRH), unless otherwise indicated. In Chapters three and four, all 
studies were conducted in the stable HEK293/ratGnRH-R expressing cell 
line (referred to as SCL60 cells), unless otherwise indicated. 
 
 
3.2  RESULTS 
 
3.2.1  FOXO1 and FOXO3a phosphorylation and sub-cellular 
localisation in response to GnRH treatment 
 





The primary pathway regulating FOXO function is the PI3K/Akt signalling pathway, 
in which FOXOs are phosphorylated at Akt phosphorylation sites, following PI3K 
activation by several proteins, including G-proteins (Van Der Heide et al., 2004). A 
short time-course treatment of cells with 1μM GnRH, demonstrated that FOXO3a 
was only phosphorylated at Ser
253





minutes (Fig. 3-1A). Whether GnRH-induced phosphorylation of FOXO3a at Ser
253
 
was specifically mediated by GnRH binding and activation of the Type I GnRH-R, 
was also examined. For this purpose, a GnRH antagonist (Cetrorelix) was used. Co-
treatment with Cetrorelix inhibited GnRH-targeted phosphorylation at Ser
253
 (Fig. 3-
1B). This confirmed that phosphorylation of FOXO3a at Ser
253
 was mediated by 
GnRH-R activation.  
 
A longer time-course treatment of SCL60 cells with 1μM GnRH over 24 hours 
resulted in decreased phosphorylation of FOXO3a at Ser
253
 of up to 35% (Fig. 3-1C). 
A GnRH dose-response treatment for FOXO3a phosphorylation at Ser
253
 site was 
also performed, producing an EC50 of 1.2nM, which is in agreement with activation 







Figure 3-1: Phosphorylation of FOXO3a at Ser
253
 in response to GnRH.  
(A) SCL60 cells were serum-starved 24 hours before being treated with 1µM GnRH for the indicated 
times, or left untreated (NS). (B) SCL60 cells were serum-starved 24 hours before being treated for 10 
minutes with 1µM GnRH, 1µM Cetrorelix, or both or left untreated (NS). (C) SCL60 cells were 
treated with 1µM GnRH for the indicated times. (D) SCL60 cells were serum-starved 24 hours before 
being treated with 10µM, 1µM, 1nM, 100nM, 10nM, 1nM GnRH or left untreated (NS) for 10 
minutes. Levels of p-FOXO3a(Ser
253
) were analysed using a p-FOXO3a(Ser
253
)-specific antibody. 
Quantification of the immunoblots were performed using β-actin as a loading control. Data are shown 
as mean fold change over NS±SEM from at least 3 independent experiments. (b is significantly 






Phosphorylation at other sites on FOXOs was also examined by Western Blot 





sites following GnRH treatment (Supplementary Fig. 7-1A). Additionally, GnRH 




 (Supplementary Fig. 7-
1B and C), no did GnRH treatment lead to the phosphorylation of FOXO4 at the 
Ser
193
 Akt-phosphorylation site (Supplementary Fig. 7-1D).  
 
GnRH-targeted phosphorylation of FOXO3a at Ser
253
 in the LNCaP prostate cancer 
cell line was also examined. In contrast to SCL60 cells, GnRH did not mediate 
phosphorylation of FOXO3a at the Ser
253
 Akt phosphorylation site in LNCaP cells 




), but not p-FOXO1(Ser
256
), is redistributed 
between the nucleus and cytoplasm in response to GnRH in SCL60 cells 
 










) was low in non-stimulated cells. 
Following GnRH treatment, p-FOXO3a(Ser
253
) staining increased significantly in 
both the nucleus and cytoplasm. After 30 and 60 minutes of GnRH treatment p-
FOXO3a(Ser
253
) appears to translocate from the nucleus to cytoplasm (Fig. 3-2), 
however since no quantification analysis has been performed, no robust conclusion 
can be extracted. These data are consistent with the Western Blot data showing 
increased p-FOXO3a(Ser
253
) in response to GnRH treatment. In contrast, p-
FOXO1(Ser
256
) staining was only slightly increased following GnRH treatment. 
Localisation of p-FOXO1(Ser
256





GnRH. Although these data appear to contradict the Western Blot data, it is possible 
that the antibody used was not specific and cross-reacted with other FOXOs, such as 



























) redistribution between nucleus and cytoplasm following GnRH 
stimulation in SCL60 cells.  





(green) between the nucleus and cytoplasm following 1µM GnRH treatment at the 
time intervals  indicated. DAPI (red) is a marker for nucleus and co-localisation is indicated as yellow.  
  60 minutes 
                                 DAPI            p-FOXO3a(Ser
253
)                             Merge   NS
  5 minutes 





3.2.1.3  Phosphorylation of FOXO3a at Ser
253
 in SCL60 cells is mediated by 
a Gq-coupled, PI3K/Akt-mediated signalling pathway 
 
Having demonstrating that GnRH-targeted phosphorylation of FOXO3a at Ser
253
, 
various pharmacological inhibitors were subsequently used in order to identify the 
signalling pathway that mediates this phosphorylation event. Cetrorelix and the Gq 
inhibitor YM254890 clearly inhibited phosphorylation of FOXO3a at Ser
253
 in 
response to GnRH (Fig. 3-3 (upper panel)). In addition, the PI3K/Akt signalling 
pathway appears to be involved in this phosphorylation, as the PI3K inhibitors 
Wortmannin and LY294002, and the Akt inhibitor Akt1/2 reduced FOXO3a 
phosphorylation at Ser
253
 in response to GnRH (Fig. 3-3 (lower panel)). Inhibitors of 
c-Src, EGFR, MEK, PLC, PKC and PKA were also tested. Results from these 
experiments indicated that none of these potential mediators appeared to be involved 
in phosphorylation of FOXO3at at Ser
253

















Figure 3-3: GnRH induces phosphorylation of FOXO3a at Ser
253
 via a Gq-coupled, PI3K/Akt-
mediated signalling pathway.  
SCL60 cells were serum-starved for 24 hours before cells were pre-treated for 30 minutes with: GnRH 
antagonist Cetrorelix (1μM), Gq inhibitor YM254890 (100nM), PI3K inhibitors Wortmannin (100nM) 
and LY294002 (30μM), Akt inhibitor Akt1/2 (1μM), and were then treated for 10 minutes with 1μM 
GnRH. Quantification of the immunoblots were performed using β-actin as a loading control. Blots 
are representative of 3 independent experiments. Data are shown as mean fold change over NS±SEM 







3.2.2  GnRH targets FOXO transcriptional activity 
 
3.2.2.1  GnRH targets GADD45 transcription in SCL60 cells by regulating 
FOXO3a transcriptional activity 
 
Phosphorylation is a known post-translational modification that regulates FOXO 
activity. Therefore, having demonstrated that GnRH stimulation mediates 
phosphorylation of FOXO3a, the involvement of GnRH in regulating FOXO 
transcriptional activity was examined. Three known FOXO-targeted promoter 
luciferase reporters were utilised; GADD45-, FHRE- and 6×DBE-promoter 
luciferase constructs, henceforth referred to as GADD45-, FHRE- and 6×DBE-
reporters. FHRE (FH-Response Element) is the consensus binding site within the 
promoter of the FasL gene for FOXO transcription factors (Brunet et al., 1999). DBE 
(Daf-16 family protein Binding Element) is a core binding sequence shared by all 
four FOXOs, TTGTTTAC. 
 
Cells were treated with GnRH for 24 hours following pre-incubation in either 
complete or starving medium. Cells were pre-incubated in starving medium in order 
to examine the effect of GnRH exclusively, eliminating the effect of other potential 
stimulators of the pathway of interest. Alternatively, cells were pre-incubated in 
complete medium in order to examine whether the GnRH effect was dominant 
among the other factors that potentially affect FOXO activity. GADD45-, FHRE- 
and 6×DBE-reporter activities were increased following GnRH treatment (Fig. 3-4). 
To further examine whether FOXO transcriptional activity was induced by GnRH 
acting at the Type I GnRH-R, Cetrorelix was utilised. Co-treatment with Cetrorelix 
inhibited FHRE-reporter activity, previously observed in response to GnRH 





reporter activity compared to non-stimulated control, which may suggest that  
Cetrorelix partially inhibits GnRH-independent signalling pathways, which also 
regulate FHRE-reporter activity. An explanation for this result could be related to the 
ligand-induced selective signalling (LISS) effect. Based on that, the GnRH receptor 
can assume a number of distinct active conformations that selectively target different 
intracellular signalling pathways, and therefore different GnRH analogues would 




Figure 3-4: GnRH-induced GADD45-, FHRE- and 6×DBE-reporters.  
SCL60 cells were transiently transfected with 10µg of (A) 6×DBE-, (B) FHRE- and (C) GADD45-
reporter. Cells were treated with 1µM GnRH for 24 hours or were serum-starved 16 hours before 





panels open bars denote no stimulation and close bars denote GnRH stimulation. Data are shown as 





Figure 3-5: GnRH-induced FHRE-reporter activity.  
SCL60 cells were transiently transfected with 10µg of FHRE-reporter. Cells were serum-starved for 
16 hours and then treated with 1µM GnRH for 24 hours, or with 1µM Cetrorelix or with 1µM GnRH 
plus 1µM Cetrorelix. Samples were then assayed for luciferase activity. Data are shown as mean fold 
change over NS±SEM from at least 3 independent experiments. (b is significantly different from a and 
c is significantly different from a and b; P<0.05) 
 
FOXO3a was subsequently over-expressed in order to investigate the transcriptional 
activity of FOXO3a above the endogenous FOXO1/3a/4 background. In particular, 
wild type FOXO3a (FOXO3a-WT) or a triple mutant form of FOXO3a (FOXO3a-







Ala; TM denotes triple mutant) (Burgering and Kops, 
2002). In contrast to FOXO3a-WT, FOXO3a-TM cannot be phosphorylated by Akt, 
resulting in its nuclear retention. FOXO3a-TM was therefore used in order to 





SCL60 cells were co-transfected with GADD45-reporter together with increasing 
amounts of FOXO3a-TM, followed by treatment with 1µM GnRH. The basal levels 
of GADD45-reporter activity and GnRH-induced GADD45-reporter activity were 
increased with higher levels of over-expressed FOXO3a-TM (Fig. 3-6). A pGL3 
vector backbone was also used as a control to determine background luciferase 
activity. When FOXO3a was over-expressed, the luciferase activity of pGL3 was not 
significantly increased compared to the FOXO-activated GADD45-promoter-
















Figure 3-6: GnRH-induced GADD45-reporter activity in a time-course treatment. 
SCL60 cells were transiently transfected with 5µg of GADD45-reporter and increasing amounts of 
FOXO3a-TM, and decreasing amounts of control vector (pcDNA3.1). Cells were treated with 1µM 
GnRH for the indicated time points or left untreated (NS). Samples were then assayed for luciferase 










Figure 3-7: GnRH-induced pGL3- and GADD45-reporter activity. 
SCL60 cells were transfected with 3.5μM of pGL3- or GADD45-reporter and 6.5μM of FOXO3a-
WT. Cells were treated for 24 hours with 1μM GnRH in starving medium. Samples were assayed for 
luciferase activity. Data are shown as mean fold change over NS±SEM from at least 3 independent 
experiments. (b is significantly different from a, c is significantly different from a and b, and d is 
different from a, b and c; P<0.05) 
 
Next, SCL60 cells were co-transfected with the GADD45-reporter and pcDNA3.1 
(henceforth referred to as vector control), FOXO3a-WT or FOXO3a-TM. Treatment 
with GnRH enhanced the transcriptional activity of both FOXO3a-WT and 
FOXO3a-TM by 2-fold compared to control over 24 hours of treatment (Fig. 3-8A). 
Of note is that GnRH treatment induced the same fold increase in FOXO3a 
transcriptional activity in cells that were co-transfected with either FOXO3a-WT or 
FOXO3a-TM. This is interesting with regards to previous results (see Figure 3-1A 
and C) that GnRH targets FOXO3a phosphorylation at an Akt phosphorylation site 





phosphorylation at the same phosphorylation site over 24 hours of treatment. The 
role of FOXO phosphorylation in regulating its transcriptional activity is well-
established. Combining the above findings, that GnRH targets FOXO3a de-
phosphorylation over 24 hours of treatment, and that GnRH treatment enhanced the 
transcriptional activity of both FOXO3a-WT, and FOXO3a-TM that cannot be 
phosphorylated by Akt, by the same fold, suggests that targeting of FOXO3a 
phosphorylation by GnRH is not the dominant mechanism regulating its 
transcriptional activity.  
 
While over-expression of FOXO3a-TM increased GnRH-induced GADD45-reporter 
activity compared to vector control, over-expression of FOXO3a-TMΔDB, bearing 







in addition to a deletion of the DNA binding domain (denoted by ΔDB), reduced the 
GnRH-mediated GADD45-reporter activity compared to the effect of FOXO3a-TM 
(Fig. 3-8B). This suggests that FOXO3a binds directly to the GADD45 promoter and 
regulates the expression of the GADD45 gene. A FOXO3a-TMΔCT construct that 
has a deletion of the trans-activation domain, and cannot bind potential co-factors 
that may act to regulate FOXO3a transcriptional activity (denoted by ΔCT) was also 
tested. Over-expression of FOXO3a-TMΔCT partially reduced the GnRH-mediated 
induction of GADD45-reporter activity compared with cells in which FOXO3a-TM 
was over-expressed (Fig. 3-8B). This indicates that FOXO3a acts in co-ordination 






Figure 3-8: GnRH-induced GADD45-reporter activity by direct binding of FOXO3a to the 
GADD45 promoter. 
SCL60 cells were transiently transfected with 1µg of GADD45-reporter and (A) 9µg of control vector 
(pcDNA3.1) or (A) FOXO3a-WT or (A and B) FOXO3a-TM or (B) FOXO3a-TMΔDB or FOXO3a-
TMΔCT. Cells were serum-starved 16 hours before being treated with 1µM GnRH for 24 hours. 
Samples were assayed for luciferase activity. In all panels open bars denote no stimulation and close 
bars denote GnRH stimulation. Data are shown as mean fold change over NS±SEM from at least 3 
independent experiments. (b is significantly different from a, and c is significantly different from a 
and b; P<0.05) 
 
Although GnRH does not appear to target FOXO1 phosphorylation (see Section 
3.2.1.1) a possible role for FOXO1 in GnRH-induced GADD45 expression was 
examined. For this purpose, cells were co-transfected with FOXO1-WT or FOXO1-
TM constructs. Over-expression of FOXO1-TM increased GnRH-induced GADD45-
reporter activity compared to vector control, however this was not significant 







3.2.2.2  GnRH targets FOXO3a transcriptional activity independently of 
FOXO3a phosphorylation at any of its Akt phosphorylation sites 
 
Since a clear regulation of GADD45-reporter activity by FOXO3a following GnRH 
treatment was demonstrated (Section 3.2.2.1), the role of Akt phosphorylation in 
GnRH-mediated FOXO3a transcriptional activity was examined. When raw 
luciferase assay data was analysed, the transcriptional activity of FOXO3a-WT was 
lower than the activity of FOXO3a-TM in the absence of GnRH treatment (Fig. 3-
9A). In this case raw data were used in order to be able to show the effect of the 
over-expression of FOXO3a-TM on GADD45-promoter luciferase activity. These 
results were expected since the triple mutant form of FOXO3a (FOXO3a-TM) 
cannot be phosphorylated by Akt, resulting its nuclear retention. When the 
corresponding normalised data was analysed, a similar fold-increase in GADD45-
reporter activity was observed when either FOXO3a-WT or FOXO3a-TM was over-
expressed (Fig. 3-9B). These data support the notion that phosphorylation of 
FOXO3a in response to GnRH treatment does not appear to play a role in its 
transcriptional activity. Thus, GnRH appears to target FOXO3a transcriptional 
activity independently of FOXO3a phosphorylation at any of its Akt phosphorylation 
sites.  
 
To further investigate the role of any of the individual Akt phosphorylation sites in 
regulating FOXO3a transcriptional activity, cell were co-transfected with FOXO 








change in luciferase activity following GnRH treatment was similar for the three 







, this modification is not the main modulator of its transcriptional 
activity. 
 
Figure 3-9: Effect of Akt-dependent FOXO3a phosphorylation on GnRH-induced GADD45-
reporter activity.  
(A and B) SCL60 cells were transiently transfected with 1µg of GADD45-reporter and 9µg of control 
vector (pcDNA3.1), or FOXO3a-WT or FOXO3a-TM. (C) Cells were transiently transfected with 5µg 





Ala or FOXO3a Ser
315
Ala. Cells were serum-starved 16 hours before were they treated 
with 1µM GnRH for 24 hours. Samples were then assayed for luciferase activity. In all panels open 





change over NS±SEM from at least 3 independent experiments. (b is significantly different from a, 
and c is significantly different from a and b, d is also significantly different from a, b and c; P<0.05) 
 
3.2.2.3  GnRH-induced FOXO3a transcriptional activity occurs via Gq-, 
Akt- and IKK-mediated signalling pathways 
 
Based on the finding that the transcriptional activity of FOXO3a was enhanced 
following GnRH treatment, the signalling pathways through which this occurred was 
examined next.  
 
GnRH induction of GADD45-reporter activity by FOXO3a was inhibited by co-
treatment with the Gq inhibitor (YM254890) (Fig. 3-10A). Next, the role of Akt 
phosphorylation in GnRH-induced GADD45-reporter activity via FOXO3a was 
examined. A specific Akt inhibitor (Akt1/2) (Fig. 3-10B) and a dominant-negative 
Akt construct (DN-Akt) were utilised (Fig. 3-10C). Both Akt inhibitor and DN-Akt 
construct inhibited GnRH-induced GADD45-reporter activity.  
 
FOXO3a can also be phosphorylated by that IκB kinase (IKK), which can inhibit 
FOXO3a transcriptional activity independently of Akt phosphorylation (Hu et al., 
2004). The role of IKK in GnRH-induced GADD45-reporter activity by FOXO3a 
was examined by utilising an IKK inhibitor (BMS-345541). Following 24 hour 
GnRH stimulation, GADD45-reporter activity was measured in SCL60 which had 
been transiently transfected FOXO3a-WT, in the presence of the IKK inhibitor. The 
IKK inhibitor inhibited GnRH-induced GADD45-reporter activity in cells with 
FOXO3a-TM over-expression (Fig. 3-10D). Subsequently, the role of IKK 
phosphorylation in GnRH-induced GADD45-reporter activity via FOXO3a was 
examined. Phosphorylation of FOXO3a at Ser
644





FOXO3a transcriptional activity (Hu et al., 2004). To investigate this, a mutant 
FOXO3a-TM-reporter was generated by replacing Ser
644
 with Alanine (FOXO3a-
TM Ser
644
Ala). Over-expression of FOXO3a-TM Ser
644
Ala did not inhibit GnRH-
induced GADD45-reporter activity compared to over-expression of FOXO3a-TM 
(Fig. 3-10E), suggesting that the role of IKK in regulating FOXO3a in response to 
GnRH, is not mediated by phosphorylation at the Ser
644
 site.   
 
Having demonstrated that GnRH regulates FOXO3a transcriptional activity via Akt, 




 in GnRH-induced GADD45-
reporter activity via FOXO3a, was examined. PDK1 is involved in the PI3K/Akt 




, resulting in full 
Akt activation. A time-course of GnRH treatment revealed the phosphorylation of 
Akt at Thr
308
 over 60 minutes, reaching maximal phosphorylation after 5 and 10 
minutes (Fig. 3-11 (upper panel)). No phosphorylation of Ser
473
 was detected in 
response to GnRH.  
 
The involvement of three other potential mediators (PI3K inhibitor (Wortmannin), 
PKC inhibitor (Ro-31-8220) and PLC inhibitor (ET-18-OCH3)) was next examined 
by utilising the appropriate chemical inhibitors. None of them prevented GnRH-
induced GADD45-reporter activity with FOXO3a over-expression (Supplementary 






Figure 3-10: Role of Gq, Akt and IKK in the GnRH-induced GADD45-reporter activity.  
(A, B, C, D and E) SCL60 cells were transiently transfected with 1µg of GADD45-reporter and (B, C 
and E) 9µg of control vector (pcDNA3.1) or (A and D) FOXO3a-WT or (B, C and E) FOXO3a-TM 
or (E) FOXO3a-TM Ser
644
A or (C) DN-Akt. Cells were serum-starved 16 hours before were pre-
treated for 30 minutes with (D) 1,5μM BMS-345541 inhibitor or (B) 1µM Akt1/2 inhibitor or (A) 
100nM YM254890 and thereafter were treated with 1µM GnRH for 24 hours. Samples were assayed 
for luciferase activity. In all panels open bars denote no stimulation and close bars denote GnRH 
stimulation. Data are shown as mean fold change over NS±SEM from at least 3 independent 
















Figure 3-11: Immunoblots of GnRH-induced Akt phosphorylation.  
SCL60 cells were serum-starved for 16 hours before treatment with 1µM of GnRH or left untreated 
(NS). Protein level were analysed by Western Blot using the appropriate antibody. Blots are 
representative of 3 independent experiments. 
 
3.2.2.4  The role of β-catenin in GnRH-induced GADD45-reporter activity 
 
An interaction between β-catenin and FOXO3a has previously been reported (Essers 
et al., 2005). Thus, a role for β-catenin as co-factor to regulate the transcriptional 
activity of FOXO3a following GnRH treatment was examined. When nuclear β-
catenin levels were increased by LiCl treatment, the transcriptional activity of 
FOXO3a increased in the absence of GnRH treatment (Fig. 3-12A). However, when 
cells were treated with both LiCl and GnRH GnRH-induced GADD45-reporter 
activity by FOXO3a-WT was decreased (Fig. 3-12B) compared with the increase 
observed with GnRH treatment alone (Fig. 3-12C). These data suggest the β-catenin-
mediated effect of GnRH-induced FOXO3a transcriptional activity, is not a dominant 
regulatory mechanism of GnRH-induced FOXO3a activity. 
 
 



















Figure 3-12: GnRH-induced transcriptional activity of FOXO3a is mediated by β-catenin. 
SCL60 cells were transfected with 3.5μM of (A, B and C) GADD45-reporter or (A and B) 6.5μM of 
FOXO3a-WT or (C) control vector. Cells were serum-starved 16 hours before (B and C) cells were 
treated for 24 hours with 1μM GnRH and/or (A and B) 20μM of LiCl. Samples were then assayed for 
luciferase activity. In all panels open bars denote no stimulation and close bars denote GnRH 
stimulation. Data are shown as mean fold change over NS±SEM from at least 3 independent 
experiments. (b is significantly different from a; P<0.05) 
 
3.2.2.5  The role of acetylation in GnRH-induced GADD45-reporter activity 
 
Acetylation is another post-translational modification that regulates FOXO 
transcriptional activity. In order to examine whether GnRH targets FOXO3a 





SIRT1 was utilised. SIRT1 is a de-acetylase which de-acetylates FOXO3a leading to 
its nuclear translocation (Motta et al., 2004).  
 
Over-expression of SIRT1 decreased basal GADD45-reporter activity by 2-fold (Fig. 
3-13A). However, following a 24 hour treatment with GnRH, over-expression of 
SIRT1 increased GADD45-reporter activity compared with the vector control (Fig. 
3-13B). In order to examine the effect of SIRT1 on the transcriptional activity of 
FOXO3a in response to GnRH, SCL60 cells were co-transfected with FOXO3a-WT, 
or with FOXO3a-WT and SIRT1. GADD45-reporter activity was increased 
approximately 3-fold in response to GnRH, whether SIRT1 was co-expressed or not 
(Fig. 3-13C). Finally, over-expression of SIRT1 decreased the basal level of 
GADD45-reporter activity when co-expressed with FOXO3a-WT (Fig. 3-13D). The 
data suggest FOXO3a acetylation is not a dominant regulatory mechanism of GnRH-


















Figure 3-13: The role of acetylation in GnRH-induced transcriptional activity by FOXO3a. 
SCL60 cells were transfected with 3.5μM of GADD45-reporter and 3.5μM of control vector 
(pcDNA3.1) or (C and D) 3.5μM of FOXO3a-WT or (A, B, C and D) 3.5μM of SIRT1. Cells were 
serum-starved 16 hours (B and C) before they were treated for 24 hours with 1μM GnRH. Samples 
were then assayed for luciferase activity. In all panels open bars denote no stimulation and close bars 
denote GnRH stimulation. Data are shown as mean fold change over NS±SEM from at least 3 









3.2.3  GnRH targets the expression of known FOXO3a-target genes by 
regulating FOXO3a transcriptional activity 
 
3.2.3.1  GnRH regulation of FOXO3a-target gene expression over 24 hours 
and 4 days 
 
Having demonstrated that GnRH regulates GADD45-reporter activity by targeting 
FOXO3a, the mRNA expression levels of several other FOXO-target genes was 
assessed. The expression levels of GADD45, FasL, p27kip1 and p21Cip1 mRNAs in 
response to GnRH was measured by Taqman Quantitative RT-PCR analysis. 
Significant up-regulation of GADD45 mRNA expression was observed over 24 hours 
of GnRH treatment (Fig. 3-14A), and 4 days of D-Trp
6
-GnRH I treatment (Fig. 3-
15A). D-Trp
6
-GnRH I, a GnRH agonist, is a more stable analogue of GnRH, and was 
therefore used for treatment beyond 24 hours. The expression of FasL was reduced 
over the first 24 hours of treatment (Fig. 3-14B), but was up-regulated after 24 hours 
of treatment with GnRH (Fig. 3-15B). p27Kip1 mRNA expression was reduced 
following treatment over 24 hours (Fig. 3-14C), or 4 days of treatment (Fig. 3-15C). 
p21Cip1 mRNA expression was up-regulated after 4 and 6 hours (Fig. 3-14D), but 
there was no change over 4 days of treatment (Fig. 3-15D). There was no significant 
change in the BIM mRNA level in response to GnRH or D-Trp
6
-GnRH I treatment 
over 24 hours or 4 days (Fig. 3-14E and 3-15E). 
 
3.2.3.2  GnRH regulates expression of GADD45 and FasL by FOXO3a 
 
Having identified that GnRH regulates the expression of the FOXO-target genes, 
GADD45, FasL, p27Kip1, p21Cip1 and BIM, the role of FOXO3a in GnRH-





GnRH-induced GADD45 expression has been already demonstrated utilising a 
GADD45-reporter in Section 3.2.2.1. The involvement of FOXO3a in GnRH-
induced GADD45 expression was further examined here by utilising qRT-PCR. 
  
Cells were transfected with control vector, FOXO3a-TM or FOXO3a-TMΔDB. 
Following a time-course treatment with D-Trp
6
-GnRH I, the mRNA expression 
levels of GADD45, FasL, BIM and p27Kip1 genes were measured. The pattern of 
mRNA expression for GADD45 and FasL was similar in cells transfected with 
control vector or FOXO3a-TMΔDB, (Fig. 3-16A and B). However, over-expression 
of FOXO3a-TM constructs followed by D-Trp
6
-GnRH I treatment, up-regulated the 
expression of GADD45 (Fig. 3-16B). This was consistent with previous results from 
luciferase assays (see Section 3.2.2.1). FOXO3a-TM over-expression down-
regulated the expression of FasL compared to the control vector (Fig. 3-16A).  
 
The expression of BIM, p21Cip1and p27Kip1 was also measured in a time-course 
treatment with D-Trp
6
-GnRH I, in cells which had been transfected with control 
vector, FOXO3a-TM or FOXO3a-TMΔDB. The expression pattern of each of these 
genes suggested that GnRH does not regulate BIM, p27Kip1 and p21Cip1 expression 
by FOXO3a (Supplementary Fig. 7-7). In particular, over-expression of FOXO3a-
TM showed no difference in the expression patterns of any of these genes compared 







Figure 3-14: Effect of GnRH on FOXO-target genes mRNA expression in SCL60 cells over 24 
hours. 
Relative mRNA expression of (A) GADD45, (B) FasL, (C) p27Kip1, (D) p21Cip1 and (E) BIM in 
SCL60 cells treated with 1μM GnRH over 24 hours or vehicle (NS), as determined by quantitative 
RT-PCR analysis. Data are shown as mean fold over NS±SEM over 24 hour treatment from at least 3 






Figure 3-15: Effect of GnRH on FOXO-target genes mRNA expression in SCL60 cells over 4 
days. 
Relative mRNA expression of (A) GADD45, (B) FasL, (C) p27Kip1, (D) p21Cip1 and (E) BIM in 
cells treated with 1µM D-Trp
6
-GnRH I or left untreated (each value represent the mRNA expression 
level for treated over untreated cells at each time point (e.g. 24h, 48h)) over 4 days, was determined 
by quantitative RT-PCR analysis. Data are shown as mean fold over the treated/untreated±SEM over 










Figure 3-16: Role of FOXO3a in FOXO-target genes mRNA expression following GnRH 
treatment.  
SCL60 cells were transfected with 10μg of FOXO3a-TM or FOXO3a-TMΔDB. Relative mRNA 
expression of (A), FasL (B) and GADD45 in cells treated with 1µM D-Trp
6
-GnRH over indicated 
time intervals or vehicle (NS) was determined by quantitative RT-PCR analysis. Data are shown as 








3.2.3.3  FOXO1 and FOXO3a auto-regulation 
 
A recent study has demonstrated that the FOXO1 promoter contains FOXO binding 
sites, suggesting that FOXOs can regulate their own expression (Essaghir et al., 
2009). In order to examine whether there is an auto-regulation of FOXO gene 
expression in response to GnRH, FOXO1 and FOXO3a mRNA levels in SCL60 cells 
which have been transfected with a control vector, FOXO1-WT or FOXO3a-WT 
were assessed. As expected, over-expression of FOXO1-WT and FOXO3a-WT 
caused an increase in FOXO1 (Fig. 3-17A) and FOXO3a mRNA levels (Fig. 3-18A) 
respectively, compared to vector control. In contrast, over-expression of FOXO3a-
WT did not increase FOXO1 mRNA levels (Fig. 3-17A), and over-expression of 
FOXO1-WT did not increase FOXO3a mRNA levels (Fig. 3-18A), compared to 
vector control.  
 
To further investigate a possible FOXO auto-regulatory effect in response to GnRH, 
a time-course treatment with GnRH was performed and the mRNA level of FOXO1 
and FOXO3a was measured in cells which had been transfected with FOXO3a-WT 
and FOXO1-WT constructs, respectively. Over-expression of FOXO3a-WT did not 
appear to regulate FOXO1 gene expression (Fig. 3-17B). Over-expression of 
FOXO1-WT displays a trend towards a reduction (this reduction did not reach 
statistical significance with n=3) for FOXO3a gene expression, in response to GnRH 







Figure 3-17: Effect of FOXO1 and FOXO3a on FOXO1 mRNA expression in response to GnRH. 
(A) SCL60 cells were transfected with 10μg of control vector (pcDNA3.1) or FOXO1-WT or 
FOXO3a-WT. Relative mRNA expression levels of FOXO1 in cells that were treated with 1µM 
GnRH for 24 hours was determined by quantitative RT-PCR analysis. (B) SCL60 cells were 
transfected with 10μg of control vector (pcDNA3.1) or FOXO3a-WT. Relative mRNA expression 
levels of FOXO1 in cells that were treated with 1µM GnRH over indicated time intervals or left 
untreated (NS), was determined by quantitative RT-PCR analysis. Data are shown as mean fold over 












Figure 3-18: Effect of FOXO1 and FOXO3a on FOXO3a mRNA expression in response to 
GnRH.  
(A) SCL60 cells were transfected with 10μg of control vector (pcDNA3.1) or FOXO1-WT or 
FOXO3a-WT. Relative mRNA expression levels of FOXO3a in cells that were treated with 1µM 
GnRH for 24 hours was determined by quantitative RT-PCR analysis. (B) SCL60 cells were 
transfected with 10μg of control vector (pcDNA3.1) or FOXO3a-WT. Relative mRNA expression 
levels of FOXO3a in cells that were treated with 1µM GnRH over indicated time intervals or left 
untreated (NS), was determined by quantitative RT-PCR analysis. Data are shown as mean fold over 
NS±SEM from at least 3 independent experiments. (b is significantly different from a; P<0.05) 
 
3.2.3.4  GnRH does not regulate FOXO1 and FOXO3a gene expression and 
protein synthesis 
 
In the next set of experiments, the involvement of GnRH in regulating FOXO mRNA 
levels and protein expression was examined. Cells were treated with GnRH over 24 
hours or with D-Trp
6
-GnRH I over 5 days, and mRNA levels and protein expression 
of FOXO1 and FOXO3a were assessed by qRT-PCR or Western Blot analysis, 
respectively. The results indicated that GnRH does not regulate FOXO1 and 
FOXO3a gene expression (Fig. 3-19) or protein levels (Fig. 3-20). To further 





microscopy was used to visualise FOXO1 and FOXO3a levels in cell following 
treatment with GnRH for 6 and 24 hours. FOXO3a was primarily located in the 
nucleus in untreated and treated cells, and GnRH treatment appears not to change the 
level of total FOXO3a (t-FOXO3a) (Fig. 3-21). FOXO1 appears to be localised both 
in the nucleus and cytoplasm in untreated and in 6-hour treated cells. 24 hour 




Figure 3-19: Effect of GnRH on FOXO1 and FOXO3a mRNA expression in SCL60 cells.  
Relative mRNA expression of FOXO3a and FOXO1 in SCL60 that were treated (A and B) with 1µM 
GnRH for 24 hours (C and D) or with 1µM D-Trp
6
-GnRH I over 5 days, or vehicle (NS), was 
determined by qRT-PCR analysis. Data are shown as mean fold over NS±SEM from at least 3 








Figure 3-20: Effect on total FOXO1 (t-FOXO1) and total FOXO3a (t-FOXO3a) protein levels 
following GnRH treatment.  
SCL60 cells were treated with 1µM of GnRH or left untreated (NS). Proteins level were analysed 
using the appropriate antibody. Quantification of the immunoblots was done by using β-actin as a 












Figure 3-21: t-FOXO3a levels following GnRH stimulation in SCL60 cells.  
Immunofluorescence confocal microscopy was used to visualise the change in t-FOXO3a levels 
(green) following 1µM GnRH treatment at the time intervals indicated. DAPI (red) is a marker for 







Figure 3-22: t-FOXO1 levels following GnRH stimulation in SCL60 cells.  
Immunofluorescence confocal microscopy was used to visualise the change in t-FOXO1 levels (green) 
following 1µM GnRH treatment at the time intervals indicated. DAPI (red) is a marker for nucleus 
and co-localisation is indicated in yellow.  
 
3.2.4  Monitoring the role of FOXO3a in cell-cycle regulation in response 
to GnRH  
 
Up-regulation of any of the FOXO-target genes, mediate a specific cell-growth 
inhibitory effect. For example, up-regulation of FasL mediates apoptosis whereas up-
regulation of GADD45 mediates blocking of the cell-cycle at G2 phase. Having 
shown that GnRH treatment induces the expression of these genes, cell-cycle 
analysis was performed in response to D-Trp
6





experiment was to examine whether the cell-cycle profile of SCL60 cells and PWE-
1-NB26-3 prostate cancer cells followed the effect of the GnRH-induced genes, in 
response to D-Trp
6
-GnRH I treatment The proportion of cells found in the sub-
diploid population increased approximately by 3-fold in SCL60 cells, but did not 
increase in PWE-1-NB26-3. Furthermore, the proportion of SCL60 cells in G1 phase 
were decreased from 68.4% to 31.6%, while the proportion of cells in G2 phase were 
increased from 14.6% to 40.3%, (Fig. 3-23B and D). In contrast, the proportion of 
PWE-1-NB26-3 cells found in G2 phase was decreased from 77.9% to 66.6% and in 








Cells were treated with 100nM D-Trp
6
-GnRH I for 96 hours, fixed, permeabilised and stained with 
Hoechst for analysis by flow cytometry. The graphs represent a typical/single experiment. (Data 
analysis (gating and computational analysis) was performed with the cooperation of Ms. Shonna 





3.3  DISCUSSION 
 
Scientific interest in FOXO transcription factors has increased markedly in the past 
eight years. Both in vivo and in vitro studies have been conducted in order to gain an 
understanding of the role of FOXOs in diverse cellular processes including cell 
proliferation, and the role of FOXO in diseases, including diabetes and cancer. 
However, to date, the mechanisms that regulate FOXO function are not well 
understood. 
 
In the present study, the impact of GnRH on FOXO function was examined. Taken 
together, the results presented in this Chapter demonstrate that GnRH modulates 
FOXO3a function in a model HEK293 cell line (SCL60 cells). The specific 
mechanisms by which GnRH modulates the function of FOXOs were also examined. 
The dominant GnRH-initiated pathway that regulates the function of FOXOs was 
found to involve Gq-coupling and Akt-, IKK-dependent signalling (Fig. 3-10).  
 
GnRH treatment of SCL60 cells for 24 hours resulted in increased FOXO 
transcriptional activity. The transcriptional activity initially measured was probably 
the combined transcriptional activity from all three FOXOs; FOXO1, FOXO3a and 
FOXO4. In order to begin to understand the mechanisms underlying GnRH-induced 
FOXO transcriptional activity, the effect of GnRH on FOXO1 and FOXO3a 
phosphorylation at their Akt phosphorylation sites was examined (Fig. 3-1 & SFig. 
7-1). This was considered to be a reasonable approach since phosphorylation of 
FOXOs results in their translocation to the cytoplasm, and therefore the inhibition of 
their transcriptional activity (van der Horst and Burgering, 2007). Indeed, GnRH 
treatment initially (5-60 minutes) led to FOXO3a phosphorylation at Ser
253





an Akt-targeted phosphorylation site (Fig. 3-24). However, FOXO1 phosphorylation 




Figure 3-24: Regulation of FOXO3a by phosphorylation following GnRH treatment. 
Treatment of SCL60 cells with GnRH leads to FOXO3a phosphorylation at Ser
253
 by a Gq-coupled, 
PI3K/Akt-dependent signalling pathway (direct activation of PI3K by GnRH via Gq has not been 
demonstrated in this study). Phosphorylation of FOXO3a by this pathway leads to its cytoplasmic 
localisation. Broken lines indicate an indirect regulation.  
 
The targeting of FOXO3a phosphorylation at Ser
253
 by GnRH suggested that the 
change in phosphorylation status could result in its redistribution between the 
nucleus and cytoplasm. This redistribution could have an effect on FOXO3a 
transcriptional activity. Using confocal microscopy, the cellular redistribution of 
phosphorylated FOXO3a was visualised. Indeed, phosphorylation of FOXO3a at 
Ser
253







translocation to the cytoplasm (Fig. 3-2), in line with previous work, in which 
phosphorylation of FOXO3a, independent of GnRH treatment, led to its cytoplasmic 
translocation (van der Horst and Burgering, 2007). Phosphorylation at Ser
253
 
promotes FOXO3a interaction with the 14-3-3 chaperone protein which sequesters 
FOXO3a in the cytoplasm inhibiting its transcriptional activity (Brunet et al., 1999). 
Interestingly, the confocal microscopy images revealed punctate nuclear p-
FOXO3a(Ser
253
) staining (Fig. 3-2). These puncta could correspond to a complex of 
p-FOXO3a(Ser
253
) either with chaperones such as 14-3-3 that shuttles FOXOs to the 
cytoplasm, or with other co-factors, such as β-catenin which act to regulate FOXO3a 
transcriptional activity.  
 
Next, the role of FOXO3a phosphorylation in regulating its transcriptional activity 
following GnRH treatment was assessed. Surprisingly, activation of FOXO3a 
transcriptional activity appeared to be independent of its phosphorylation status (Fig 
3-8). The finding that the transcriptional activity of FOXO3a-TM was higher than 
FOXO3a-WT was probably because FOXO3a-TM was retained in the nucleus 
because it could not be phosphorylated by Akt. Therefore the targeting of FOXO3a 
phosphorylation by GnRH does not appear to be the dominant mechanism regulating 
FOXO3a transcriptional activity. 
 
Having shown that GnRH up-regulates GADD45-reporter activity via FOXO3a 
independently of FOXO3a phosphorylation at its Akt phosphorylation sites, other 
potential signalling pathways that modulate FOXO transcriptional activity were 
investigated (Fig 3-10). GnRH-induced transcriptional activity of FOXO was found 





although it is not clear whether these three mediators belong to the same signalling 
pathway (Fig. 3-25). However, not all of these factors were involved in the 
phosphorylation of FOXO3a at Ser
253
. This finding appears to support the above 
suggestion that GnRH-targeted phosphorylation does not appear to be the dominant 
mechanism regulating FOXO3a transcriptional activity. Furthermore, while the 
targeting of FOXO3a phosphorylation was mediated by PI3K, a pharmacological 
inhibitor of PI3K did not inhibit GnRH-induced GADD45-reporter activity (Fig 7-6). 
It is possible that Akt and IKK participate in two different signalling pathways 
following GnRH treatment. Further investigation is required to determine this. It is 
important to note that in this thesis only the role of known signalling mediators that 
are recruited in pathways targeting the regulation of FOXO3a activity have been 
assessed. However, these signalling pathways may recruit a variety of additional 
mediators which may play a pivotal role in the regulation of FOXO3a activity, and 
which would be important to further dissect. 
 
The Akt inhibitor, in contrast to the PI3K inhibitor (Wortmannin) (Fig. 7-6), 
inhibited the FOXO3a-mediated GADD45-reporter activity. This was an unexpected 
result, since the activation of Akt by PI3K, via the PDK1, is a well-established 





sites, which is required for its full Akt activation (Liu et al., 2009; Vanhaesebroeck 
and Alessi, 2000). The finding that GnRH targeted the phosphorylation of Akt at 
Thr
308
 suggested that Akt was activated by PDK1 (Fig 3-11). The inability of the 
PI3K inhibitor to inhibit the FOXO3a-mediated GADD45-reporter activity suggested 
that PDK1 was activated by a PI3K-independent pathway. The mechanism by which 








Figure 3-25: Regulation of GADD45 and FasL gene expression by FOXO3a. 
GnRH regulates GADD45 and FasL gene expression by regulation of FOXO3a. In addition, GnRH 
mediates the regulationof FOXO3a transcriptional activity via a Gq-coupled, Akt-and IKK-dependent 
signalling pathway. Broken lines indicate an indirect regulation. 
 
A further interesting result was the fact that IKK was found to be involved in the 
control of GADD45-reporter activity in response to GnRH. A role for IKK in the 
regulation of FOXO3a transcriptional activity has previously been demonstrated in a 
study conducted by Hu et al. (2004). In particular, IKK phosphorylated FOXO3a at 
Ser
644
 resulting in its translocation to the cytoplasm. However, co-transfection of a 
FOXO3a-TM Ser
644
Ala construct into SCL60 cells, did not inhibit the GnRH-
induced GADD45-reporter activity (Hu et al., 2004). This suggests that in response 
to GnRH, either IKK phosphorylates FOXO3a at another putative IKK recognition 





that IKK does not mediate FOXO3a transcriptional activity directly, but instead as 
part of another signalling pathway.  
 
In addition to phosphorylation, acetylation is also an important post-translational 
modification that is involved in regulating FOXO activity. Previous studies have 
demonstrated that FOXO de-acetylation by SIRT1 led to its cytoplasmic localisation 
and a reduction in FOXO transcriptional activity (Motta et al., 2004). In contrast to 
these results, over-expression of SIRT1 increased GADD45-reporter activity 
compared to vector control following GnRH stimulation in SCL60 cells (Fig. 3-13). 
It is possible that SIRT1 de-acetylates another transcription factor, other than 
FOXO3a, which could bind to and regulate GnRH-induced GADD45-reporter 
activity. In order to test this possibility, SCL60 cells were co-transfected with 
FOXO3a and SIRT1, and GADD45-reporter activity measured. Co-expression of 
FOXO3a with SIRT1 reduced basal FOXO3a transcriptional activity compared with 
over-expression of FOXO3a alone, which is in line with previous work (Motta et al., 
2004). Following GnRH treatment, co-expression of FOXO3a and SIRT1 increased 
GADD45-reporter activity, but the increase was to the same level as observed in 
cells which had been transfected with FOXO3a alone. This suggested that, although 
SIRT1 de-acetylates FOXO3a, GnRH-R activation regulates FOXO3a transcriptional 
activity via an alternative pathway or post-translational modification, which is 
dominant compared to the pathway that led to FOXO3a acetylation.  
 
The effect of β-catenin on the transcriptional activity of FOXO3a following GnRH 
stimulation was also examined. β-catenin has previously been shown to interact with 





GnRH stimulation has also been demonstrated (Gardner et al., 2007). Based on these 
studies, a role of β-catenin in regulating FOXO3a transcriptional activity in response 
to GnRH was expected. In order to confirm this functional interaction, LiCl 
treatment was used in order be able to further increase β-catenin accumulation in the 
nucleus, above GnRH-mediated β-catenin nuclear accumulation (Fig. 3-12). Treating 
with LiCl increased the transcriptional activity of FOXO3a. However, following 
treatment with both LiCl and GnRH treatment, the transcriptional activity of 
FOXO3a decreased. This suggests that GnRH possibly alters the way in which 
FOXO3a interacts with β-catenin, and that the binding of β-catenin to FOXO3a, 
following GnRH treatment, down-regulates its transcriptional activity. However, the 
transcriptional activity of FOXO3a increased following GnRH stimulation alone, 
even though β-catenin accumulates in the nucleus. Thus, the inhibitory effect of β-
catenin on FOXO3a may not be the dominant mechanism for regulating FOXO3a 
activity in response to GnRH. This may account for the observed increase in 
FOXO3a transcriptional activity following GnRH stimulation alone in the absence of 
LiCl. 
 
It is important to note that although LiCl treatment increased β-catenin nuclear 
accumulation (Rao et al., 2005), it may also target other signalling pathways which 
could interfere with the GnRH-induced signalling pathways. Therefore, it would be 
important to further examine the role of β-catenin in regulating FOXO3a 
transcriptional activity by utilising an alternative regulator for β-catenin cellular 







Upon establishing that GnRH treatment targets FOXO3a transcriptional activity, a 
role for FOXO3a in GnRH-induced cell-growth inhibition and apoptosis was 
examined. qRT-PCR analysis demonstrated that the expression of apoptotic (FasL) 
and cell-cycle regulatory (GADD45, p21Cip1 and p27Kip1) FOXO-target genes 
were regulated following 4 days of treatment with D-Trp
6
-GnRH I (Fig. 3-15). 
Additionally, the expression profiles of the FOXO-target genes over 4 days of D-
Trp
6
-GnRH I treatment was analysed. Following D-Trp
6
-GnRH I stimulation, the 
expression of cell-cycle regulatory proteins GADD45 and p21Cip1 increased over 24 
hours, reaching maximal expression after 6 hours. In contrast, expression of the pro-
apoptotic protein FasL and the cell-cycle regulatory protein p27Kip1 decreased over 
24 hours of treatment. Further treatment with D-Trp
6
-GnRH I over 3 days increased 
the expression of FasL and GADD45 proteins, whereas the expression of p27Kip1 
protein was down-regulated.  
 
Since GnRH has been shown to target cell-growth inhibition, (Kraus et al., 2006), the 
above result suggest that D-Trp
6
-GnRH I treatment blocks cell-cycle progress prior 
to inducing an apoptotis. In particular, the up-regulation of GADD45 gene expression 
possibly results in blockade of cell-cycle progress at G2 phase. In addition, the up-
regulation of FasL gene expression possibly induces apoptosis. Finally, D-Trp
6
-
GnRH I treatment could mediate a decrease of the cell population in G1 phase by the 
reduction of p27Kip1 gene expression.  
 
Thus, cell-cycle analysis of SCL60 cells was performed following 4 days of 
treatment with D-Trp
6
-GnRH I to examine the above speculation (Fig. 3-23). Indeed, 







-GnRH I, which may be a consequence of the induction of GADD45 
expression. Following D-Trp
6
-GnRH I stimulation, the proportion of apoptotic cells 
(sub-diploid population) was increased by 4-fold, possibly as a result of FasL 
expression. The cell population that was found in G1 phase was reduced, possibly 
due to the decrease in p27Kip1 expression. The results from cell-cycle analysis were 
in line with a study conducted by Miles et at. (2004) (Miles et al., 2004). However, 
cell-cycle analysis following a time-course treatment, would be required in order to 
determine how GnRH causes cell-cycle changes over time, and clarify whether these 
above-mentioned genes are the main mediators of this regulation.  
 
Taken together, the research presented in this Chapter describes a novel regulatory 
mechanism initiated by GnRH-R activation. This involves the regulation of FOXO3a 
transcriptional activity, and the expression of FOXO-target genes by GnRH. In 
Chapters four and five, the impact of GnRH regulation of FOXO3a transcriptional 
activity on cell function will be assessed. Chapter four describes a role for FOXO3a 
in the well-documented GnRH-induced cell-growth inhibition and apoptosis. Chapter 
five describes a novel role for FOXO3a in GnRH-induced LHβ-subunit expression in 



























4.0  ABSTRACT 
In this Chapter, the role of FOXO3a in the GnRH-induced cell-growth 
inhibition was examined. The results presented demonstrate that FOXO3a 
protects cells from the GnRH-induced cell-growth inhibition. In addition, 
GnRH recruits FOXO3a to regulate FasL expression to induce cell-growth 
inhibition. The role of FOXO3a in the GnRH-induced cell-growth inhibition by 
targeting GADD45 expression is also assessed.  
 
4.1  BACKGROUND AND OBJECTIVES  
 
Activation of the GnRH-R by GnRH has been shown to inhibit cell proliferation and 
induce apoptosis in cancer-delivered cell lines. The anti-proliferative and apoptotic 
effects of GnRH on tumour cells are also well-documented (Reviewed in Kraus et al. 
2006). Several studies have reported that these events can occur as a result of 
changes in the expression profiles of specific cell-cycle regulatory and apoptotic 
genes (Imai et al., 1998a; Wu et al., 2009). Many of these are FOXO-target genes. 
FOXOs are involved in a number of biological processes, including cell-fate decision 
and tumour suppression in a variety of cancers (Fu and Tindall, 2008). Indeed, 
FOXO3a activation not only promotes apoptosis in vitro, but also restricts tumour 
growth in vivo in breast cancer cells (Yang and Hung, 2009), while constitutively 
active FOXO4 reduces tumour size (Greer and Brunet, 2005).  
 
The regulation of FOXO3a transcriptional activity by GnRH-R activation has been 
demonstrated in Chapter three, and in this chapter the role of FOXO3a signalling 
pathway in the GnRH-induced cell-growth inhibition was examined. In particular the 





 to explore the potential role for FOXO3a activity in mediating the anti-
proliferative and apoptotic effect of GnRH 
 to examine the role of FOXO3a in the cell-cycle regulation following GnRH 
stimulation. 
 
4.2  RESULTS 
 
4.2.1  Role of FOXO3a in GnRH-induced cell-growth inhibition 
 
4.2.1.1  Generation of FOXO3a knock-down cell lines 
 
To elucidate the role of FOXO3a in GnRH-induced cell-growth inhibition, FOXO3a 
knock-down stable cell lines were generated using lentivirus-delivered short hairpin 
RNA (shRNA). Firstly, the conditions for optimal transduction efficiency were 
determined. SCL60 cells were transduced with GFP-lentivirus at ratios (cells to 
lentivirus) of 1:1, 1:2 and 1:5 in the presence or absence of polybrene (0.6μg/ml) 
over 1, 2, 3, 4 and 5 days (Supplementary Fig. 7-8). Polybrene is a positively 
charged molecule that binds to cell surfaces and neutralizes the surface charge of the 
cell, increasing the efficiency of infection (Aubin et al., 1988). The optimal 
conditions for lentivirus transduction of SCL60 cells were the following: 3 days of 
transduction with lentivirus in the absence of polybrene at a ratio of 1:5.  
 
Subsequently, cells were transduced with lentivirus-delivered shRNA to knock-down 
the expression of FOXO3a. Cells were also transduced with lentivirus-delivered 
scrambled shRNA to generate a control cell line. Western Blot analysis confirmed 
that transduction of cells with lentivirus-delivered shRNA against FOXO3a reduced 





double shRNA combination (shRNA codes: sh2978 and sh1687) (this clone will 
henceforth be referred to as SCL840). A control cell line was also generated (this 
clone will henceforth be referred to as SCL839) (Fig. 4-1). 
 
The generation of a stable FOXO3a knock-down prostate cancer cell line (PWE-1-
NB26-3) was also attempted in order to confirm the involvement of FOXO3a in cell-
growth inhibition following GnRH treatment in another cell system. However, clones 




Figure 4-1: FOXO3a protein level in the control and FOXO3a knock-down stable cell lines.  
SCL60 cells were transduced for 3 days with lentivirus-delivered short hairpin RNA (shRNA) against 
FOXO3a or lentivirus-delivered scrambled shRNA at a ratio of 1:5 (cells:lentivirus). A single clone of 
control cells (SCL839) and FOXO3a knock-down cells (SCL840) was isolated, and the reduction of 
total FOXO3a (t-FOXO3a) protein level was measured compared to the control cells by Western Blot 
analysis.  
 
4.2.1.2  FOXO3a knock-down does not affect GnRH-R functionality  
 
Variations of GnRH-R expression levels differentially affect the GnRH-induced 
apoptotic machinery in different cell lines and contribute to cell type-specific cell-





the SCL839 and SCL840 cell lines that had been generated, the effect of transduction 
with lentivirus on the level of GnRH-R expression, and the ability of the GnRH-R to 
activate intracellular signalling pathways following GnRH treatment was examined. 
[
125
I]-GnRH receptor binding assays demonstrated that SCL840 expressed slightly 
lower numbers of receptors at the cell-surface compared to SCL839 cells (Fig. 4-
2A). In addition, a [
3
H]-inositol phosphate assays were performed in order to assess 
the ability of the two cell lines to activate intracellular signalling. Treatment of 
SCL839 generated approximately an IC50 of 1nM and treatment of SCL840 
generated an IC50 of 10nM (Fig. 4-2B). Nevertheless, the maximal responses were 
6343 cpm for SCL839 and 2243 cpm for SCL840 (Fig. 2-4C). These results 
suggested that both SCL839 and SCL840 clones had the ability of functional 









Figure 4-2: [125I]-GnRH receptor binding and [3H]-inositol phosphate assay performed in 
SCL839 and SCL840 cells.  
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GnRH in SCL840 (black squares) and SCL839 (red circles) expressed as percent of maximum 
response. (C) Maximal inositol phosphate production in response to (10
-6
M) GnRH in SCL840 (black 
squares) and SCL839 (red circles). Data are shown as mean±SEM from at least 3 independent 
experiments performed in triplicate.  
 
4.2.1.3  FOXO3a protects SCL60 cells from GnRH-induced cell-growth 
inhibition 
 
The effect of GnRH treatment on the cell-growth rate of the SCL839 and SCL840 












35% higher cell-growth inhibition in the SCL840, in spite of having slightly lower 
receptor numbers, compared to SCL839 cells (Fig. 4-3A). To further confirm the 
differential effect of D-Trp
6
-GnRH I on cell-growth inhibition in these two cell lines, 
a cell-growth assay, in the presence or absence of 0.5nM D-Trp
6
-GnRH I treatment, 
was performed over 5 days. Cell-growth inhibition in response to D-Trp
6
-GnRH I 
was higher for the SCL840 cells (Fig. 4-3B) compared with SCL839 cells (Fig. 4-
3C), which is consistent with the cell viability assay (see Fig. 4-3A) In addition, the 
cell-growth rate of SCL840 cells was reduced compared to the control SCL839 cells 
in absence (Fig. 4-4A) or in presence of 0.5nM D-Trp
6
-GnRH I (Fig. 4-4B). 
 
When the data in figure 4-3 was further analysed, the cell-growth rate was found to 
be reduced by approximately 23.5% for control SCL839 cells, and by 73% for 
SCL840 cells, followed treatment with 0.5nM D-Trp
6
-GnRH I (analysis was 
performed with Graph Prism 5.00, growth rate was calculated by taking the 
derivative of the curve equation describing the number of cells over time) (Fig. 4-5). 
Cell-doubling times for these two cell lines, measured in the presence or absence of 
D-Trp
6
-GnRH I treatment respectively, were 1.8 and 1.4 hours for SCL839, and 7.8 
and 2.3 SCL840 cells (Table 4-1). 
 
The growth rate of SCL60 cells was also examined and compared to that of SCL839 
and SCL840 cells. The growth rate of SCL60 cells was similar to that of SCL839 
without D-Trp
6
-GnRH I treatment (Fig. 4-4A), while it was comparable to the 
growth rate of the SCL840 cells in the presence to 0.5nM D-Trp
6







Figure 4-3: Effect of GnRH on cell-growth rate in SCL840 and control SCL839 cell lines. 
(A) SCL839 and SCL840 cells in 12-well plates were treated on day 0 with the indicated doses of 
GnRH analogue (D-Trp
6
-GnRH). Cells were fixed, stained with sulforhodamine B, and quantified 
spectrophotometrically following cell-growth for 5 days. (B and C) SCL840 and SCL839 cells were 
plated in 100mm plates and treated at day 1 with 0.5nM D-Trp
6
-GnRH I or left untreated. Cell number 
was counted on subsequent days using a haemocytometer. (The vertical black line indicates that cells 
were treated in day 1, the horizontal green line indicates the number of cells in day 0). The data are 
from four independent experiments performed in triplicate. Data are shown as mean±SEM from at 






Figure 4-4: Effect of GnRH on cell growth rate. 
(A and B) SCL839 and SCL840 cells were plated in 100mm plates. Thereafter, (B) cells were treated 
at day 1 with 0.5nM D-Trp
6
-GnRH I (the vertical black line indicates that cells were treated in day 1) 
or (A) left untreated (the horizontal green line indicates the number of cells in day 0). (A and B) Cell 
number was counted the following days using a haemocytometer. Data are shown as mean±SEM from 















-GnRH I treatment Doubling time (hours) 
SCL839 No 1.44 (0.98-4.47) 
 Yes 1.82 (0.96-3.75) 
SCL840 No 2.32 (1.92-3.24) 
 Yes 7.88 (2.69-high ) 





4.2.1.4  The effect of FOXO3a on FasL expression in response to D-Trp
6
-
GnRH I treatment 
 
FOXO3a plays a role in GnRH-induced FasL expression as demonstrated in Section 
3.2.3.2 in Chapter three. To confirm the involvement of FOXO3a in FasL gene 
expression in response to D-Trp
6
-GnRH I, SCL839 and SCL840 cells were treated 
with D-Trp
6
-GnRH I over 5 days, and FasL mRNA levels measured. FasL gene 







-GnRH I treatment (Fig. 4-6). These data suggest that FOXO3a 
negatively regulates FasL expression following GnRH treatment.  
 
FasL activates the Fas receptor to induce apoptosis through the activation of a 
signalling pathway which involves mediators including FADD, caspase 3 and 
caspase 8. To further confirm that FOXO3a mediates GnRH-induced FasL 
expression, Western Blot analysis was performed to examine whether the levels of 
FADD, caspase 3 and caspase 8 proteins were differentially regulated in SCL839 and 
SCL840 cells. However, no protein bands could be detected in the Western Blots 
performed, possibly due to poor expression levels.  
 
 
Figure 4-6: The effect of D-Trp
6
-GnRH I on FasL mRNA expression in SCL839 and SCL840 
cells.  
Relative mRNA expression of FasL in SCL839 cells and SCL840 cells that were treated with 0.5nM 
D-Trp
6
-GnRH I for the indicated times was determined by quantitative RT-PCR analysis. Data are 








4.2.1.5  Effect of Akt and IKK signalling on GnRH-induced cell-growth 
inhibition in SCL60, SCL839 and SCL840 cells 
 
GnRH-induced FOXO3a transcriptional activity occurs via Akt- and IKK-dependent 
signalling pathways as demonstrated in Section 3.2.2.3 in Chapter three. 
Furthermore, the involvement of FOXO3a in GnRH-induced cell-growth inhibition 
was also demonstrated in Section 3.2.4.3. Therefore, the role of IKK and Akt in 
GnRH-induced cell-growth inhibition was examined next. SCL60 cells were pre-
treated with pharmacological inhibitors of IKK or Akt, and cell-growth was 
measured following 100nM D-Trp
6
-GnRH I treatment. Pre-treatment with IKK or 
Akt1/2 inhibitors reduced cell-growth rate over 5 days by approximately 20% and 
30% respectively in the absence of D-Trp
6
-GnRH I treatment (Fig. 4-7A). However, 
Akt1/2 inhibitor shows a trend towards a reduction (19%) of GnRH-induced cell-
growth inhibition, even though the reduction did not reach statistical significance 
(Fig. 4-7B).  
 
Akt and IKK were found to inhibit GnRH-induced FOXO3a transcriptional activity 
in SCL60 cells (see Section 3.2.2.3). Furthermore, the Akt inhibitor partially rescues 
GnRH-induced cell-growth inhibition in SCL60 cells (Fig. 4-7B). Thus, it is possible 
that Akt (and possibly IKK) could be involved in the GnRH-FOXO3a inhibitory 
signalling pathway. If Akt and IKK are involved in this pathway, by regulating 
FOXO3a transcriptional activity, then Akt and IKK inhibitors would be expected to 
differentially effect GnRH-induced cell-growth inhibition in SCL839 and SCL840, 
because FOXO3a protein levels are lower in SCL840 compared to SCL839 cells. To 
test this hypothesis, SCL839 and SCL840 cells were pre-treated with Akt and IKK 







I treatment. While the IKK inhibitor had no significant effect on the cell-growth rate 
of both cell lines (Fig. 4-8A and C), the Akt inhibitor reduced the cell growth rate 
only in SCL840 cells (Fig. 4-8A). Even so, neither of these two inhibitors completely 
rescued GnRH-induced cell-growth inhibition (Fig. 4-8B and D). However, the Akt 
inhibitor reduced the level of GnRH-induced cell-growth inhibition of SCL840 to 
approximately the same level as for SCL839 following D-Trp
6
-GnRH I treatment 
alone (Fig. 4-8D compared to Fig. 4-8B, denoted by arrows). This result could 
implicate Akt involvement with FOXO3a in the GnRH-induced cell-growth 
inhibition signalling pathway.  
 
 
Figure 4-7: Effect of Akt and IKK on GnRH-induced cell-growth inhibition in SCL60 cells.  
(A and B) SCL60 cells were treated with 1.5µM of IKK inhibitor (BMS-345541) or 1µM of Akt 
inhibitor (Akt1/2) and (B) 100nM of GnRH analogue (D-Trp
6
-GnRH I). Cells were fixed, stained with 
sulforhodamine B, and quantified spectrophotometrically following cell growth for 5 days. Data are 
shown as mean±SEM from at least four independent experiments performed in triplicate. (b is 












Figure 4-8: Effect of Akt and IKK on GnRH-induced cell-growth inhibition in SCL839 and 
SCL840 cells.  
(A, B, C and D)SCL839 and SCL840 cells were treated with 1.5µM of IKK inhibitor (BMS-345541) 
or 1µM of Akt inhibitor (Akt1/2) and (B and D) 0.5nM of GnRH analogue (D-Trp
6
-GnRH I). Cells 
were fixed, stained with sulforhodamine B, and quantified spectrophotometrically following cell 
growth for 5 days. Data are shown as mean±SEM from at least three independent experiments 







4.2.1.6  Monitoring the role of FOXO3a in cell-cycle regulation in response 
to GnRH  
 
The role of FOXO3a in GnRH-induced cell-growth inhibition was also confirmed by 
flow cytometry analysis. This is a simple method for detecting sub-diploid cell 
populations, an indication of apoptotic cells, by staining DNA. Cell-cycle analysis 
also allows the detection of the proportion of cells found at specific stages of the cell-
cycle. In response to D-Trp
6
-GnRH I treatment, the sub-diploid population was 
increased approximately 3-fold in SCL839 cells (Fig. 4-9A and C), and 
approximately 7-fold in SCL840 cells (Fig. 4-9B and D). Thus, SCL840 cells are 
more sensitive to D-Trp
6
-GnRH I-induced cell-growth inhibition compared to the 
SCL839 cells, confirming the cell viability assay results presented earlier (see 
Section 4.2.3). The proportion of cells found in G1 and G2 were similar in both 
stable cell lines in the absence of D-Trp
6
-GnRH I treatment. The proportion of cells 
in G1 phase decreased from 60.1% to 46.4% in SCL839 cells following D-Trp
6
-
GnRH I treatment (Fig. 4-9A and C), and from 60% to 36.5% in SCL840 cells (Fig. 
4-9B and D), while no change in proportion of cells in G2 phase was observed in 
response to D-Trp
6












Cells were treated with 0.5nM D-Trp
6
-GnRH I for 96 hours, fixed, permeabilised and stained with 







 4.3  DISCUSSION 
 
Although the signalling pathways that mediate GnRH-induced cell-growth inhibition 
in different cell systems have been examined previously (Kraus et al., 2006), there is 
no report implicating FOXO3a in these pathways. The results presented thus far 
indirectly implicate a role for FOXO3a in GnRH-induced cell-growth inhibition. 
GnRH has previously been demonstrated to induce the expression of the FOXO-
target genes, FasL and GADD45 (Imai et al., 1998a; Wu et al., 2009). The results 
presented in Chapter three demonstrated that GnRH regulates the FasL and GADD45 
expression by targeting FOXO3a activity.  
 
In order to directly examine the role of FOXO3a, a stable FOXO3a knock-down cell 
line was generated (SCL840 cells, together with control SCL839 cells) (Fig. 4-1). 
Stable cell lines were generated instead of transiently knocking-down FOXO3a 
expression because stable knock-down cell lines ensure long-term reduction of 
FOXO3a protein levels, which are useful for experiments that run over days rather 
hours. However, by generating a stable cell line, other parameters should be taken 
into account. Transduction of cells with lentivirus-delivering shRNA may cause 
phenotypic changes in the generated stable lines. For example, in SCL60 cells, it 
may alter the function and/or the expression of the GnRH-R. However, GnRH-R 
binding assays showed no significant differences in the number of GnRH-R 
expressed at the cell surface of the two stable cell lines (control and knock-down). 
GnRH stimulation of Inositol phosphate was also similar in both cell lines, indicating 
that functional Gq coupling was comparable (Fig. 4-2). Nevertheless, it would be 





Unfortunately, there was lack of significant reduction of FOXO3a protein levels in 
all other clones. Generation of a prostate cancer FOXO3a knock-down cell line 
expressing GnRH-R was also attempted, but again no clones with a significant 
reduction of FOXO3a expression were obtained.  
 
In order to assess the role of FOXO3a in GnRH-induced cell growth inhibition, cells 
numbers were counted after treatment with D-Trp
6
-GnRH I (Fig. 4-3). The relative 
growth rate of SCL840 cells was slower compared to that of the SCL839 cells. A 
role for FOXO3a in cell proliferation, visualised by microscopy, was also confirmed 
in cell viability assays. Interestingly, reduction of FOXO3a levels in SCL840 cells, 
increased cell-growth inhibition following D-Trp
6
-GnRH I stimulation, which 
suggests that FOXO3a protects cells from GnRH-induced cell-growth inhibition. 
Cell-cycle analysis also confirmed the involvement of FOXO3a in protecting cells 
from GnRH-induced cell-growth inhibition via the monitoring of the sub-diploid 
population which represents the apoptotic cells. This result, is in contrast with most 
previous studies in other cell systems demonstrating that FOXO activation promoted 
cell-growth inhibition and apoptosis (Brunet et al., 1999; Ramaswamy et al., 2002; 
Roy et al., 2010). However, Srinivasan et al. (2005) demonstrated that activation of 
FOXO3a was required for neuron survival (Srinivasan et al., 2005), suggesting that 
the role of FOXO3a in cell-growth may be cell-type specific. 
 
The role of FasL in FOXO3a-mediated GnRH-induced cell-growth inhibition was 
also examined (Fig. 4-6). Previous studies have also examined the role of FasL in the 
GnRH-induced cell-growth in different cell systems (Morgan et al., 2008). In 





signalling apoptotic pathway was assessed. Small elevations of phosphorylated 
FADD, which is involved in the FasL apoptotic pathway, were detectable in SCL60 
cells in response to GnRH (Morgan et al., 2008). The involvement of FasL in the 
GnRH-induced cell-growth inhibition has been proposed in several other studies 
(Imai et al., 1997; Imai et al., 1998a). In contrast, Huang et al. (2002) demonstrated 
that GnRH did not up-regulate FasL expression, while it mediated cell-growth 
inhibition in leiomyoma cells (Huang et al., 2002), again suggesting that the 
mechanism of GnRH-induced cell-growth inhibition is cell-type specific. 
 
 
FOXO3a level Gene Effect on GnRH-induced cell-
growth inhibition 
Control ↑        FasL (Fig. 3-16A) ↑↑     (Fig. 4-4A and B,       
          SCL60 cells) 
Over-expressed 
(FOXO3a-TM) 
↓       FasL  (Fig. 3-17A) ↓        (not measured) 
Knock-down ↑↑    FasL  (Fig. 4-6) ↑↑↑   (Fig. 4-3A) 
Control ↑      GADD45 (Fig. 3-16A) ↑↑     (Fig. 4-4A and B,  
          SCL60 cells) 
Over-expressed 
(FOXO3a-TM) 
↑↑    GADD45 (Fig. 3-17B) ↑        (not measured) 
Knock-down (not measured) ↑↑↑   (Fig. 4-3A) 
 
Table 4-2: This table summarises the effect of GnRH on the expression of FasL and GADD45, 
and the effect of GnRH on the cell-growth inhibition in the SCL60 model cell line, with regards 
to FOXO3a levels (Arrows denote relative increase or decrease in gene expression and cell-growth 
inhibition)  
 
Based on the results presented in this Chapter, GnRH potentially recruits FOXO3a in 
order to regulate FasL expression to induce cell-growth inhibition. This reveals a 





number of other observations strengthen the above speculation. Cell-cycle analysis in 
SCL839 and SCL840 cells demonstrated that the sub-diploid (apoptotic) population 
of SCL840 cells was increased compared with that of the SCL839 cells in response 
to D-Trp
6
-GnRH I (Fig 4-9). This suggests that the different cell-growth inhibition 
effects of D-Trp
6
-GnRH I, as demonstrated in the cell-viability assays, between the 
two stable cell lines, was due to the induction of apoptosis and not cell-cycle 
blockade. This is a reasonable explanation which is further supported by the finding 
that GnRH-induced FasL expression was higher in SCL840 cells compared to 
SCL839 cells, as observed by qRT-PCR analysis (Fig. 4-6). This result was expected 
since over-expression of FOXO3a in SCL60 cells decreased FasL gene expression.  
 
In summary, GnRH treatment increases FasL expression resulting in induction of 
apoptosis in SCL60 cells, while over-expression of FOXO3a reduced FasL 
expression and apoptosis in SCL60 cells. Furthermore, knocking-down FOXO3a 
further increased FasL expression and apoptosis in response to GnRH treatment in 
SCL840 cells, compared to control cells (see Table 4-2). These observations 
therefore appear to suggest that in response to GnRH treatment, FOXO3a acts to 
repress FasL expression. ChIP analysis will be helpful to further understand the 
activity of FOXO3a at the FasL promoter in response to GnRH stimulation. 
 
Interestingly, IKK and Akt inhibitors, previously shown to inhibit GnRH-induced 
GADD45 activity, were unable to completely rescue SCL60, SCL839 and SCL840 
cells from GnRH-mediated cell-growth inhibition. The Akt inhibitor did not 
completely rescue GnRH-mediated cell-growth inhibition in SCL60 cells, and it 





in SCL839 cells by 4.2%. Moreover, growth inhibition for SCL840 cells was 
approximately 25% higher compared to inhibition of SCL839 cells. Interestingly, the 
Akt inhibitor reduced the GnRH-induced cell-growth inhibition of SCL840 cells by 
approximately the same level as for SCL839 cells after GnRH treatment alone. This 
suggests that, the Akt inhibitor showed a trend towards a reduction of the additive 
GnRH-induced cell-growth inhibition effect in SCL840 cells compared to SCL839 
cells. This suggests that the Akt inhibitor may block a GnRH-induced signalling 
pathway that mediates the more profound anti-proliferative effect in SCL840 cells 
compared to SCL839 cells, and that FOXO3a is part of this pathway.  
 
The involvement of FOXO3a and FasL, as part of the same signalling pathway, in 
the GnRH-induced cell-growth inhibition process has been already suggested in this 
Chapter. In addition, the role of GADD45, as downstream target of FOXO3a, in 
GnRH-induced cell-growth inhibition was also examined. However, whether GnRH 
induces cell-growth inhibition in SCL60 cells by activating GADD45 expression by 
FOXO3a, was not clear. Thus, while FOXO3a appears to be involved in the 
induction of apoptosis, by regulating FasL expression following GnRH treatment, the 
role of FOXO3a in the GnRH-induced cell-cycle blockade, by induction of GADD45 
was not clear (see Table 4-2). The results from this Chapter demonstrated that Akt 
inhibitor partially rescues GnRH-induced cell-growth inhibition in SCL60 cells. As 
was mentioned above, GnRH possibly induces cell-growth inhibition by blocking 
cell-cycle progress at G2 phase, by up-regulating GADD45 expression. Since 
FOXO3a mediates GnRH-induction of GADD45 expression, a role for FOXO3a in 
mediating GADD45 expression in GnRH-induced cell-growth inhibition is strongly 





increase in sub-diploid population in SCL840 cells compared to SCL839 cells, which 
can be explained by the increase of FasL expression. However, there is no difference 
in the proportion of the G2 population between the two cell lines. However, 
differences in GADD45 expression are expected because of different FOXO3a levels 
should lead to differences on the cell-cycle profile between the SCL839 and SCL840 
cells. In addition, following D-Trp
6
-GnRH I treatment, the change in the proportion 
of SCL839 and SCL840 found in G2 phase was similar, although FOXO3a levels 
were lower in SCL840 cell line. This result suggests that GnRH treatment cause cell-
growth inhibition by up-regulating GADD45 expression, but not exclusively by 
FOXO3a, and possibly involving another transcription factor.  
 
In conclusion, a role of FOXO3a in GnRH-induced cell-growth inhibition is 
proposed in this Chapter. The involvement of FOXO3a regulated expression of FasL 
and GADD45 in response to GnRH is also suggested to play a role in this process. 
Although this research was conducted in a heterologous HEK293/ratGnRH-R 
expressing model cell line, it is likely that these findings apply to other cell systems 
to highlight additional novel roles for the targeting of FOXO3a activity by GnRH. 
Indeed, this is demonstrated in Chapter five, which describes a novel role for 












THE ROLE OF FOXOs IN THE REGULATION OF LHβ 















 5.0  ABSTRACT 
 
In this Chapter, the role of FOXO1 and FOXO3a in GnRH-induced expression 
of LHβ, FSHβ and the GnRH-R in gonadotropes was examined. The data 
presented demonstrates that FOXO3a and FOXO1 are expressed in human 
pituitary gonadotropes, and a role for FOXO3a in the regulation of LHβ 
expression in response to GnRH treatment is highlighted. In addition, the 
regulation of Egr1 expression via a FOXO3a-dependent signalling pathway was 
demonstrated. Chromatin immunoprecipitation (ChIP) assays were used to 
assess FOXO3a recruitment to Egr1 and LHβ promoters. FOXO3a targets Egr1 
expression to, at least in part, indirectly regulate LHβ promoter activity. β-
catenin is also involved in the regulation of the LHβ expression in co-ordination 
with FOXO3a in response to GnRH. These findings suggest that GnRH 
regulates LHβ-subunit expression through one or more FOXO3a-mediated 
mechanisms. 
 
5.1  BACKGROUND AND OBJECTIVES 
 
Gonadotropin-releasing hormone (GnRH) is an essential regulator of the 
reproductive process, and stimulates the synthesis of the gonadotropins (LH and 
FSH) in pituitary gonadotropes, thereby regulating gametogenesis and 
steroidogenesis. GnRH is synthesised and secreted by hypothalamic GnRH neurons, 
and delivered to the anterior pituitary gland where it binds to the GnRH-R expressed 
on the surface of the gonadotrope (Naor, 2009; Seeburg et al., 1987; Vale et al., 
1977).  
Diverse signalling pathways have been reported to regulate LHβ-subunit expression 
in response to GnRH, including the ERK/p38MAPK/JNK cascades and factors such 





two DNA binding sites for Egr1 and SF1, and one for Pitx1 which is flanked by the 
Egr1 and SF1 binding sites (Halvorson et al., 1996; Keri and Nilson, 1996; Quirk et 
al., 2001; Tremblay and Drouin, 1999). Although the presence of all three of these 
factors as a complex on the promoter of the LHβ gene is required for optimal LHβ 
expression (Dorn et al., 1999; Jiang et al., 2005; Tremblay and Drouin, 1999), only 
Egr1 levels are regulated by GnRH-R activation (Dorn et al., 1999; Tremblay and 
Drouin, 1999). It therefore appears that GnRH up-regulates LHβ mRNA expression 
levels via induction of Egr1 expression in gonadotrope cells. 
 
Although the aforementioned mechanism has been extensively described, it is not yet 
been completely understood. Recent studies highlighting the co-operativity between 
β-catenin and FOXO3a in mediating gene expression (Essers et al., 2005; 
Hoogeboom et al., 2008; Kwon et al., 2010), suggested a potential role for FOXOs in 
regulating gonadotrope function. FOXO3a is one of four members of the “O” sub-
group of Forkhead box (FOX) transcription factors, and plays an important role in a 
variety of cellular processes such as tumour suppression, cell-cycle regulation and 
metabolism (Burgering, 2008). To date, there are no studies demonstrating a role for 
FOXOs in GnRH-induced gonadotropin expression. Therefore, the main objectives 
of this Chapter were the following: 
 to examine whether FOXO1 and FOXO3a are expressed in gonadotropes 
 to investigate whether GnRH regulates LHβ, FSHβ or GnRH-R expression 
via FOXO1 or FOXO3a 







5.2  RESULTS 
 
5.2.1  The role of FOXOs in GnRH-induced regulation of LHβ, FSHβ 
and GnRH-R expression 
 
Having identified the involvement of GnRH in FOXO3a transcriptional activity in 
Chapter three, the role of FOXOs in GnRH-induced regulation of LHβ, FSHβ and 
GnRH-R expression in gonadotropes was examined. To investigate this, LβT2 cells 
were used as model gonadotrope cell line. These cells were co-transfected with LHβ-
promoter, FSHβ-promoter or GnRH-R-promoter reporters together with control 
vector, wild type FOXO1 (FOXO1-WT) or wild type FOXO3a (FOXO3a-WT). 
Over-expression of FOXO1 increased the basal GnRH-R- and FSHβ-reporter 
activity, whereas has no affect on basal transcriptional activity of the LHβ-reporter 
was observed compared to vector control. Over-expression of FOXO3a did not alter 
basal FSHβ-reporter activity but slightly decreased basal LHβ-reporter activity 
compared to vector control (Fig. 5-1A, C and E). 
 
LβT2 cells were treated with 1µM GnRH, and the role of FOXO1 and FOXO3a in 
the GnRH-induced LHβ, FSHβ and GnRH-R expression was examined. GnRH 
treatment increased LHβ-, FSHβ- and GnRH-R-reporter activity in cells transfected 
with control vector (Fig. 5-1B, D and E). FOXO1-WT over-expression decreased 
GnRH-induced GnRH-R-reporter activity, but has no detectable effect on LHβ- or 
FSHβ-reporter activity compared to vector control. FOXO3a-WT over-expression 
increased GnRH-induced LHβ-reporter activity by 3-fold compared to vector control 
but did not affect FSHβ-reporter activity compared to vector control (Fig. 5-1B, D 





regulation of LHβ but not in FSHβ regulation. FOXO3a also appears to have a 
negative role in GnRH stimulation of GnRH-R expression; however this potential 
role for FOXO3a was not further examined in this thesis. It is also interesting that 
after over-expression of FOXO1 the FSHβ expression was increased significantly, 
while the GnRH-induced FSHβ expression was not increased. This possibly means 
that FOXO1 acts as a transcription factor for FSHβ, however GnRH does not 
regulate its transcriptional activity. The next section of work aims to delineate the 














Figure 5-1: LHβ, FSHβ and GnRH-R-reporter activity levels in response to GnRH.  
LβT2 cells were transiently transfected (A and B) with 5µg of LHβ-, (C and D) FSHβ- and (E and F) 
GnRH-R-reporter and 5µg of control vector (pcDNA3.1) or FOXO1-WT or FOXO3a-WT. Cells were 
treated (B and F) with 1µM GnRH for 6 hours (D) or with 1µM GnRH plus activin for 8 hours. 
Samples were then assayed for luciferase activity. In all panels open bars denote no stimulation and 
close bars denote GnRH stimulation. Data are shown as mean fold change over NS±SEM from at least 
3 independent experiments (in (E) and (F), assay with over-expression with FOXO3a-WT is n=2). (b 





5.2.2  GnRH regulates LHβ-subunit expression via FOXO3a activity 
 
To further investigate the role of FOXO3a in GnRH-induced LHβ-reporter activity, 
LβT2 cells were co-transfected with LHβ-reporter, together with FOXO3a-TM, 







Ala; TM denotes triple mutant) (Burgering and Kops, 2002), or with FOXO3a-
TMΔDB with the same three Akt phosphorylation site mutations in addition to a 
deletion of the DNA binding domain (denoted by ΔDB). In contrast to FOXO3a-WT, 
FOXO3a-TM cannot be phosphorylated by Akt, resulting in its nuclear retention, 
thus eliminating the effect of Akt signalling on the localisation/redistribution of 
FOXO3a. While over-expression of FOXO3a-TM increased GnRH-induced LHβ-
reporter activity compared to vector control, over-expression of FOXO3a-TMΔDB 
reduced GnRH-mediated LHβ-reporter activity compared to the effect of FOXO3a-
TM (Fig. 5-2A). 
 
To further confirm the involvement of FOXO3a in GnRH-induced LHβ expression, 
the effect of transiently knocking-down FOXO3a expression by lentivirus-delivered 
short hairpin RNA (shRNA) was examined in LHβ-reporter activity experiments. 
Attempts to generate stable FOXO3a knock-down LβT2 cell lines using lentivirus-
delivered shRNA were unsuccessful. The cells were not viable after 8-10 days of 
transduction with lentivirus-delivered shRNA with or without the addition of the 
selective antibiotic, implying that the level of FOXO3a protein may be an important 
for the viability of gonadotropes. Therefore, transiently transduced cells were used in 
further experiments. In order to achieve the highest transient reduction of FOXO3a 





targeted towards FOXO3a, and FOXO3a protein levels were measured after 1, 2, 3 
and 5 days of transduction by Western Blot analysis. Maximum FOXO3a protein 
level reduction was achieved after 4 days of transduction with lentivirus-delivery 
shRNA1624 (Supplementary Fig. 7-9). Control cells were also generated by 
transduction with lentivirus-delivered scrambled shRNA (these cells will henceforth 
be referred to as control cells).   
 
Basal LHβ-reporter activity was reduced in FOXO3a knock-down cells compared to 
control cells (Fig. 5-2B), and GnRH induction of LHβ expression was lower in 
FOXO3a knock-down LβT2 cells compared to control cell levels (Fig. 5-2C). Taken 
together, these data suggest that FOXO3a regulates LHβ expression, either directly 
by acting at the LHβ promoter, or indirectly by targeting the expression and/or co-








Figure 5-2: GnRH stimulates LHβ-reporter activity by FOXO3a.  
(A) LβT2 cells were co-transfected with 2µg of LHβ-reporter and 8µg of control vector (pcDNA3.1), 
FOXO3a-TM or FOXO3a-TMΔDM. Cells were serum-starved for 24 hours followed by treatment 
with 1µM GnRH for 6 hours. Samples were then assayed for luciferase activity. For knock-down 
cells, lentivirus-delivered shRNA against FOXO3a or scrambled shRNA (control cells) was added to 
LβT2 cells. The following day, virus was removed and cells incubated with fresh medium (B and C). 
Cells were subsequently co-transfected with LHβ-reporter and serum-starved for 24 hours after 
transfection, (C) followed by stimulation with 1µM GnRH for 6 hours. In all panels open bars denote 
no stimulation and close bars denote GnRH stimulation. Data are shown as mean fold change over 
NS±SEM from at least 3 independent experiments. (b is significantly different from a, and c is 





5.2.3  GnRH regulation of Egr1 expression by FOXO3a  
 
Egr1 is a well-known intermediate in the GnRH-induced LHβ expression pathway 
(Kaiser et al., 2000; Maudsley et al., 2007; Weck et al., 2000). Having identified the 
involvement of FOXO3a in GnRH-induced LHβ expression, the role of FOXO3a in 
the GnRH-induced Egr1 expression, was examined next. Given that GnRH treatment 
causes a maximal increase in LHβ-reporter activity after 6 hours of treatment, the 
effect of FOXO3a on GnRH-induced Egr1-reporter activity over 2, 3, 4 and 5 hours 
was examined, on the assumption that GnRH increases the Egr1 expression prior to 
LHβ expression reaching its maximum level. LβT2 gonadotrope cells were co-
transfected with an Egr1-reporter and either the FOXO3a-WT or FOXO3a-TM 
constructs, and treated with 1µM GnRH. A 5 hour time-course treatment with GnRH 
in vector controlled LβT2 cells showed that GnRH-induced Egr1 activity was 
increased reaching maximal expression after 5 hours. The same trend was observed 
in cells with FOXO3a-WT or FOXO3a-TM over-expression, in which over-
expression of FOXO3a-WT or FOXO3a-TM increased the GnRH-induced Egr1-
reporter activity compared to vector control, strongly implicating FOXO3a in GnRH-
induced Egr1 expression (Fig. 5-3).  
 
The effect of FOXO3a on GnRH-induced Egr1 expression in response to GnRH over 
6 hours of treatment was examined in order to compare the effect of FOXO3a on 
Egr1 expression at the same time point that GnRH induced maximal LHβ expression. 
LβT2 cells were co-transfected with Egr1-reporter and the FOXO3a-TM construct. 
Over-expression of FOXO3a-TM up-regulated Egr1-reporter activity in response to 





Notably, over-expression of FOXO3a-TMΔDB increased basal Egr1-reporter activity 




Figure 5-3: Time-course treatment with GnRH for Egr1-reporter activity.  
LβT2 cells were co-transfected with 0.1µg Egr1-reporter and 9.9µg of control vector (pcDNA3.1), 
FOXO3a-WT or FOXO3a-TM. Cells were serum-starved 24 hours after transfection followed by 
stimulation with 1µM GnRH hours. Samples were then assayed for luciferase activity. Data are shown 












Figure 5-4: The role of FOXO3a in the GnRH-induced Egr1 expression.  
LβT2 cells were co-transfected with 0.1µg Egr1-reporter and (A and B) 9.9µg of control vector 
(pcDNA3.1), FOXO3a-TM or (B) FOXO3A-TMΔDB. (A and B) Cells were serum-starved 24 hours 
after transfection followed by stimulation (B) with 1µM GnRH for 6 hours. Samples were then 
assayed for luciferase activity. In all panels open bars denote no stimulation and close bars denote 
GnRH stimulation. Data are shown as mean fold change over NS±SEM from at least 3 independent 
experiments. (b is significantly different from a, and c is significantly different from a and b; P<0.05) 
 
5.2.4  GnRH regulation of LHβ-subunit expression by targeting Egr1 
expression by FOXO3a 
 
Despite the data showing that GnRH induced Egr1 and LHβ expression via 
FOXO3a, it was not clear whether FOXO3a regulated GnRH-induced LHβ 
expression via an Egr1-independent pathway. To test this possibility, the induction of 
LHβ-reporter activity in LβT2 cells was examined by over-expression of FOXO3a-
TM or Egr1, or Egr1 together with FOXO3a-TM. Egr1 over-expression alone 
increased basal LHβ expression (Fig. 5-5A), but did not up-regulate LHβ expression 
in response to GnRH (Fig. 5-5B). Although over-expression of FOXO3a-TM up-





FOXO3a-TM and Egr1 failed to increase LHβ-reporter activity in response to GnRH 
(Fig. 5-5B). 
 
To further investigate the role of Egr1 and FOXO3a in LHβ expression in response 
to GnRH, LβT2 cells were transfected with either a -136 ovine LHβ-promoter 
reporter fragment (dLH7-luc) or a -136 ovine LHβ-promoter reporter fragment with a 
double deletion of the Egr1 binding sites (mutated distal and proximal mdpEgr1 
(mdpLH7-luc construct)) (Fig. 5-5C). Over-expression of FOXO3a-TM up-regulated 
dLH7-reporter activity compared to vector control, but did not significantly up-
regulate mdpLH7-reporter activity. Thus, FOXO3a was unable to up-regulate LHβ 
expression in the absence of the Egr1 binding sites on the LHβ promoter. Taken 
together, these data suggest a role for FOXO3a in GnRH-induced Egr1 expression, 
which is essential for maximal LHβ expression. 
 
5.2.5  GnRH regulation of LHβ expression via FOXO3a requires β-
catenin activity 
 
In a previous study by Gardner et al. (2007), GnRH treatment promoted the 
stabilisation and nuclear accumulation of β-catenin in LβT2 cells (Gardner et al., 
2007). β-catenin acts as a co-activator of GnRH-induced LHβ expression by forming 
a complex with Egr1 and SF1, which act together at the LHβ promoter to drive 
maximal LHβ expression (Salisbury et al., 2007). Thus, the potential role of 
FOXO3a in the functioning of this complex in response to GnRH was assessed. In 
particular, whether FOXO3a acts together with, or independently of β-catenin to 
regulate GnRH-induced LHβ expression in LβT2 cells was examined. LβT2 cells 





or with FOXO3a-TM together with Axin (Fig. 5-6A). Axin is known to promote the 
degradation of cellular β-catenin (Salisbury et al., 2007). As expected, Axin over-
expression suppressed LHβ-reporter activity in response to GnRH compared to 
vector control. However, co-expression of Axin together with FOXO3a-TM also 
suppressed LHβ-reporter activity compared to FOXO3a-TM over-expression alone 
(Fig. 5-6A), suggesting that FOXO3a and β-catenin co-operate to drive LHβ-reporter 
activity. 
 
Additionally, a possible involvement of β-catenin, as a co-factor with FOXO3a in 
Egr1 activity in response to GnRH was assessed. In particular, it was examined 
whether FOXO3a acts together with, or independently of β-catenin to regulate 
GnRH-induced Egr1 expression in LβT2 cells was examined. LβT2 cells were co-
transfected with the Egr1-reporter together with FOXO3a-TM or Axin alone, or with 
FOXO3a-TM together with Axin (Fig. 5-6B). Although over-expression of 
FOXO3a-TM increased Egr1-reporter activity, Axin over-expression failed to 
suppress Egr1-reporter activity in response to GnRH compared to vector control. In 
addition, co-expression of Axin together with FOXO3a-TM did not change Egr1-
reporter activity compared to FOXO3a-TM over-expression alone (Fig. 5-6A). Taken 
together these data suggest that β-catenin does not co-operate with FOXO3a to 









5.2.6  GnRH regulation of FOXO3a binding at Egr1 and LHβ 
promoters 
 
Since a potential role for FOXO3a in driving the expression of LHβ and Egr1 in 
response to GnRH has been demonstrated, whether FOXO3a acts directly at the 
promoters of these two genes, and whether it acts as an activator or suppressor was 
examined next.  
 
In order to assess the specific role of FOXO3a at these two promoters, ChIP assays 
were performed (calculations for RT-PCR analysis for the ChIP assay are described 
in Supplementary Table 7-10). The DNA that was immuno-precipitated with 
FOXO3a or IgG (control) antibody in response to GnRH was amplified by Taqman 
qRT-PCR using primers for the promoter regions or primers that anneal to distal 
upstream regions of the LHβ and Egr1 genes (Fig. 5-7).  
 
The results suggest that GnRH treatment increased the binding of FOXO3a to the 
LHβ promoter to regulate LHβ-subunit expression (Fig. 5-8A). In contrast, GnRH 
treatment appeared to result in the release of FOXO3a from the Egr1 promoter at 6 
hours, which may indicate that under basal conditions FOXO3a acts to repress Egr1 
expression (Fig. 5-8B), again suggesting that FOXO3a negatively regulates Egr1 






Figure 5-5: Egr1 and FOXO3a in the GnRH-induced LHβ expression.  
(A and B) LβT2 cells were co-transfected with 2µg LHβ-reporter and 4µg of control vector 
(pcDNA3.1), FOXO3a-TM, Egr1 or FOXO3a-TM+Egr1 as indicated. (C) LβT2 cells were co-
transfected with 2µg dLH7- or mdpLH7
(1)
-reporter and 8µg of control vector (pcDNA3.1) or 
FOXO3a-TM. Cells were serum-starved 24 hours after transfection followed by stimulation with 1µM 
GnRH for 6 hours. Samples were then assayed for luciferase activity. In all panels open bars denote 
no stimulation and close bars denote GnRH stimulation. Data are shown as mean fold change over 
NS±SEM from at least 3 independent experiments. (b is significantly different from a, and c is 
significantly different from a and b; P<0.05) 
(1)
mdpLH7-luc: -136/-29 ovine LHβ-reporter fragment with a double deletion of the two Egr1 






Figure 5-6: GnRH-induced LHβ-reporter activity requires the presence of FOXO3a and β-
catenin. 
LβT2 cells were co-transfected with 2g of (A) LHβ- or (B) Egr1-reporter and 4g of control vector 
(pcDNA3.1), FOXO3a-TM or Axin as indicated. Cells were serum-starved 24 hours after transfection 
followed by stimulation with 1M GnRH for 6 hours. In all panels open bars denote no stimulation 
and close bars denote GnRH stimulation. Data are shown as mean fold change over NS±SEM from at 
least 3 independent experiments. (b is significantly different from a, c is significantly different from a, 






Figure 5-7: Schematic representation of the mouse LHβ and Egr1 genes, and the primers pairs 
that bind to the promoter of the genes, or upstream of the promoter (control primers). 
Primers corresponding to LHβ and Egr1 are located in the promoter of these genes, and the control 
primers located at a region upstream of the promoter.  
 
 
Figure 5-8: GnRH regulation of FOXO3a binding to LHβ and Egr1 promoter.  
The regulation of FOXO3a binding to the promoter of LHβ and Egr1 in response to GnRH was 
measured by ChIP and quantitative RT-PCR using primers for the LHβ and Egr1 promoter and 
primers for distal upstream region of the LHβ gene and Egr1 gene. LβT2 cells were stimulated with 
1M GnRH for 6 hours. Data are shown as mean fold change over “control primers”±SEM from 3 





5.2.7  Immunohistochemistry of FOXOs in pituitary tissues  
 





Having confirmed the involvement of FOXO3a in the regulation of GnRH-induced 
LHβ-reporter activity in the LβT2 cells, immunohistochemistry was utilised in order 
to examine whether FOXO1 and FOXO3a are expressed in the pituitary. Pituitary 
tissues from human, rat and mouse tissues were utilised. In order to examine whether 
there was expression of FOXOs in these tissues, optimisation of antibodies was 
required, since different dilutions will be optimal for each tissue depending on the 
FOXO expression level. In addition, immunohistochemistry with and without an 
antigen retrieval step for unmasking the epitopes through pressure cooking was 
performed. 
 
Immunostaining of pituitary tissues from rat and mouse showed low staining for 
LHβ, but no staining for FOXO1 and FOXO3a (FOXO1 and FOXO3a antibody with 
and without antigen retrieval used at the following dilutions: 1:20, 1:500, 1:1,000, 
1:5,000 and 1:10,000). 
 
Immunostaining of pituitary tissues from adult human was also performed. FOXO1, 
FOXO3a and p-FOXO3a(Ser
253
) antibodies in serial dilutions of 1:10, 1:50, 1:200, 
1:1,000 were used showing very low staining or nonspecific background with 
antigen retrieval, while without antigen retrieval, specific and clear staining for all of 
the above serial antibody dilutions was not observed. However, immunostaining 
showed expression of FOXO1 and FOXO3a (and localisation of p-FOXO3a(Ser
253
)) 





For the tyramide double-staining detection method, tissues were stained with a series 
of dilutions of 1:400, 1:600 and 1:800 for FOXO1, FOXO3a and p-FOXO3a(Ser
253
) 
antibodies. The 1:800 dilution was found to be the optimal dilution for all three 
antibodies. Next, the tissues were double-stained with the second primary antibody 
(LHβ) at dilutions of 1:200, 1:500 and 1:1000. The optimal dilution for this antibody 
was 1:200 for double-staining with FOXO1 and p-FOXO3a(Ser
253
), and 1:500 for 
double-staining with FOXO3a. Only satisfactory staining images are presented in 
this Chapter with optimal antibody dilutions.  
 
5.2.7.2  Adult human gonadotropes express FOXO1 and FOXO3a 
 
Having confirmed the involvement of FOXO3a in the regulation of LHβ promoter 
activity in response to GnRH in LβT2 cells, immunohistochemistry was used to 
examine the expression of FOXO1 and FOXO3a in the pituitary of adult human 
males. Immunohistochemical staining throughout the anterior pituitary revealed 
broad expression of FOXO1 and FOXO3a. FOXO1 was located predominantly in the 
cytoplasm, whereas FOXO3a was located exclusively in the nucleus (Fig 5-9). To 
localise FOXO1 and FOXO3a to gonadotropes, double immunofluorescent staining 
for LH and FOXO1 or FOXO3a was performed. In cells positive for LHβ (i.e. 
gonadotropes), FOXO3a was found to be expressed in the nucleus (Fig. 5-10A) 
whereas FOXO1 was mainly expressed in the cytoplasm (Fig. 5-10B). The control 
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       B. 
 
Figure 5-10: FOXO1 and FOXO3a expression and immuno-localisation in adult human 
pituitary gonadotropes.   
Confocal dual immunofluorescence images of adult human pituitary sections immunoreactive for (A) 
FOXO1 or (B) FOXO3a (Red fluorescence, TSA-Cy3) and LHβ (green fluorescence, TSA-
fluorescence). Nuclei are stained in blue by DAPI. Arrows indicate the gonadotrope cells that also co-





5.2.8 GnRH-induced FOXO3a phosphorylation  
 
Having shown that FOXO3a is expressed in human pituitary tissues, phosphorylation 
of FOXO3a in response to GnRH was examined in LβT2 gonadotrope cells. Firstly, 
immunohistochemical staining revealed phosphorylated FOXO3a in human pituitary 
gonadotropes (Fig 5-11A). p-FOXO3a(Ser
253
) was localised both in the nucleus and 
in cytoplasm (Fig. 5-11A). In cells positive for LHβ (i.e. gonadotropes) p-
FOXO3a(Ser
253
) was found to be similarly expressed (Fig. 5-11B).  
 
Next, immunofluorescence confocal microscopy was used in order to determine 
visually whether p-FOXO3a(Ser
253
) was redistributed between nucleus and 
cytoplasm in LβT2 gonadotrope cells in response to GnRH. p-FOXO3a(Ser
253
) was 
localised in both the nucleus and the cytoplasm, and no significant translocation was 
observed in response to GnRH. Phosphorylation of FOXO3a at Ser
253
 was increased 
following 5 minutes treatment with 1µM GnRH. However, after 10 and 60 minutes 
of treatment, levels of p-FOXO3a(Ser
253
) returned to non-stimulated levels (Fig. 5-
12A). This was consistent with the results of a Western Blot analysis, where 
phosphorylation of FOXO3a at Ser
253
 was increased following 5 minutes treatment 
with 1µM GnRH. Western Blot analysis demonstrated that phosphorylation of 
FOXO3a at Ser
253
 was also increased following 30 minutes treatment with 1µM 























) staining in gonadotropes.  
(A) Immunohistochemistry in human anterior pituitary p-FOXO3a(Ser
253
) (brown) is expressed in the 
nucleus (purple) and in the cytoplasm. Negative control is used to evaluate non-specific binding. (B) 
Co-localisation of p-FOXO3a Ser
253
 in human anterior pituitary tissue. p-FOXO3a(Ser
253
) is indicated 
































Figure 5-12: FOXO3a phosphorylation in LβT2 cells.  
(A) LβT2 cells were seeded into eight-well chamber slides and serum-starved (24h) before stimulation 
with 1μM GnRH for indicated times, or left untreated (NS). Cells were fixed and immuno-
cytochemistry performed. Detection of the immuno-reactive proteins was achieved using Alexafluor 
(488nM, green) conjugate for p-FOXO3a(Ser
253
). The merged image also shows DAPI staining (red) 
and co-localisation as yellow. (B) Western Blot analysis for p-FOXO3a(Ser253), in LβT2, which were 
treated with 1μM GnRH for the indicated times, or left untreated (NS). Blot is representative of 3 
independent experiments.  
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In the present study the expression of FOXO1 and FOXO3a in LβT2 cells and in 
human pituitary tissue was demonstrated. A role for FOXO3a in mediating GnRH-
induced LHβ and Egr1 expression was shown. ChIP assay results led to speculation 
that FOXO3a binds to the LHβ promoter, but it is released from the Egr1 promoter, 
following GnRH treatment. Overall, the results from this Chapter suggested that 
GnRH targets FOXO3a activity to regulate LHβ expression directly, through the 
binding of FOXO3a to the LHβ promoter in complex with co-factors, and indirectly 
through the release of FOXO3a from the Egr1 promoter, on which it probably acts as 
a repressor. 
 
The expression of FOXO1 and FOXO3a in the human pituitary, as well as 
expression of both transcription factors in human pituitary gonadotropes was 
demonstrated using double immunofluorescence confocal microscopy (Fig 5-10). Of 
particular interest was the differential localisation patterns of the two FOXOs in 
human pituitary gonadotropes; FOXO3a was found exclusively in the nucleus and 
FOXO1 in the cytoplasm. The co-localisation of FOXO3a to the nucleus was 
pertinent as this was the factor that influenced LHβ and Egr1 expression, and was 
shown to bind to the promoters of these genes. In contrast, FOXO1 was localised to 
the cytoplasm and had no effect on LHβ and Egr1 expression. 
 
Several lines of evidence that GnRH-induced LHβ expression is mediated by 
FOXO3a were provided. First, over-expression of FOXO3a up-regulated LHβ 
expression (Fig. 5-1). Second, in FOXO3a knock-down LβT2 cells, the basal level of 





receptor activation in the FOXO3a knock-down LβT2 cells did not lead to an 
increase in LHβ expression (Fig 5-2C). On the contrary, LHβ expression was 
reduced compared to that of control cells. These findings support the proposal that 
FOXO3a is an important mediator for GnRH-induced LHβ expression. 
 
The involvement of FOXO3a in modulating physiological LH levels was revealed in 
a study by Castrillon et al. (2003). In particular, FOXO3a-/- mice exhibited serum 
levels of LH which were higher compared to the control FOXO3a+/+ mice 
(Castrillon et al., 2003). Since the FOXO3a knock-down was not specific to the 
pituitary, and would therefore be expected to affect the biology of multiple tissues 
including other reproductive tissues, there are two possible explanations for this 
observation. Either, FOXO3a normally represses LH production in the pituitary 
gonadotrope, or FOXO3a is involved in some form of feedback regulation from the 
ovary or testis. Although over-expression or knocking-down of FOXO3a in LβT2 
cells in the present study resulted in a direct effect on LHβ-subunit expression, it is 
unclear what the mechanistic role of FOXO3a is in regulating LH levels in vivo. 
Furthermore, FOXO3a regulation of LHβ expression in LβT2 cells is restricted to the 
GnRH effect, while in the in vivo situation, this effect is also supplemented by a 
number of physiological factors such as steroid and peptide hormones affecting 
gonadotropes (Ooi et al., 2004). It is known that gonadotrope cells only comprise 5-
15% of the cells in anterior pituitary (Ooi et al., 2004),and that there are four other 
types of secretory cell types present in the anterior pituitary which secrete factors that 






The study by Castrillon et al. (2003) also demonstrated that FOXO3a-/- female mice 
were viable and showed age-dependent infertility without histological abnormalities 
of the pituitary tissue (Castrillon et al., 2003). They further reported that FOXO3a is 
not required for gonadotropin responsiveness in ovarian follicles (Castrillon et al., 
2003). These data, in combination with the findings from this Chapter, that GnRH 
can regulate LHβ expression via a FOXO3a-mediated mechanism, may suggest that 
the infertility in the FOXO3a-/- mice could be due to the inability of GnRH, through 
FOXO3a regulation, to optimally increase LHβ expression or the release of mature 
LH from the gonadotropes leading to reduced serum LH levels. 
 
The present data demonstrated that GnRH treatment stimulates the transcriptional 
activity of FOXO3a, but not of FOXO1 to regulate LHβ expression (Fig. 5-1). This 
is consistent with the results from Chapter three in which GnRH was shown to 
regulate the transcriptional activity of FOXO3a but not FOXO1 in the heterologous 
SCL60 cell system. Since both FOXO1 and FOXO3a share common DNA binding 
sites, one could argue that they could mediate expression from the same promoters 
(Burgering, 2008). However, GnRH-induced LHβ-subunit expression is mediated by 
FOXO3a, and not by FOXO1, suggesting that GnRH may regulate these two 
transcription factors via distinct signalling pathways. Alternatively, the exclusive 
localisation of FOXO1 to the cytoplasm of gonadotrope cells may not allow FOXO1 
mediation of GnRH-induced LHβ expression. 
 
Having demonstrated that GnRH regulates LHβ expression by targeting FOXO3a 
activity, the mechanism by which this occurs was further investigated. Following the 





number of possible mechanisms related to the regulation of LHβ expression were 
examined. Firstly, whether FOXO3a regulates the expression of LHβ or Egr1 or both 
by direct binding to their promoters was examined. Secondly, whether FOXO3a 
could regulate the LHβ promoter independently of Egr1 in response to GnRH was 
investigated, and finally, whether FOXO3a regulates LHβ gene expression in co-
operation with other co-factors was assessed. Results from the ChIP assay suggested 
that upon GnRH stimulation, FOXO3a binds to the LHβ promoter, increasing its 
transcriptional activity (Fig. 5-8). In contrast, FOXO3a appears to be released from 
the Egr1 promoter in response to GnRH. These findings suggested that FOXO3a acts 
as an enhancer at the LHβ promoter and as a repressor at the Egr1 promoter. The 
latter was further supported by over-expression of FOXO3a-TMDB, which led to 
an increase in Egr1-reporter activity compared to control cells. This may also 
indicate that FOXO3a acts synergistically with other co-factors on the Egr1 
promoter. The reduction of Egr1-reporter activity by co-expression of FOXO3a-
TMDB may indicate that FOXO3a-TMDB competes with endogenous FOXO3a 
for binding with its functional co-factors (Fig 5-4). Thus, FOXO3a-TMΔDM release 
from the LHβ promoter in response to GnRH would result in the sequestration of co-
factors that are essential for maximal Egr1 gene expression.  
 
Having demonstrated in a time-course treatment with GnRH for Egr1-reporter 
activity, with over-expression of FOXO3a-WT and FOXO3a-TM, that Egr1 
expression increases over 4 hours but decreases thereafter (Fig. 5-3), another 
possible mechanism with regards to the role of FOXO3a on Egr1 gene expression 





possibly by binding of FOXO3a to the Egr1 promoter over 4 hours of treatment with 
GnRH. Thereafter, FOXO3a is released from the Egr1 promoter, and Egr1 protein 
binds to the LHβ promoter inducing LHβ expression.  
 
FOXO3a regulates the GnRH-induced LHβ expression, however this regulation is 
partly dependent on GnRH-induced Egr1 expression. To assess the role of Egr1 in 
GnRH-induced LHβ expression via FOXO3a, two LHβ-reporters, the dLH7-reporter 
(-136 to -29bp) and the mpdLH7-reporter (-136 to -29bp) were utilised (Fig. 5-5). 
Although the length of the dLH7 promoter (-136/-29) was about 550bp shorter than 
the full length LHβ promoter (-692 to -29bp), over-expression of FOXO3a led to an 
increased GnRH-induced LHβ expression compared to control. This suggests that the 
effect of FOXO3a on the LHβ promoter is restricted to the proximal promoter (PP) 
region (mapped within -320bp of the transcription
 
start site) of the promoter 
(Maudsley et al., 2007). In addition, the result demonstrating that over-expression of 
FOXO3a does not significantly increase the mpdLH7-reporter activity compared 
with vector control confirms the previous results, that GnRH-induced LHβ 
expression is dependent on FOXO3a-regulated Egr1 expression. This suggests that 
FOXO3a is released from the Egr1 promoter in response to GnRH, up-regulating its 
expression level, since it acts as a repressor (Fig. 5-13). Egr1 protein then binds to 
the LHβ promoter, possibly as a complex with β-catenin and FOXO3a for maximal 
LHβ expression (Fig 5-13). Absence of FOXO3a, which binds to LHβ promoter in 
response to GnRH in this complex prevents maximal activity of LHβ expression. 
 
Maximal activity of LHβ expression requires the presence of SF1, Egr1 and β-





FOXO3a in this regulation by both direct binding on the LHβ and Egr1 promoters, 
and by interaction with other co-factors was suggested. A study using a yeast two-
hybrid system by Essers et al. (2005) demonstrated that β-catenin interacts with 
FOXO3a (Essers et al., 2005). Whether or not FOXO3a acts together with, or 
independently of β-catenin at the LHβ promoter was examined. Over-expression of 
Axin, which promotes degradation of cellular β-catenin levels, reduced GnRH-
induced LHβ expression; however co-expression of Axin with FOXO3a did not 
restore the GnRH-induced LHβ-reporter activity that could be obtained by over-
expression of FOXO3a alone. 
 
Overall, results presented in this Chapter implicate FOXO3a in the regulation of 
GnRH-induced LHβ-subunit expression, in addition to the previously published roles 
of Egr1, SF1, PITX1 and β-catenin. In summary, GnRH treatment up-regulates Egr1 
gene expression, possibly by releasing FOXO3a from the Egr1 promoter. Thereafter, 
Egr1 protein binds to the LHβ promoter inducing LHβ expression. GnRH treatment 
also induces FOXO3a localisation to the LHβ promoter. FOXO3a and Egr1 act 
synergistically on the LHβ promoter for maximal LHβ gene expression. In addition, 
FOXO3a-mediated GnRH-induced LHβ maximal expression appears to require β-








Figure 5-13: Model of LHβ and Egr1 gene regulation by FOXO3a in response to GnRH. 
The results from this chapter suggest that in the absence of GnRH treatment, FOXO3a represses Egr1 
expression.  In response to GnRH treatment, FOXO3a appears to be released from the Egr1 promoter, 
resulting in increased Egr1 gene expression; Egr1 then binds to the LHβ promoter to drive LHβ 
expression. A complex of FOXO3a, Egr1 and β-catenin on the LHβ promoter is required for maximal 






















 6.1  THESIS MOTIVATION  
 
GnRH-Rs belong to the Rhodopsin-like family of the GPCRs and are activated 
following the binding of GnRH (Millar and Newton, 2010). GnRH-R activation 
targets a variety of signalling pathways that mediate important cellular processes. 
Among these are GnRH-induced cell-growth inhibition in cancer-derived cell lines 
(Cheng and Leung, 2005; Everest et al., 2001; Franklin et al., 2003; Kraus et al., 
2006; Limonta et al., 2003; Maudsley et al., 2004; Miles et al., 2004; Morgan et al., 
2008), and GnRH-induced LH and FSH synthesis and secretion in pituitary 
gonadotropes (Naor, 2009). The importance of GnRH-induced cell-growth inhibition 
is easily understood by the fact that GnRH analogues are currently used for cancer 
treatment (Bifulco et al., 2004; Carr et al., 1993; Hofstra et al., 1999; Klijn and de 
Jong, 1982; Mizutani et al., 1998; Tolis et al., 1982). In addition, because GnRH 
plays a central role in reproduction, the regulation of gonadotropin production by 
GnRH analogues is used for treatment of infertility (White et al., 2008b). 
 
Although both of the aforementioned cellular processes have been extensively 
described, the mechanisms and signalling pathways that mediate them are not yet 
completely understood. When the current study was initiated, a role for FOXO 
transcription factors in regulating GnRH-induced cell-growth inhibition and 
gonadotropin synthesis had not been proposed. Nevertheless, the important role of 
FOXOs in cell-cycle regulation and induction of apoptosis is well-documented (Fu 
and Tindall, 2008). The involvement of FOXOs in cell proliferation has been shown 





signalling pathway. These facts provided the basis for pursuing the research 
described in this thesis.  
 
6.2  THESIS OBJECTIVES 
 
Since no previous studies had described the regulation of FOXOs by GnRH-R 
activation, the initial objective in Chapter three was to examine whether GnRH 
regulates FOXO activity. Thereafter, the mechanisms by which FOXO regulation is 
mediated following GnRH-R activation were investigated. The regulation of FOXO 
activity by post-translational modifications and the action of co-factors is well-
established. Therefore, the role of such modifications (phosphorylation and 
acetylation), and the effect of β-catenin on FOXO activity in response to GnRH, 
were also examined in Chapter three. In addition, the regulation of FOXO-target 
genes following GnRH-R activation was assessed, and a cell-cycle analysis of 
GnRH-R-expressing cells was performed. 
  
In complementary studies presented in Chapter four, a role for FOXO3a in 
mediating GnRH-induced cell-growth inhibition was assessed. GnRH-induced cell-
growth inhibition pathways, and the diverse factors that mediate them have 
previously been examined by many research groups (Cheng and Leung, 2005; 
Everest et al., 2001; Franklin et al., 2003; Kraus et al., 2006; Limonta et al., 2003; 
Maudsley et al., 2004; Miles et al., 2004; Morgan et al., 2008). By generating a 
FOXO3a knock-down cell line, the potential importance of FOXO3a in regulating 






Finally, the mechanisms that mediate the synthesis of LHβ and FSHβ in 
gonadotropes were further explored in Chapter five. The role of transcription factors 
and co-factors, such as Egr1, SF1, Sp1 and more recently -catenin in regulating 
LHβ promoter activity are now fairly well-characterised (Thackray et al., 2010). 
Recent studies highlighting the co-operativity between -catenin and FOXOs in 
mediating gene expression (Essers et al., 2005; Hoogeboom et al., 2008; Kwon et al., 
2010), suggested a potential role for FOXOs in regulating gonadotrope function. The 
expression of FOXOs in gonadotropes was assessed by double immunostaining in 
human pituitary tissues, and the involvement of FOXOs in regulating LHβ, FSHβ 
and GnRH-R promoter activity in response to GnRH was examined. 
 
6.3  CONCLUSIONS 
 
In Chapter three, the regulation of FOXO3a activity following GnRH treatment was 
demonstrated. This novel regulation is described for the first time in this thesis using 
the SCL60 model cell line. The mechanism by which GnRH regulates FOXO activity 
appears to link two known signalling pathways; GnRH-activated PI3K/Akt signalling 
and growth factor-activated PI3K/Akt-induced regulation of FOXO activity. Further 
exploration of the mechanism of this regulation demonstrated FOXO3a 
phosphorylation at an Akt phosphorylation site (Ser
253
), and its subsequent 
translocation from nucleus to the cytoplasm. Since GnRH treatment promoted the 
phosphorylation and activation of Akt (phosphorylation at Thr
308
), it remains unclear 





), or indeed phosphorylation of FOXO1 and 









), which is 
apparently required for its full activation. By utilising a panel of pharmacological 
inhibitors and dominant-negative mutants, the pre-dominant signalling pathway by 
which GnRH regulates FOXO3a activity was identified. GnRH does not regulate 
FOXO transcriptional activity via a PI3K-dependent pathway, but instead via another 
Akt- and IKK-dependent pathway. It is not clear whether these mediators are part of 
the same signalling pathway, or how Akt is activated by a PI3K-independent 
pathway.  
 
One of the unexpected findings in this chapter was that FOXO3a de-phosphorylation 
by GnRH over 24 hours of treatment was not the dominant mechanism regulating 
FOXO3a transcriptional activity. This arises from the observation that although 
GnRH targets FOXO3a de-phosphorylation over 24 hours of treatment, GnRH 
treatment increased FOXO3a transcriptional activity by the same fold in cells co-
transfected with either FOXO3a-WT, or FOXO3a-TM that cannot be phosphorylated 
by Akt, clearly indicating that phosphorylation is not the dominant post-translational 
modification that regulates FOXO3a transcriptional activity following GnRH 
treatment. A further important finding presented in this chapter was the correlation of 
the expression profile of FOXO-target genes (FasL, GADD45, p21Cip and p27Kip1) 
in response to GnRH, with the cell-cycle profile of SCL60 cells, which was assessed 
by a cell-cycle analysis. 
 
Having demonstrated that GnRH regulates FOXO3a transcriptional activity in 
Chapter three, a FOXO3a knock-down cell line was generated in order to examine 





three suggested that FOXO3a protects cells from GnRH-induced cell-growth 
inhibition. Cell-cycle analysis of FOXO3a knock-down cells revealed a negative role 
for FOXO3a in GnRH-induced cell-cycle arrest and apoptosis, in which FOXO3a 
mediates G2 phase arrest and apoptosis, probably by regulating GADD45 and FasL 
gene expression respectively. 
 
The impact of GnRH regulation on FOXO3a transcriptional activity in the 
gonadotropes was assessed in Chapter five. In particular, a role for FOXO3a in 
GnRH-induced LHβ-subunit expression was investigated. Initially, expression of 
FOXO1 and FOXO3a was demonstrated in gonadotropes in human pituitary tissue. 
Although the role of FOXO1 in gonadotropes remains unclear, FOXO3a was found 
to regulate LHβ expression. Interestingly, in this study, the role of FOXO3a as a 
transcription factor on the Egr1 promoter was also demonstrated. Expression of the 
Egr1 gene, and binding of Egr1 to the promoter of LHβ, is required for maximal LHβ 
expression. Taken together, the results presented in Chapter five demonstrate the 
involvement of FOXO3a in LHβ expression, by both direct binding on the LHβ and 
Egr1 promoters, and by interaction with other co-factors such as β-catenin. 
 
6.4  FUTURE RESEARCH AND PERSPECTIVES 
 
Work presented in this thesis described for the first time the regulation of FOXO3a 
transcriptional activity by GnRH-R activation. In addition, this thesis assessed the 
biological significance of this regulation. By investigating the role of the FOXO3a in 





gonadotropins, new opportunities arise for further investigation of the current 
findings, or for exploring novel applications of these findings. 
 
The regulation of FOXO3a activity by GnRH was demonstrated in Chapter three. 
By utilising pharmacological inhibitors, the signalling pathway that mediates the 
GnRH-induced FOXO3a transcriptional activity was characterised. Akt and IKK 
have been shown to mediate this effect, whereas this regulation appears to be 
independent of PI3K. The results demonstrated that PDK1 targets phosphorylation 
and subsequent activation of Akt in response to GnRH. Although several of studies 
have previously demonstrated PI3K-independent activation of Akt via a variety of 
mechanisms (Vanhaesebroeck and Alessi, 2000), further investigation in order to 
determine alternative mechanisms for PDK1 or Akt activation in response to GnRH 
stimulation would be of great interest, and would highlight a novel signalling 
modality. 
 
By generating a FOXO3a knock-down cell line, the role of FOXO3a in GnRH-
induced cell-growth inhibition was examined in vitro in Chapter four. Generating 
other FOXO3a knock-down stable cell lines using cancer-derived cell lines from 
human tumours that endogenously express GnRH receptor would be important to 
confirm the role of FOXO3a in the GnRH-induced cell-growth inhibition. The main 
advantage by using cancer-derived cell lines in order to examine the role of FOXO3a 
in GnRH-induced cell-growth inhibition, is that these cell systems are more relevant 
to the pathophysiological situations that exist in vivo. 
 
In addition to these proposed in vitro assays, tumour xenograft studies could be used 





SCL60 or other cancer-derived cell lines) could be implanted into nude mice, and the 
size of the tumour following GnRH treatment then measured to enable confirmation 
of the in vitro data. However, in an in vivo experiment other factors could impact 
directly or indirectly on the GnRH-induced antiproliferative effect. Nevertheless, the 
in vivo experiments would mimic the conditions that exist in an organism in contrast 
to an in vitro cell viability assay. 
 
The role of FOXO3a in LHβ, but not in FSHβ, expression was demonstrated in 
Chapter five, by chronic treatment with GnRH. In contrast, FOXO1 had no effect on 
LHβ and FSHβ expression following chronic GnRH treatment. A potential issue that 
should be highlighted from this approach, is the fact that in this study gonadotropin 
expression is stimulated by continuous GnRH administration instead of pulsatile 
treatment. The frequency of GnRH release influences the differential regulation of 
LHβ and FSHβ expression in gonadotropes of the pituitary, since low GnRH pulses 
(>120-240min) favour the expression of FSH, while high pulses (<1hour) favour the 
expression of LH (Ferris and Shupnik, 2006). Thus, treatment with low or high 
GnRH pulses could reveal additional roles for FOXO1 and FOXO3a in gonadotropin 
synthesis. In addition, having proposed in Chapter five that FOXO3a binds to LHβ 
promoter, but it is released from the Egr1 promoter following continuous GnRH 
treatment, a possible role of FOXO3a in how different pulsatile GnRH treatments 
influence the expression of LHβ and FSHβ could be also examined by performing 
ChIP assays in time-course intervals with pulsatile GnRH treatment. 
 
Finally, having demonstrated that GnRH-R activation regulates the transcriptional 





investigated. Of interest are tissues and cell types that express both FOXOs and high 
levels of GnRH-Rs. Thus far, expression of both FOXOs and GnRH-R has been 
demonstrated in placenta (Lappas et al., 2010), in gonadotropes in human pituitary 
(see Chapter five), in prostate cancer cells (unpublished data) and in the 
endometrium (Rudd et al., 2007; Ward et al., 2008). In the latter case, the regulation 
of the transcriptional activity of progesterone and estrogen receptors via FOXO was 
demonstrated (Rudd et al., 2007). Thus, a possible impact of GnRH on the human 
endometrium by targeting FOXO activity, is interesting and worth further 
investigation. Taken together, studies detailed in this thesis may provide the basis for 






































 APPENDIX 7.1: Supplier Details 
Abgene Epson, UK 
Active Motif Rixensart, Belgium 
ATCC Teddington, UK, (http://www.atcc.org/) 
BD Biosciences New Jersey, USA 
BMG Lab technology Aylesbury, UK 
BioRad Laboratories  Hertfordshire, UK 
Carl Zeiss New York, USA 
Cell Signalling Technologies Hertfordshire, UK 
GE Healthcare Buckinghamshire, UK 
Graph Prism Software Inc. San Diego, USA 
Immunotech Marseilles, France 
Invitrogen  Paisley, UK 
Labsystem Victoria, Australia 
Novo Laboratory WA, USA 
Perkin Elmer Cambridgeshire, UK 
Promega Madison, USA 
Qiagen  Crawley, UK 
Roche Welwyn, Garden City, UK  
Santa Cruz Biotechnology Heidelberg, Germany 
Sigma Dorset, UK 
 














Figure 7-1: Immunoblots of GnRH-induced FOXO3a and FOXO1 phosphorylation in SCL60 
cells. 
SCL60 cells were serum-starved 24 hours before treatment with 1µM GnRH for the indicated times, 









) were analysed using the appropriate antibodies. Data are shown 









Figure 7-2: Immunoblots of GnRH-induced FOXO3a phosphorylation in LNCaP prostate 
cancer cells.  
LNCaP cells were serum-starved 24 hours before treatment with 1µM GnRH for the indicated times, 
or left untreated (NS). Level of p-FOXO3a(Ser
253
) were analysed using the appropriate antibody. Data 
are shown as mean fold change over NS±SEM from at least 3 independent experiments. (b is 




















































) distribution between nucleus and cytoplasm following GnRH 
stimulation in SCL60 cells.  
Immunofluorescence confocal microscopy was performed to visualise the redistributed of p-
FOXO1(Ser
256
) (green) between the nucleus and cytoplasm following 1µM GnRH treatment at the 
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SCL60 cells were serum-starved 24 hours before cells were pre-treated for 30 minutes with: PLC 
inhibitor ET-18-OCH3 (20µM), PKC inhibitors Ro-31-8220 (100nM) and Go9638 (21µM),  GnRH-I 
antagonist Cetrorelix (1μM), c-Src inhibitor PP2 (5µM), EGFR inhibitor AG1478 (100nM), MEK 
inhibitor PD98059 (20µM) and PKA inhibitor H89 (10µM), followed by treatment for 10 minutes 








GnRH        -         +           -          +          -           +          -         + 
                              ET-18-OCH3 Ro-31-8220       Go9638 
GnRH      -         +         -          +         -        +         -        +          -         +        -        +    


















Figure 7-5: The role of FOXO1 in GnRH-induced GADD45-reporter activity.  
SCL60 cells were transiently transfected with 1µg of GADD45-reporter and 9µg of control vector 
(pcDNA3.1) or FOXO1-WT or FOXO1-TM. Cells were treatment with 1µM GnRH for 24 hours. 
Samples were then assayed for luciferase activity. Data are shown as mean fold change over NS±SEM 
from at least 3 independent experiments. (b is significantly different from a, and c is significantly 
different from a and b; P<0.05) 
 
 
Figure 7-6: The role of PI3K, PKC and PLC in the GnRH-induced GADD45-reporter activity.  
SCL60 cells were transiently transfected with 1µg of GADD45-reporter and 9µg of control vector 
(pcDNA3.1) or FOXO3a-TM. Cells were serum-starved 16 hours before they were pre-treated for 30 
minutes with 100nM PI3K inhibitor (Wortmannin), 100nM PKC inhibitor (Ro-31-8220) or 20µM 
PLC inhibitor (ET-18-OCH3). Thereafter were treated with 1µM GnRH for 24 hours. Samples were 
then assayed for luciferase activity. Data are shown as mean fold change over NS ±SEM from at least 







Figure 7-7: The role of FOXO3a in FOXO-target genes mRNA expression following GnRH 
treatment.  
SCL60 cells were transfected with 10μM of FOXO3a-TM or FOXO3a-TMΔDB. Relative mRNA 
expression of (A) p21Cip1, (B) p27Kip1 and (C) BIM in cells treated with 1µM D-Trp
6
-GnRH over 
the indicated time intervals or vehicle (NS) was determined by quantitative RT-PCR analysis. Data 
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Figure 7-8: Transduction efficiency of lentivirus in SCL60 cells. 
SCL60 cells were transduced with GFP-tagged lentivirus. Transduction was performed with different 
ratios of virus to cells (1:1, 2:1 and 5:1) and cells without transduction with lentivirus were used as 
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Figure 7-9: LβT2 transient FOXO3a knock-down cells.  
LβT2 cells were transduced with lentivirus-delivering shRNA against FOXO3a (FOXO3a knock-
down cells) or with lentivirus-delivering scrambled shRNA (control cells). The following day viruses 
were removed and cells were incubated with fresh complete medium. Total FOXO3a protein levels 












Figure 7-10: qRT-PCR calculations for ChIP assay. 
Column 1: Calculation was done as for the real-time PCR analysis. Column 2: Value that obtained 
from the division of the value obtained by using the IgG antibody to the value obtained by using the 
FOXO3a antibody (with or without GnRH treatment). In each case this value (obtained by using the 
FOXO3a antibody) is normalised with the value obtained by using the IgG antibody (IgG antibody is 
using as a control and its not affected by GnRH treatment). Column 3: Value that obtained from the 
division of the value obtained from treated cells with GnRH to the value obtained from the un-treated 
cells. Column 4: Value that obtained from the division of the value obtained by using primers against 




Column 1 Column 2 Column 3 Column 4
primers CHIP Ab GnRH Ct Avg Ct DDCt 2-DDCt
LH control IgG no 40 38.595953 1.405 0.377618
no 38.17845 -0.416552 1.334734 0.696657
no 40 1.405 0.377618
foxo3a no 37.60941 -0.98559 1.980123 1.934966
no 39.09879 0.503785 0.705254 1.348007
no 38.15283 -0.442168 1.358644
LH control IgG yes 40 39.835532 0.165 0.891929 2.608981
yes 39.5066 -0.328404 1.255624 1.01316
yes 40 0.165 0.891929
foxo3a yes 36.64243 -3.19257 9.142381 5.048291
yes 39.27408 -0.56092 1.47521 5.114727 1
yes 37.5942 -2.2408 4.726591 4.588283
LH promoter IgG no 40 38.991854 1.009 0.496891
no 40 1.009 0.496891 1.678937
no 36.97556 -2.015437 4.04303
foxo3a no 35.78966 -3.20134 9.198126 4.422108
no 36.06443 -2.926566 7.602985 7.424441
no 36.53888 -2.452124 5.472212
LH promoter IgG yes 40 40 0 1
yes 40 0 1 1 11.97074
yes 40 0 1
foxo3a yes 28.99443
yes 35.1423 -4.857704 28.99443 28.99443
yes
Egr1 control IgG no 31.18275 31.594262 -0.411255 1.329842
no 31.99407 0.400072 0.75782 1.026467
no 31.60597 0.011968 0.991739 1.218699
foxo3a no 31.15601 -0.43799 1.354716
no 31.39523 -0.198769 1.147719 1.250955
no 31.27158 -0.322424 1.25043 0.822035
Egr1 control IgG yes 30.50733 30.799041 -0.29167 1.224056
yes 30.94446 0.145462 0.90409 1.010564
yes 30.94533 0.146332 0.903545 1.001813
foxo3a yes 30.64985 -0.149151 1.108917
yes 30.78881 -0.01019 1.007088 1.012396 1
yes 30.91744 0.118442 0.921182 0.325635
Egr1 promoter IgG no 40 40 0 1
no 40 0 1 1
no 40 0 1 11.07727
foxo3a no
no 36.53047 -3.46953 11.07727 11.07727
no 0.267683
Egr1 promoter IgG yes 40 40 0 1
yes 40 0 1 1
yes 40 0 1 2.965197
foxo3a yes 38.57386 -1.426144 2.687275
yes 40 0 1 2.965197
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APPENDIX 7.4: Abbreviation of amino acids  
 











Amino acid Abbreviation One letter code 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamine Gln Q 
Glutamic acid Glu E 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Try W 
Tyrosine Tyr Y 











































Insert size (bp):  2000   
Species of gene(s): M. musculus (mouse) 
 
Insert size (bp):   1700   


















































Insert size (bp):  2038   
Species of gene(s): H. sapiens (human) 
 
Insert size (bp):   2038   



















































Insert size (bp):   2038   





Insert size (bp):   2038   















































Insert size (bp):   2038   





Insert size (bp):   Unknown   



















































Insert size (bp):   Unknown   
Species of gene(s):  H. sapiens (human) 
Relevant mutations/deletions: delta CT 
 
 
Insert size (bp):   1800   



















































Insert size (bp):   2038   
Species of gene(s):  H. sapiens (human) 
Relevant mutations/deletions: His212R 
 
Insert size (bp):  Unknown   












































Insert size (bp):  Unknown   
Species of gene(s): H. sapiens (human) 
 
Insert size (bp):   Unknown   
Species of gene(s):  H. sapiens (human) 
Relevant mutations/deletions: His
363



































Insert size (bp):   96   
Species of gene(s):  H. sapiens (human) 
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